RU2790209C2 - Improved peptide drugs for treatment of nash and other disorders - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new conjugate of a variant of an extracellular GLP-1 receptor domain with a surfactant compound; it can be used in medicine. The invention discloses a peptide product containing polypeptide conjugated by Lys17 residue with functionalized saccharide, in an amino acid sequence of which Glu16* and Lys20* residues are cycled through their side chains to form lactam.

EFFECT: invention can be used in the treatment of non-alcoholic fat liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

10 cl, 10 ex, 9 tbl, 31 dwg

Description

Related application

This application claims U.S. Provisional Application No. 62/613396, filed January 3, 2018, which is incorporated herein by reference in its entirety.

The field of technology to which the invention belongs

The rising prevalence of diabetes mellitus is a global health crisis with epidemic proportions, and is a major cause of morbidity and mortality among patients, as well as a major economic burden. Obesity is an important risk factor for developing type 2 diabetes, and about 90% of patients with type 2 diabetes are overweight or obese. Obesity is a rapidly growing problem worldwide, and more than 65% of US adults are overweight. The disclosure of the invention provides improved peptide pharmaceuticals for the treatment of disorders associated with obesity and/or diabetes such as non-alcoholic steatohepatitis (NASH) and polycystic ovary syndrome (PCOS).

The essence of the invention

This document describes peptide products and their use in the treatment of disorders associated with insulin resistance and/or obesity such as type 2 diabetes, metabolic syndrome, cardiovascular disease (including coronary artery disease such as atherosclerosis and myocardial infarction), hypertension, NASH and PCOS, and in the treatment of conditions associated with such disorders. Peptide products include a peptide covalently linked to a surface active moiety containing a hydrophilic saccharide group and a hydrophobic group. In some embodiments, the peptide is a metabolic hormone such as GLP-1, glucagon, oxyntomodulin, or exendin (eg, exendin-4), or an analog or variant thereof. Peptide products have improved properties, including increased duration of action and bioavailability.

Link Inclusion

All publications and patent applications mentioned in this specification are herein incorporated by reference in the same way as if each individual publication or patent application were specifically and individually indicated as being incorporated by reference.

Brief description of the drawings

On FIG. 1 shows specific peptide products, all of which are included in the present invention.

On FIG. 2 shows specific peptide products, all of which are included in the present invention.

On FIG. 3 shows specific peptide products, all of which are included in the present invention.

On FIG. 4 shows specific peptide products, all of which are included in the present invention.

Fig. 5 illustrates the X-ray crystal structure of the N-terminal/extracellular domain binding site of the GLP-1 receptor and shows the critical hydrophobic ligand-binding region (Val19*, Phe22*, Trp25* and Leu26* from exendin-4 ligand and the exendin-4 sequence beyond Glu15 interacts as an amphiphilic helix with this region).

Fig. 6 illustrates the structure of three representative peptide products, EU-A992, EU-A1022 and EU-A1169, in which the epsilon (side chain) amino group of the lysine residue at position 24 of the peptide forms an amide bond with 1-O-octyl beta-D-glucuronic acid, 1-O-octyl beta-D-melibiuronic acid or 1-O-octyl-alpha-D-melibiuronic acid, respectively.

Fig. 7 is a more detailed illustration of the EU-A992 structure.

On FIG. 8 shows the concentrations of peptide products EU-A993 and EU-A1023 and native hormone GLP-1 (7-36) during incubation in human plasma at 37°C.

On FIG. 9 shows the blood glucose response in db/db mice following subcutaneous injections of EU-A992, EU-A1167, and EU-A1168 (each at 250 nmol/kg) at t=0 and 7 hours.

On FIG. 10 shows weight loss in diet-induced obese (DIO) mice following subcutaneous injection of EU-A1024 peptide product at two different doses on days 1 (at T=0 and 7 h), 3, 6, 9, 12, 15 18, 21 and 24.

On FIG. 11 shows the change in whole body adipose tissue mass and lean mass in DIO mice treated as measured by NMR on days 1 (pre-dose) and 26.

On FIG. 12A-12B show the effect of test compounds on body weight in the NASH diet-induced obesity (DIO) mouse model.

On FIG. 13A-13B show the effect of test compounds on whole body adipose tissue mass in DIO-NASH mice.

On FIG. 14A-14B show the effect of test compounds on plasma triglyceride (TG) and total cholesterol (TC) levels in DIO-NASH mice.

On FIG. 15A-15B show the effect of test compounds on plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST) in DIO-NASH mice.

On FIG. 16 shows the effect of test compounds on liver weight in DIO-NASH mice.

On FIG. 17A-17E show the effect of test compounds on hepatic steatosis using hematoxylin and eosin staining in DIO-NASH mice (the large elliptical structure in FIG. 17C represents a vein).

On FIG. On FIG. 18A-18B show the effect of test compounds on liver steatosis after biopsy in terms of area % lesion and total liver lipids as determined by histological quantification in DIO-NASH mice.

On FIG. 19A-19B show the effect of test compounds on liver triglyceride (TG) and total cholesterol (TC) levels in DIO-NASH mice.

Fig. 20 shows the effect of test compounds on hepatic total alpha-1 (col1a1) collagen measured immunohistochemically in DIO-NASH mice.

On FIG. 21 shows the effect of test compounds on total liver galectin-3 measured immunohistochemically in DIO-NASH mice.

On FIG. 22A-22E show the effect of test compounds on the assessment of hepatic steatosis in DIO-NASH mice.

On FIG. 23A-23E show the effect of test compounds on liver inflammation score in DIO-NASH mice.

On FIG. 24A-24E show the effect of test compounds on hepatocyte ballooning score in DIO-NASH mice.

On FIG. 25A-25E show the effect of test compounds on NAS score (non-alcoholic fatty liver disease activity score) in DIO-NASH mice.

On FIG. 26A-26E show the effect of test compounds on the degree of liver fibrosis in DIO-NASH mice, where liver fibrosis was assessed by picrosirius red staining.

On FIG. 27A-27F show the effect of test compounds in DIO-NASH mice on hepatic expression of mRNAs involved in fibrosis, inflammation, monocyte recruitment and differentiation.

On FIG. 28A-28F show the effect of test compounds in DIO-NASH mice on hepatic expression of mRNAs involved in monocyte recruitment and differentiation.

On FIG. 29A-29I show the effect of test compounds in DIO-NASH mice on hepatic expression of mRNAs involved in fibrous fiber formation.

On FIG. 30A-30F show the effect of test compounds in DIO-NASH mice on hepatic expression of mRNAs involved in hepatic stellate cell activation and myofibroblast proliferation.

On FIG. 31A-31F show the effect of test compounds in DIO-NASH mice on hepatic expression of mRNAs involved in pyroptosis.

Detailed Description of the Invention

Definitions

Unless otherwise defined or expressly stated otherwise when used herein, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which this application pertains.

The use of the word in the singular in the description and the appended claims includes both the singular and the plural. As used herein, the word "other" means "second" or more.

The abbreviation "aka" means also known as.

As used herein, the term "exemplary" means "serving as an example, exemplary, or illustrative". Any embodiment or feature described herein as "exemplary" is not necessarily to be construed as preferable or advantageous over other embodiments or features.

In some embodiments, the term "about" or "approximately" means within ±10% or 5% of the specified value. Whenever the term "about" or "approximately" precedes the first numerical value in a series of two or more numerical values, or in a series of two or more ranges of numerical values, the term "about" or "approximately" is applied to each of the numerical values in this series of numeric values, or within this series of ranges of numeric values.

"Peptide" includes two or more naturally occurring and/or unnatural amino acid residues, typically linked via peptide bonds. Such amino acids may include naturally occurring structural variants, naturally occurring non-proteinogenic amino acids, or synthetic non-naturally occurring analogues of naturally occurring amino acids. The terms "peptide" and "polypeptide" are used interchangeably herein. Peptides include short peptides (about 2-20 amino acids), medium length peptides (about 21-50 amino acids) and long peptides (> about 50 amino acids, which can also be called "proteins"). In some embodiments, the peptide product includes a surfactant fragment covalently linked to the peptide, consisting of no more than 50, 40, or 30 amino acids. Synthetic peptides can be synthesized, for example, using an automated peptide synthesizer. Peptides can also be produced recombinantly in cells expressing nucleic acid sequences that encode the peptides. Conventional notations are used herein to depict peptide sequences: the left end of the peptide sequence is the amino (N)-terminus and the right end of the peptide sequence is the carboxyl (C)-terminus.

For general amino acids, standard one-letter and three-letter abbreviations are used throughout this document. Although the abbreviations used in the amino acid sequences disclosed herein are L-amino acids, unless otherwise indicated as D- or DL-, or the amino acid is achiral, the analog of the D-isomer can generally be used at any position (e.g., for resistance to proteolytic degradation). Abbreviations for other amino acids used herein include: Ac3c = 1-aminocyclopropane-1-carboxylic acid; Ac4c = 1-aminocyclobutane-1-carboxylic acid; Ac5c = 1-aminocyclopentane-1-carboxylic acid; Ac6c = 1-aminocyclohexane-1-carboxylic acid; Aib = α-aminoisobutyric acid (or 2-methylalanine or Cα-methylalanine); Bip = 3-(biphenyl-4-yl)alanine; Bip2Et = 3-(2'-ethylbiphenyl-4-yl)alanine; Bip2EtMeO = 3-(2'-ethyl-4'-methoxybiphenyl-4-yl)alanine; Cit = citrulline; Deg = 2,2-diethylglycine; Dmt = (2,6-dimethyl) tyrosine; 2FPhe = (2-fluorophenyl)alanine; 2FMePhe or 2FαMePhe = Cα-methyl-(2-fluorophenyl)alanine; HArg = homoarginine; MeLys or αMeLys = Cα-methyllysine; MePhe or αMePhe = Cα-methylphenylalanine; MePro or αMePro = Cα-methylproline; Nal1 or Nal (1) = 3-(1-naphthyl)alanine; Nal2 or Nal (2) = 3-(2-naphthyl)alanine; Nle=norleucine; Orn = ornithine; and Tmp = (2,4,6-trimethylphenyl)alanine. 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) and the dipeptide fragment Tic-Phe with a reduced amide bond between residues (designated as Tic-Ψ[CH2-NH]-Ψ-Phe) have the following structures:

Unless specifically stated otherwise, or the context clearly indicates otherwise, the present invention encompasses any and all forms of a peptide that can be made, whether that peptide is made synthetically (for example, using a peptide synthesizer) or by a cell (for example, by recombinant production). Such forms of the peptide may include one or more modifications that may be made during synthetic or cellular production of the peptide, such as one or more post-translational modifications, whether or not one or more of the modifications are intentional. The peptide may have the same type of modification at two or more different locations and/or may have two or more different types of modifications. Modifications that may be made during synthetic or cellular production of the peptide, including chemical and post-translational modifications, include, but are not limited to, glycosylation (for example, N-linked glycosylation and O-linked glycosylation), lipidation, phosphorylation, sulfation, acetylation (for example , N-terminal acetylation), amidation (eg, C-terminus amidation), hydroxylation, methylation, intramolecular or intermolecular disulfide bond formation, lactam formation between two side chains, pyroglutamate formation, and ubiquitination. The peptide may have one or more modifications anywhere, such as at the N-terminus, C-terminus, one or more amino acid side chains, or the peptide backbone, or any combination thereof. In some embodiments, the peptide is acetylated at the N-terminus and/and has a carboxamide (-CONH2) group at the C-terminus, which may increase the stability of the peptide.

Potential modifications to the peptide also include deletion of one or more amino acids, addition/insertion of one or more natural and/or non-natural amino acids, or substitution of one or more natural and/or non-natural amino acids, or any or all combinations thereof. The substitution may be conservative or non-conservative. Such modifications may be intentional, such as site-directed mutagenesis or chemical synthesis of the peptide, or may be accidental, such as mutations occurring in the host cell that produces the peptide, or errors due to PCR amplification. The non-natural amino acid may have the same chemical structure as the analogous natural amino acid but have a D stereochemistry, or it may have a different chemical structure and D or L stereochemistry. Natural amino acids may be used, for example, to promote α-helix formation and/or to improve the stability of the peptide (for example, to counteract proteolytic degradation).

A peptide having one or more modifications to a reference peptide may be referred to as an "analogue" or "variant" of the reference peptide, as appropriate. An "analog" typically retains one or more essential properties (eg, receptor binding, receptor or enzyme activation, receptor or enzyme inhibition, or other biological activity) of the reference peptide. A "variant" may or may not retain the biological activity of the reference peptide and/or may have other biological activity. In some embodiments, the reference peptide analog or variant has an amino acid sequence different from the reference peptide.

The term "conservative substitution" refers to the replacement of an amino acid in a peptide with a functionally, structurally or chemically similar natural or non-natural amino acid. In certain embodiments, each of the following groups includes natural amino acids that are conservative substitutions for each other:

1) Glycine (Gly/G), alanine (Ala/A);

2) Isoleucine (Ile/I), leucine (Leu/L), methionine (Met/M), valine (Val/V);

3) Phenylalanine (Phe/F), tyrosine (Tyr/Y), tryptophan (Trp/W);

4) Serine (Ser/S), threonine (Thr/T), cysteine (Cys/C);

5) Asparagine (Asn/N), glutamine (Gln/Q);

6) Aspartic acid (Asp/D), glutamic acid (Glu/E); And

7) Arginine (Arg/R), Lysine (Lys/K), Histidine (His/H).

In additional embodiments, each of the following groups includes natural amino acids that are conservative substitutions for each other:

1) non-polar: Ala, Val, Leu, Ile, Met, Pro (proline/P), Phe, Trp;

2) hydrophobic: Val, Leu, Ile, Phe, Trp;

3) aliphatic: Ala, Val, Leu, Ile;

4) aromatic: Phe, Tyr, Trp, His;

5) polar or hydrophilic uncharged: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln, Tyr;

6) aliphatic hydroxyl- or sulfhydryl-containing: Ser, Thr, Cys;

7) amide-containing: Asn, Gln;

8) acidic: Asp, Glu;

9) basic: Fox, Arg, His; And

10) small: Gly, Ala, Ser, Cys.

In other embodiments, amino acids may be grouped as follows:

1) hydrophobic: Val, Leu, Ile, Met, Phe, Trp;

2) aromatic: Phe, Tyr, Trp, His;

3) neutral hydrophilic: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln;

4) acidic: Asp, Glu;

5) basic: Lys, Arg, His; And

6) residues that affect the orientation of the frame: Pro.

Examples of non-natural or non-proteinogenic amino acids include, but are not limited to, alanine analogs (e.g., α-ethylGly [α-aminobutyric acid or Abu], α-n-propylGly [norvaline or Nva], α-tert-butylGly [Tbg], α- vinylGly [Vg or Vlg], α-allylGly [Alg], α-propargylGly [Prg], 3-cyclopropyl-Ala [Cpa] and Aib), leucine analogs (eg Nle), proline analogs (eg α-MePro) , phenylalanine analogs {e.g. Phe (2-F), Phe (2-Me), Tmp, Bip, Bip (2'-Et-4'-OMe), Nal1, Nal2, Tic, α-MePhe, α-MePhe (2-F) and α-MePhe(2-Me)}, tyrosine analogs (eg Dmt and α-MeTyr), serine analogs (eg homoserine [isothreonine or hSer]), glutamine analogs (eg Cit), analogs arginine (eg, hArg), lysine analogs (eg, homolysin [hLys], Orn, and α-MeLys), α, α-disubstituted amino acids (eg, Aib, α, α-diethylGly [Deg], α-cyclohexylal [2- Cha], Ac3c, Ac4c, Ac5c and Ac6c) and other non-natural amino acids disclosed in A. Santoprete et al., J. Pept. Sci. 17:270-280 (2011). α,α-Disubstituted amino acids can provide conformational restriction or stabilization of the α-helix. A reduced amide bond between two residues (as, for example, in Tic-Ψ[CH2-NH]-Ψ-Phe) increases protease resistance and may, for example, also alter receptor binding.

The disclosure covers all pharmaceutically acceptable salts of peptides, including positive net charge salts, negative net charge salts, and net charge salts.

Saccharides include monosaccharides, disaccharides, and oligosaccharides (eg, trisaccharides, tetrasaccharides, and so on). The reducing saccharide exists in ring form and in open chain form in equilibrium, which generally favors the ring form. The functionalized saccharide of the surfactant residue has a functional group suitable for forming a covalent bond with the amino acid of the peptide.

"Alkyl" group refers to an aliphatic hydrocarbon group. The alkyl group may be saturated or unsaturated and may be linear (linear), branched or cyclic. In some embodiments, the alkyl group is not cyclic. In some embodiments, the alkyl group contains 1-30, 6-30, 6-20, or 8-20 carbon atoms. A "substituted" alkyl group is substituted with one or more substituents. In some embodiments, one or more substituents are independently selected from halogen, nitro, cyano, oxo, hydroxy, alkoxy, haloalkoxy, aryloxy, thiol, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, amino, alkylamino, dialkylamino, arylamino, alkoil, carboxyl, carboxylate, esters, amides, carbonates, carbamates, ureas, alkyl, haloalkyl, fluoroalkyl, aralkyl, alkyl chains containing an acyl group, heteroalkyl, heteroalicycle, aryl, alkoxyaryl, heteroaryl, hydrophobic natural compounds (e.g. steroids), etc. .P.

In some embodiments, the substituent alkyl group is straight or branched C1-C6 alkyl, which may be referred to as "lower alkyl". Non-limiting examples of lower alkyl groups include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including all isomeric forms such as n-butyl, isobutyl, sec-butyl and t-butyl), pentyl (including all isomeric forms , such as n-pentyl) and hexyl (including all isomeric forms such as n-hexyl).

In some embodiments, an alkyl group is attached to the Nα atom of a residue (eg, Tyr or Dmt) of the peptide. In some embodiments, the N-alkyl group is straight or branched C1-C10 alkyl or aryl-substituted alkyl such as benzyl, phenylethyl, or the like. One or two alkyl groups may be attached to the Nα atom of the N-terminal residue.

In some embodiments, the alkyl group is a 1-alkyl group that is attached to the C-1 position of the saccharide (eg, glucose) via a glycosidic bond (eg, an O-, S-, N-, or C-glycosidic bond). In some embodiments, such a 1-alkyl group is an unsubstituted or substituted C ₁ -C ₃₀ , C ₆ -C ₃₀ , C ₆ -C ₂₀ or C ₈ -C ₂₀ alkyl group.

In some embodiments, the alkyl group (eg, 1-alkyl group) is substituted with one or more (eg, 2 or 3) groups independently selected from aryl, -OH, -OR ¹ , -SH, -SR ¹ , -NH ₂ , - NHR ¹ , -N(R ¹ ) ₂ , oxo (=O), -C(=O)R ² , carboxyl (-CO2H), carboxylate (-CO ₂ ^- ), -C(=O)OR ¹ , - OC(=O)R ³ , -C(=O)N(R ¹ ) ₂ , -NR ⁴ C(=O)R ³ , -OC(=O)OR ⁵ , -OC(=O)N(R ¹ ) ₂ , -NR ⁴ C(=O)OR ⁵ , and -NR ⁴ C(=O)OR ⁵ , where:

R ¹ at each occurrence is independently hydrogen, alkyl or aryl, or both R ¹ and the nitrogen atom to which they are bonded form a heterocyclyl or heteroaryl ring;

R ² at each occurrence is independently alkyl, heterocyclyl, aryl or heteroaryl;

R ³ at each occurrence is independently hydrogen, alkyl, heterocyclyl, aryl or heteroaryl;

R ⁴ at each occurrence is independently hydrogen or alkyl; And

R ⁵ at each occurrence is independently alkyl or aryl.

In some embodiments, an alkyl group (eg, a 1-alkyl group) is internally and/or terminally substituted with a carboxyl/carboxylate group, an aryl group, or an -O-aryl group. In some embodiments, an alkyl group (eg, a 1-alkyl group) is substituted with a carboxyl or carboxylate group at the distal end of the alkyl group. In other embodiments, the alkyl group (eg, 1-alkyl group) is substituted with an aryl group at the distal end of the alkyl group. In other embodiments, an alkyl group (eg, a 1-alkyl group) is substituted with an -O-aryl group at the distal end of the alkyl group.

The terms "halogen", "halogenide" and "halogen" refer to fluoride, chloride, bromide and iodide.

The term "acyl" refers to -C(=O)R where R is an aliphatic group which may be saturated or unsaturated and may be linear, branched or cyclic. In certain embodiments, R contains 1-20, 1-10, or 1-6 carbon atoms. The acyl group may be optionally substituted with one or more groups such as halogens, oxo, hydroxyl, alkoxy, thiol, alkylthio, amino, alkylamino, dialkylamino, cycloalkyl, aryl, acyl, carboxyl, esters, amides, hydrophobic natural compounds (e.g., steroids), etc.

The terms "heterocyclyl" and "heterocyclic" refer to a monocyclic non-aromatic group or a multicyclic group that includes at least one non-aromatic ring, where at least one non-aromatic ring contains one or more heteroatoms independently selected from O, N and S. A non-aromatic ring containing one or more heteroatoms may be attached or fused to one or more saturated, partially unsaturated, or aromatic rings. In some embodiments, the heterocyclyl or heterocyclic group has 3 to 15, or 3 to 12, or 3 to 10, or 3 to 8, or 3 to 6 atoms in the ring structure. Heterocyclyl or heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, azocanyl, oxiranyl, oxetanyl, tetrahydrofuranyl (oxolanyl), tetrahydropyranyl, oxepanyl, and oxocanyl.

The term "aryl" refers to a monocyclic aromatic hydrocarbon group or a multicyclic group that includes at least one aromatic hydrocarbon ring. In some embodiments, the aryl group has 6 to 15, or 6 to 12, or 6 to 10 atoms in the ring structure. Aryl groups include, but are not limited to, phenyl, naphthalenyl (naphthyl), fluorenyl, azulenyl, anthryl, phenanthryl, biphenyl, and terphenyl. The aromatic hydrocarbon ring of the aryl group may be attached or fused to one or more saturated, partially unsaturated or aromatic rings, for example dihydronaphthyl, indenyl, indanyl and tetrahydronaphthyl (tetralinyl). The aryl group may be optionally substituted with one or more (e.g. 2 or 3) substituents independently selected from halogen (including -F and -Cl), cyano, nitro, hydroxyl, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, amino, alkylamino , dialkylamino, alkyl, haloalkyl (including fluoroalkyl such as trifluoromethyl), acyl, carboxyl, esters, amides, and the like.

The term "heteroaryl" refers to a monocyclic aromatic group or a multicyclic group that contains at least one aromatic ring, where at least one aromatic ring contains one or more heteroatoms independently selected from O, N and S. Heteroaromatic ring may be attached or fused to one or more saturated, partially unsaturated or aromatic rings, which may contain only carbon atoms or which may contain one or more heteroatoms. In certain embodiments, the heteroaryl group has 5 to 15, or 5 to 12, or 5 to 10 ring atoms. Monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl (thiophenyl), oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridonyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridazinonyl and triazinyl. Неограничивающие примеры бициклических гетероарильных групп включают индолил, бензотиазолил, бензотиадиазолил, бензоксазолил, бензизоксазолил, бензотиенил (бензотиофенил), хинолинил, тетрагидроизохинолинили, изохинолинили, бензимидазолили, бензотриазолили, индолизинили, бензофуранили, изобензофуранил, хромонил, кумаринил, циннолинил, хиназолинил, хиноксалинил, индазолил, нафтиридинил , phthalazinyl, quinazolinyl, purinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, dihydroisoindolyl, and tetrahydroquinolinyl.

The term "steroid core" refers to a core of steroids containing a combination of four fused rings, labeled A, B, C, and D, as shown below:

The steroid core may carry one or more groups such as halogens, hydroxyl, oxo, alkyl, acyl, carboxyl, esters, amides, and the like. Steroid core-containing moieties include, but are not limited to, cholesterol and the like.

The term “pharmaceutically acceptable” refers to a substance (e.g., active ingredient or excipient) that is suitable for use in contact with the tissues and organs of the subject without undue irritation, allergic response, immunogenicity, and toxicity, commensurate with a reasonable benefit-risk ratio, and is effective. for its intended application. The "pharmaceutically acceptable" excipient or carrier of the pharmaceutical composition is also compatible with the other ingredients of the composition.

The term "therapeutically effective amount" refers to an amount of a compound which, when administered to a subject, is sufficient to prevent, reduce the risk of developing, delay onset, slow progression, or cause regression of the medical condition being treated, or to some extent alleviate the health condition or one or more symptoms. or complications of this condition, at least some part of the objects receiving this connection. The term "therapeutically effective amount" also refers to an amount of a compound that is sufficient to elicit a biological or medical response of a cell, tissue, organ, or human that is requested by the attending physician or clinician.

The terms "treat," "treat," and "treat" include alleviating, ameliorating, inhibiting the progress of, modifying, or eliminating a medical condition or one or more symptoms or complications associated with that condition, and alleviating, improving, or eliminating one or more causes of the condition. . Reference to "treatment" of a medical condition includes the prevention of that condition. The terms "prevent", "prevent" and "prevention" include exclusion, reduction in the risk of developing and delaying the onset of a medical condition or one or more of the symptoms or complications associated with that condition.

The term "medical conditions" (or "conditions" for short) includes diseases and disorders. The terms "diseases" and "disorders" are used interchangeably herein.

Obesity and insulin resistance

Obesity leads to insulin resistance, which is manifested by a decrease in the ability of body cells to respond to insulin stimulation by reducing the number of insulin receptors and reducing the connection of insulin receptors with critical intracellular signaling systems. Obesity also leads to metabolic syndrome, which is a collection of disorders including insulin resistance, hypertension, atherosclerosis, etc. Insulin resistance often leads to type 2 diabetes. Prolonged hyperglycemia increases the risk of micro- and macrovascular complications, sensory neuropathy, myocardial infarction, stroke, macrovascular and all-cause mortality. Type 2 diabetes, metabolic syndrome and other diseases associated with obesity and insulin resistance are a huge financial and health burden worldwide.

metabolic hormones

Incretins are metabolic hormones that cause a decrease in blood glucose levels. Incretins are released after a meal and stimulate insulin production and secretion from pancreatic beta cells of the islets of Langerhans in a blood glucose dependent mechanism. Incretins also slow down the rate at which nutrients are absorbed into the bloodstream, slowing down gastric emptying, which induces a feeling of satiety and thereby suppresses appetite. In addition, incretins inhibit the release of glucagon from the alpha cells of the islets of Langerhans. The two main incretins are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP, also known as glucose-dependent insulinotropic polypeptide), which are secreted by intestinal L-cells and are members of the glucagon peptide superfamily. GLP-1 and GIP are rapidly degraded by dipeptidyl peptidase 4 (DPP-4). People with type 2 diabetes have impaired insulin secretion by pancreatic beta cells in response to GLP-1.

GLP-1 has other beneficial effects. For example, GLP-1 stimulates pancreatic beta cell proliferation, increases peripheral insulin sensitivity and hepatic glucose uptake and glycogen production, and improves cardiac function (eg, left ventricular function).

Like GLP-1, oxyntomodulin (OXM) is derived from preproglucagon and is secreted from L cells in the intestine in response to food intake. OXM is essentially a glucagon with a C-terminal extension of 8 amino acid residues. OXM activates both the glucagon receptor (GCGR) and the GLP-1 receptor (GLP1R), but is 10–100 times less potent than both glucagon and GLP-1. OXM induces satiety and reduces body fat (eg, white adipose tissue). OXM causes weight loss by reducing food intake and body fat.

Glucagon is produced from preproglucagon in the pancreatic alpha cells of the islets of Langerhans. Glucagon causes satiety, induces lipolysis in adipose tissue and increases energy expenditure. Glucagon reduces body weight by reducing food intake and stimulating fat burning.

The amino acid sequences of biologically active forms of human GLP-1, glucagon and oxyntomodulin are shown below:

GLP-1 (using glucagon numbering):

His ₁ -Ala ₂ -Glu ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Val ₁₀ -Ser ₁₁ -Ser ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Glu ₁₅ -Gly ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Ala ₂₄ -Trp ₂₅ -Leu ₂₆ -Val ₂₇ -

Lys ₂₈ -Gly ₂₉ -Arg ₃₀ (SEQ. ID. NO. 1)

Glucagon:

His ₁ -Ser ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Ser ₁₆ -Arg ₁₇ -Arg ₁₈ -Ala ₁₉ -Gln ₂₀ -Asp ₂₁ -Phe ₂₂ -Val ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Met ₂₇ -

Asn ₂₈ -Thr ₂₉ (SEQ ID NO 2)

Oxyntomodulin:

His ₁ -Ser ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Ser ₁₆ -Arg ₁₇ -Arg ₁₈ -Ala ₁₉ -Gln ₂₀ -Asp ₂₁ -Phe ₂₂ -Val ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Met ₂₇ -

Asn ₂₈ -Thr ₂₉ -Lys ₃₀ -Arg ₃₁ -Asn ₃₂ -Arg ₃₃ -Asn ₃₄ -Asn ₃₅ -Ile ₃₆ -Ala ₃₇ (SEQ. ID. NO. 3)

Amino acid residues in the GLP-1 and glucagon sequences can be changed while maintaining biological activity. For example, a substitution with Ala has performed well in the N-terminal region of GLP-1, especially at positions 2, 3, 5, 8, 11 and 12 (Adelhorst et al., J. Biol. Chem., 269:6275-6278 [ 1994]). In addition, short N-terminal GLP-1 analogs can strongly bind and activate GLP1R (Mapelli et al., J. Med. Chem., 52:7788-7799 [2009]; and Haque et al., Peptides, 31:950 -955 and 1353-1360 [2010]). Chimeric analogs capable of binding to both GLP1R and GCGR can be generated by grafting C-terminal residues from GLP-1 onto N-terminal glucagon residues (Hjorth et al., J. Biol. Chem., 269: 30121- 30124 [1994]).

The present invention relates to peptide products containing a peptide hormone of the gastrointestinal tract (for example, GLP-1, GIP, glucagon, oxyntomodulin or exendin (for example, exendin-4]), or an analogue or variant thereof, which is covalently linked to a surfactant fragment.The peptide products are potent agonists of the receptor(s) of the respective peptide, promote metabolic homeostasis, and have a longer duration of action and increased bioavailability.In some embodiments, the peptide products are GLP-1 receptor (GLP1R) agonists.GLP1R agonists stimulate glucose-dependent insulin secretion in blood and increase insulin sensitivity with a reduced risk of hypoglycemia and induce a feeling of satiety that reduces food intake and therefore reduces weight gain or causes weight loss.In other embodiments, the peptide products are dual GLP1R and glucagon receptor (GCGR) agonists, which adds benefits GCGR activation, including stimulation of fat burning, loss of body fat mass and prevention of hypoglycemia.

Peptide Products

Peptides and proteins often have drawbacks in their use as drugs, including drug instability, aggregation, short duration of action, and poor bioavailability. This document discloses peptide products that have improved properties as pharmaceuticals, including improved stability, half-life, duration of action and bioavailability, and reduced immunogenicity. Peptide products include a peptide covalently linked to a surface active moiety containing a hydrophilic saccharide group and a hydrophobic group. In some embodiments, the peptide is attached to a saccharide group, which in turn is attached to a hydrophobic group. In some embodiments, the peptide is a metabolic hormone such as GLP-1, glucagon, oxyntomodulin, or exendin (eg, exendin-4), or an analog or variant thereof. Peptide products are useful in the treatment of, for example, insulin resistance, diabetes, obesity, metabolic syndrome, and cardiovascular disease and related conditions such as NASH and PCOS.

In some embodiments, the peptide product contains GLP-1, or an analog or variant thereof, covalently linked to a surfactant moiety (eg, an alkyl glycoside, such as a 1-alkyl glycoside). The GLP-1 peptide may have a native or non-native amino acid sequence or structure. The alkyl group may be unsubstituted or substituted (eg carboxyl/carboxylate, aryl or hydroxyaryl group). In certain embodiments, the alkyl glycoside is 1-O-alkyl-D-glucuronic acid.

In other embodiments, the peptide product contains glucagon, or an analog or variant thereof, covalently linked to a surfactant moiety (eg, an alkyl glycoside, such as a 1-alkyl glycoside). The glucagon peptide may have a native or non-native amino acid sequence or structure. The alkyl group may be unsubstituted or substituted (eg carboxyl/carboxylate, aryl or hydroxyaryl group). In certain embodiments, the alkyl glycoside is 1-O-alkyl-D-glucuronic acid.

In further embodiments, the peptide product contains oxyntomodulin, or an analog or variant thereof, covalently linked to a surfactant moiety (eg, an alkyl glycoside, such as a 1-alkyl glycoside). The oxyntomodulin peptide may have a native or non-native amino acid sequence or structure. The alkyl group may be unsubstituted or substituted (eg carboxyl/carboxylate, aryl or hydroxyaryl group). In certain embodiments, the alkyl glycoside is 1-O-alkyl-D-glucuronic acid.

In other embodiments, the peptide product contains an exendin (eg, exendin-4) or an analog or variant thereof covalently linked to a surfactant moiety (eg, an alkyl glycoside such as a 1-alkyl glycoside). The exendin peptide may have a native or non-native amino acid sequence or structure. The alkyl group may be unsubstituted or substituted (eg carboxyl/carboxylate, aryl or hydroxyaryl group). In certain embodiments, the alkyl glycoside is 1-O-alkyl-D-glucuronic acid.

Some embodiments relate to peptide products of Formula I-A comprising a surfactant X covalently attached to a peptide, wherein the peptide contains a linker amino acid U and at least one other amino acid:

Формула I-A

Formula IA

where surfactant X is a moiety of Formula I:

Формула I

Formula I

wherein:

R ^1a is independently at each occurrence a bond, H, a protecting group, a saccharide, an unsubstituted or substituted C ₁ -C ₃₀ alkyl group, an unsubstituted or substituted aralkyl (-alkylaryl) group, an unsubstituted or substituted alkyloxyaryl group, or a group containing a steroid nucleus;

R ^1b , R ^1c and R ^1d are each independently a bond, H, a protecting group, a saccharide, an unsubstituted or substituted C ₁ -C ₃₀ alkyl group, an unsubstituted or substituted aralkyl group, an unsubstituted or substituted alkyloxyaryl group, or a group containing a steroid core;

R ² in each occurrence independently represents a bond, a bond to U, H, a substituted or substituted C ₁ -C ₃₀ alkyl group, an unsubstituted or substituted aralkyl group, an unsubstituted or substituted alkyloxyaryl group, a group containing a steroid nucleus, -NH-, - S-, -O-NH-, spacer, -triazolo-, NH(C=O)-CH ₂ - or -(CH ₂ ) _m -maleimide;

W ¹ in each case independently represents -CH ₂ -, -CH ₂ -O-, -CH ₂ -S-, -CH ₂ -NH-, -(C=O)-, -(C=O)-NH -, -(C=S)- or -(C=S)-NH-;

W ² is at each occurrence independently -O-, -S-, -NH- or -CH ₂ -;

in at least one instance, R ^1a , R ^1b , R ^1c , R ^1d or R ² is an unsubstituted or substituted C ₁ -C ₃₀ alkyl, aralkyl, alkyloxyaryl or a group containing a steroid nucleus;

m is an integer from 1 to 10; And

n is 1, 2 or 3; And

the peptide has Formula II:

aa ₁ -aa ₂ -aa ₃ -aa ₄ -aa ₅ -aa ₆ -aa ₇ -aa ₈ -aa ₉ -aa ₁₀ -aa ₁₁ -aa ₁₂ -aa ₁₃ -aa ₁₄ -aa ₁₅ -aa ₁₆ -aa ₁₇ -

aa ₁₈ -aa ₁₉ -aa ₂₀ -aa ₂₁ -aa ₂₂ -aa ₂₃ -aa ₂₄ -aa 25 -aa ₂₆ -aa _{27 -aa 28} -aa ₂₉ -aa ₃₀ -aa ₃₁ -aa ₃₂ -aa ₃₃ -

aa ₃₄ -aa ₃₅ -aa ₃₆ -aa ₃₇ -Z Formula II (SEQ. ID. NO. 1108)

wherein:

Z is -OH, -NHR ³ or -N(R ⁴ )His, where:

R ³ is H, unsubstituted or substituted with C ₁ -C ₁₂ alkyl or a PEG-containing group of less than 10 Da; And

R ⁴ is H, C ₂ -C ₁₀ acyl (eg acetyl) or -C(=O)-aryl (eg benzoyl);

aa1 is His, N(R ³ )His, N(R ⁴ )His or pGlu-His;

aa2 is Ser, D-Ser, Ala, Gly, Pro, MePro, Aib, Ac4c or Ac5c;

aa3 is Gln or Cit;

aa4 is Gly or D-Ala;

aa5 is Thr or Ser;

aa6 is Phe, Trp, 2FPhe, MePhe, 2FMePhe or Nal2;

aa7 is Thr or Ser;

aa8 is Ser or Asp;

aa9 is Asp or Glu;

aa10 is Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys, or U;

aa11 is absent or is Ser, Asn, Bip or U;

aa12 is absent or is Lys, Glu, Ser, Arg or U;

aa13 is absent or is Tyr, Gln, Cit or U;

aa14 is absent or is Leu, Met, Nle, Glu, Lys, or U;

aa15 is absent or is Asp, Glu or U;

aa16 is absent or is Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg, or U;

aa17 is absent or is Arg, hArg, Gln, Glu, Cit, Aib, Ac4c, Ac5c, Lys, or U;

aa18 is absent or is Arg, hArg, Ala, Aib, Ac4c, Ac5c or U;

aa19 is absent or is Ala, Val, Aib, Ac4c, Ac5c or U;

aa20 is absent or is Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c, or U;

aa21 is absent or is Asp, Glu, Leu, Aib, Ac4c, Ac5c or U;

aa22 absent or is Phe, Trp, Nal2, Aib, Ac4c, Ac5c or U

aa23 is absent or is Val, Ile, Aib, Ac4c, Ac5c or U;

aa24 is absent or is Ala, Gln, Glu, Cit or U;

aa25 is absent or is Trp, Nal2 or U;

aa26 is absent or is Leu or U;

aa27 is absent or is Met, Val, Leu, Nle, Lys, or U;

aa28 is absent or is Asn, Lys, Glu, Gln, Cit or U;

aa29 is absent or is Thr, Gly, Aib, Ac4c, Ac5c or U;

aa30 is absent or is Lys, Aib, Ac4c, Ac5c, Arg or U;

aa31 is absent or is Arg, Aib, Ac4c, Ac5c or U;

aa32 is absent or is Asn, Aib, Ac4c, Ac5c or U;

aa33 is absent or is Arg, Aib, Ac4c, Ac5c or U;

aa34 is absent or is Asn, Aib, Ac4c, Ac5c or U;

aa35 is absent or is Asn, Aib, Ac4c, Ac5c or U;

aa36 is absent or is Ala, Ile, Aib, Ac4c, Ac5C or U;

aa37 is absent or is U;

U is a natural or non-natural amino acid containing a functional group used for covalent attachment to the surfactant X;

any two of aa1-aa37 may optionally be cyclized through their side chains to form a lactam; And

with the proviso that one or at least one of aa10-aa37 is a linker amino acid U covalently linked to a surfactant X.

The surfactant moiety can also be attached to the linker amino acid U of the peptide via R ^1a , R ^1b , R ^1c or R ^1d . For example, W ² may be -O- and one occurrence of R ^1a may be a bond to a hydroxyl-bearing natural or non-natural amino acid (eg, serine, homoserine, or threonine), or W ² may be -S- and one occurrence of R ^1a may be a bond to a thiol/sulfhydryl-containing natural or non-natural amino acid (eg, cysteine or homocysteine), or W ² may be -NH-, and one occurrence of R ^1a may be a bond to an amine-containing natural or non-natural amino acid (eg, lysine or ornithine). In some embodiments, the U attached to the surfactant moiety via R ^1a is a non-natural amino acid. The linker amino acid U attached to the surfactant moiety via R ^1a may be the L or D isomer. In some embodiments, U is the D isomer.

In some embodiments, n is 1. In other embodiments, n is 2, and the first glycoside is attached to the second glycoside via a link between the W ² of the first glycoside and -OR ^1b , -OR ^1c or -OR ^1d of the second glycoside. In other embodiments, n is 3 and the first glycoside is attached to the second glycoside through a link between the W ² of the first glycoside and -OR ^1b , -OR ^1c or -OR ^1d of the second glycoside, and the second glycoside is attached to the third glycoside through a link between the W ² of the second glycoside and -OR ^1b , -OR ^1c or OR ^1d of the third glycoside.

In some embodiments of Formula I-A peptide products, surfactant X is:

Формула I

Formula I

wherein:

R ^1a is H, a protecting group, a saccharide, an unsubstituted or substituted C ₁ -C ₃₀ alkyl group, or a group containing a steroid nucleus;

R ^1b , R ^1c and R ^1d are independently H, a protecting group, a saccharide, or an unsubstituted or substituted C ₁ -C ₃₀ alkyl group;

R ² is a bond with U, -NH-, -S-, -triazolo-, -NH(C=O)-CH ₂ - or -(CH ₂ ) _m -maleimide;

W ¹ is -CH ₂ -, -CH ₂ -O-, -CH ₂ -S-, -(C=O)-, -(C=O)-NH-, -(C=S)- or - (C=S)-NH-;

W ² represents -O- or -S-;

m is 1-10; And

at least one of R ^1a , R ^1b , R ^1c and R ^1d is an unsubstituted or substituted C ₁ -C ₃₀ alkyl group or a group containing a steroid nucleus.

, в которой R² представляет собой связь с U. В некоторых воплощениях W¹ представляет собой -C(=O)NH-, а R² представляет собой связь между W¹ и аминокислотным остатком U (например, боковая цепь аминогруппы остатка лизина) пептида.In some embodiments, surfactant X has the structure

, in which R ² is a bond to U. In some embodiments, W ¹ is -C(=O)NH- and R ² is a bond between W ¹ and an amino acid residue U (e.g., the amino side chain of a lysine residue) of the peptide .

. В некоторых воплощениях W¹ представляет собой -CH₂-O-, CH₂S- или -(C=O)-NH-, и R² представляет собой -(CH₂)_m-малеимидную группу, которая образует связь с подходящей функциональной группой аминокислоты остаток U пептида (например, тиольная группа остатка цистеина образует тиоэфирную связь с малеимидной группой).In other embodiments, the surfactant X is

. In some embodiments, W ¹ is -CH ₂ -O-, CH ₂ S-, or -(C=O)-NH-, and R ² is -(CH ₂ ) _m -maleimide group which forms a bond with an appropriate functional the amino acid group of the U residue of the peptide (for example, the thiol group of the cysteine residue forms a thioether bond with the maleimide group).

In additional embodiments, surfactant X has the structure:

Формула I

Formula I

wherein:

R ^1a is H, a protecting group, a saccharide, an unsubstituted or substituted C ₁ -C ₃₀ alkyl group, or a group containing a steroid nucleus;

R ^1b , R ^1c and R ^1d are independently H, a protecting group, or an unsubstituted or substituted C ₁ -C ₃₀ alkyl group;-

R ² is a bond to U;

W ¹ represents -(C=O)-NH-;

W ² represents -O-; And

at least one of R ^1a , R ^1b , R ^1c and R ^1d is an unsubstituted or substituted C ₁ -C ₃₀ alkyl group or a group containing a steroid nucleus.

In certain embodiments, surfactant X has the structure:

Формула I

Formula I

wherein:

R ^1a is an unsubstituted or substituted C ₁ -C ₃₀ alkyl group;

R ^1b , R ^1c and R ^1d are H;

R ² is a bond to U;

W ¹ represents -(C=O)-NH-; And

W ² is -O-.

In some embodiments, surfactant X is a 1-O-alkyl beta-D-glucuronyl moiety:

where R ^1a is an unsubstituted or substituted C ₁ -C ₃₀ , C ₁ -C ₂₀ or C ₆ -C ₂₀ alkyl group and R' is a peptide that is attached to the surfactant moiety through an N-terminal alpha-amino group or side the amino group chain of a natural or non-natural amino acid (eg lysine or ornithine). In certain embodiments, R ^1a is an unsubstituted or substituted C ₈ -C ₂₀ , C ₁₂ -C ₂₀ or C ₁₂ -C ₁₆ alkyl group.

In some embodiments, the alkyl group attached to the saccharide is an unsubstituted or substituted C ₁ -C ₃₀ , C ₁ -C ₂₀ , C ₆ -C ₃₀ or C ₆ -C ₂₀ alkyl group. In some embodiments, the alkyl group attached to the saccharide is an unsubstituted or substituted C ₈ -C ₂₀ , C ₆ -C ₁₈ or C ₁₂ -C ₁₈ alkyl group.

In some embodiments, at least one occurrence of R ^1a , R ^1b , R ^1c , R ^1d or R ² is an unsubstituted or substituted C ₁ -C ₃₀ alkyl group. In some embodiments, the alkyl group is attached to at least one occurrence of R ^1b , R ^1c or R ^1d via an ether bond (-O-alkyl). In other embodiments, the alkyl group is attached to at least one occurrence of R ² via an ether bond (-O-alkyl) or an amide bond [-C(=O)NH-alkyl].

In some embodiments, at least one or only occurrence of R ^1a is an unsubstituted or substituted C ₁ -C ₃₀ , C ₆ -C ₃₀ , C ₆ -C ₂₀ or C ₈ -C ₂₀ alkyl group. In some embodiments, at least one or only occurrence of R ^1a is an unsubstituted or substituted C ₁₂ -C ₂₀ alkyl group.

In some embodiments, the alkyl group (eg, 1-alkyl group) is internally and/or terminally substituted with a carboxyl or carboxylate group. In some embodiments, an alkyl group (eg, a 1-alkyl group) is substituted with a carboxyl or carboxylate group at the distal end of the alkyl group.

In additional embodiments, in at least one instance, or only one instance, R ^1a is a saccharide. In certain embodiments, the saccharide is galactose. Galactose can be alpha or beta linked. In some embodiments, the galactose is alpha-linked galactopyranose, beta-linked galactopyranose, alpha-linked galactofuranose, or beta-linked galactofuranose.

In some embodiments, the saccharide group of the surfactant component is a monosaccharide. In some embodiments, the monosaccharide is a suitably functionalized glucose, galactose, or mannose, such as glucuronic acid, galacturonic acid, or mannuronic acid. In other embodiments, the saccharide is a disaccharide. In some embodiments, the disaccharide contains two glucose molecules or one glucose molecule and one galactose molecule. In certain embodiments, the disaccharide is diglucuronic acid or suitably functionalized melibiose, maltose, isomaltose, gentiobiose, or lactose, such as melibiuronic acid, malturonic acid, isomalturonic acid, gentiobiuronic acid, or lacturonic acid. The terms "-uronic acid" and "-uronil" are used interchangeably herein with respect to the saccharide group of the surfactant component.

In some embodiments, surfactant X is a 1-alkyl glycoside, wherein an unsubstituted or substituted alkyl group is attached to the C-1 position of the saccharide via a glycosidic bond. The glycosidic bond may be an O-, S-, N- or C-glycosidic bond. In certain embodiments, the glycosidic bond is an O-glycosidic bond. The 1-alkyl group may be a beta or alpha anomer. In certain embodiments, the 1-alkyl group is the beta anomer.

In some embodiments, the surfactant X is selected from 1-eicosyl beta-D-glucuronic acid, 1-octadecyl beta-D-glucuronic acid, 1-hexadecyl beta-D-glucuronic acid, 1-tetradecyl beta-D-glucuronic acid, 1-dodecyl beta-D-glucuronic acid, 1-decyl beta-D-glucuronic acid, 1-octyl beta-D-glucuronic acid, 1-eicosyl beta-D-diglucuronic acid, 1-octadecyl beta-D-diglucuronic acid, 1-hexadecyl beta-D-diglucuronic acid, 1-tetradecyl beta-D-diglucuronic acid, 1-dodecyl beta-D-diglucuronic acid, 1-decyl beta-D-diglucuronic acid, 1-octyl beta-D-diglucuronic acid, 1-eicosyl beta-D-isomalturonic acid, 1-octadecyl beta-D-isomalturonic acid, 1-hexadecyl beta-D-isomalturonic acid, 1-tetradecyl beta-D-isomalturonic acid, 1-dodecyl beta-D-isomalturonic acid, 1-decyl beta-D-isomalturonic acid, 1-octyl beta-D-isomalturonic acid, 1-eicosyl beta-D-gentiobiuronic acid, 1octadecyl beta- D-gentiobiuronic acid, 1-hexadecyl beta-D-gentiobiuronic acid, 1-tetradecyl beta-D-gentiobiuronic acid, 1-dodecyl beta-D-gentiobiuronic acid, 1-decyl beta-D-gentiobiuronic acid, 1-octyl beta- D-gentiobiuronic acid, 1-eicosyl beta-D-melibiuronic acid, 1-octadecyl beta-D-melibiuronic acid, 1-hexadecyl beta-D-melibiuronic acid, 1-tetradecyl beta-D-melibiuronic acid, 1-dodecyl beta- D-melibiuronic acid, 1-decyl beta-D-melibiuronic acid, 1-octyl beta-D-melibiuronic acid, functionalized 1-eicosyl beta-D-glucose, 1-octadecyl beta-D-glucose, 1-hexadecyl beta-D -glucose, 1-tetradecyl beta-D-glucose, 1-dodecyl beta-D-glucose, 1-decyl beta-D-glucose, 1-octyl beta-D-glucose, 1-eicosyl beta-D-maltoside, 1octadecyl beta -D-maltoside, 1-hexadecyl beta-D-maltoside, 1-tetradecyl beta-D-maltoside, 1-dodecyl beta-D-maltoside, 1-decyl beta-D-maltoside, 1-octyl beta-D-maltoside, 1-eikosyl beta-D-melibioside, 1octadecyl beta-D-m elibioside, 1-hexadecyl beta-D-melibioside, 1-tetradecyl beta-D-melibioside, 1-dodecyl beta-D-melibioside, 1-decyl beta-D-melibioside, 1-octyl beta-D-melibioside, corresponding to 1- alkyl glycosides with a 6-carboxyl group or 6,6'-dicarboxyl groups, the corresponding 1-alkyl alpha-anomers, and the like. In certain embodiments, surfactant X is 1-alkyl beta-D-glucuronic acid.

As illustrative examples, the 1-O-octyl beta-D-melibiouronyl moiety (top left), the 1-O-hexadecyl beta-D-gentiobiuronyl moiety (top right), the 1-O-dodecyl beta-D-malturonyl moiety ( bottom left, one or both carboxyl groups may be attached to the peptide), and a 1-O-tetradecyl beta-D-isomalturonyl moiety (bottom right) attached to the amino group of the peptide (e.g., the side chain amino group of a lysine residue).

In some embodiments of the invention, the surfactant is attached to the linker amino acid U of the peptide via an amide bond.

The peptide of the peptide product may be covalently linked to one or more surfactant moieties. In certain embodiments, the peptide product has a single surfactant moiety. In other embodiments, the peptide product has two surfactant moieties, which may be the same or different. In other embodiments, the peptide product has three surfactant moieties, which may be the same or different.

The linker amino acid U can be any natural or non-natural amino acid that has a functional group suitable for covalent attachment to the surface active moiety. In some embodiments, U is a dibasic natural or non-natural amino acid (e.g., an amino acid having a side chain such as lysine or ornithine), a diacid natural or non-natural amino acid (e.g., an amino acid having a side chain carboxyl group, such as glutamic acid or aspartic acid). acid), a natural or non-natural amino acid having a thiol/sulfhydryl group (e.g. cysteine), a natural or non-natural amino acid having a hydroxyl group (e.g. serine or threonine), or a non-natural amino acid having a -N3 group, an acetylenic group, a haloacetyl group ( for example, -NHC(=O)CH ₂ Br) or --(CH ₂ ) _m -maleimide group, where m is 1-10. The haloacetyl group or maleimide group of the linker amino acid may be coupled to, for example, the thiol group of the saccharide group of the surfactant moiety, or vice versa. The azide group or alkyne group of the linker amino acid can perform a 1,3-dipolar cycloaddition with the alkyne group or azide group, respectively, of the saccharide group of the surfactant moiety, using, for example, a copper catalyst, to form a triazole. In certain embodiments, U is a lysine, ornithine (Orn), cysteine, or glutamic acid residue. As with any amino acid residue of a peptide, U may be an L- or D-amino acid.

The linker amino acid U may be an internal and/or terminal amino acid residue of the peptide. The functional group U that forms a covalent bond with the surfactant moiety may be the side chain functional group of an internal or terminal amino acid residue, or may be the alpha-amino group of an N-terminal amino acid residue or the alpha-carboxyl group of a C-terminal amino acid residue.

In some embodiments, the side chain functional groups of two amino acid residues (indicated by an asterisk), such as a lysine residue and a glutamic acid residue, of the peptide are linked to form a cyclic structure, such as lactam. The lactam formed between the functional groups of the side chain of the lysine residue and the glutamic acid residue can stabilize the α-helical structure of the peptide. The cyclic structure can also be formed by a disulfide bond between the thiol group of two cysteine residues, which can restrict conformation and promote α-helix formation. A "click reaction" between the side chain azide and alkyne groups of two non-natural amino acid residues can also form a heterocyclic structure (triazole) that restricts the conformation and stabilizes the α-helix (Le Chevalier et al., J. Peptide Sci., 15: 451-454 [2009]). In addition, side chain alkene groups of two unnatural amino acid residues can be cyclized by olefin metathesis to form a C=C double bond, which can then be reduced to a single C-C bond (Verdine and Hilinski, Meth. Enzymol., 503: 3-33 [2011 ]).

In some embodiments, the peptide products of Formula I-A comprise at least the amino acid residues aa1-aa17, aa1-aa18, aa1-aa19, or aa1-aa20 of SEQ. ID. NO. 1108. In other embodiments, the peptide products of Formula I-A include at least the amino acid residues aa1-aa27, aa1-aa28, aa1-aa29 or aa1-aa30 of SEQ. ID. NO. 1108.

In some embodiments, Formula I-A peptide products have Formula III-A:

aa ₁ -aa ₂ -aa ₃ -aa ₄ -aa ₅ -aa ₆ -aa ₇ -aa ₈ -aa ₉ -aa ₁₀ -aa ₁₁ -aa ₁₂ -aa ₁₃ -aa ₁₄ -aa ₁₅ -aa ₁₆ -aa ₁₇ -aa _18-

aa ₁₉ -aa ₂₀ -aa ₂₁ -aa ₂₂ -aa ₂₃ -aa ₂₄ -aa ₂₅ -aa ₂₆ -aa ₂₇ -aa ₂₈ -aa ₂₉ -Z Formula III-A

(SEQ ID NO 1109)

wherein:

Z is -OH or -NHR3, where R ³ is H, unsubstituted or substituted C ₁ -C ₁₂ alkyl, or a PEG-containing group of less than 10 Da;

aa1 is His, N(R ³ )His, N(Ac)His or pGlu-His;

aa2 is Ser, Ala, Gly, MePro, Aib, Ac4c or Ac5c;

aa3 is Gln or Cit;

aa4 is Gly or D-Ala;

aa5 is Thr or Ser;

aa6 is Phe, Trp, 2FPhe, MePhe, 2FMePhe or Nal2;

aa7 is Thr or Ser;

aa8 is Ser or Asp;

aa9 is Asp or Glu;

aa10 is Tyr, Leu, Met, Nal2, Bip, Bip2EtMeO, Glu, Lys, or U (X);

aa11 is absent or is Ser, Asn, Bip or U (X);

aa12 is absent or is Lys, Glu, Ser, Arg, or U (X);

aa13 is absent or is Tyr, Gln, Cit or U (X);

aa14 is absent or is Leu, Met, Nle, Glu, Lys, or U (X);

aa15 is absent or is Asp, Glu or U (X);

aa16 is absent or is Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg, or U (X);

aa17 is absent or is Arg, hArg, Gln, Glu, Lys, Cit, Aib, Ac4c, Ac5c, or U (X);

aa18 is absent or is Arg, hArg, Ala, Aib, Ac4c, Ac5c or U (X);

aa19 is absent or is Ala, Val, Aib, Ac4c, Ac5c or U (X);

aa20 is absent or is Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c, or U (X);

aa21 is absent or is Asp, Glu, Leu, Aib, Ac4c, Ac5c or U (X);

aa22 is absent or is Phe, Trp, Nal2, Aib, Ac4c, Ac5c or U (X);

aa23 is absent or is Val, Ile, Aib, Ac4c, Ac5c, or U (X);

aa24 is absent or is Ala, Gln, Glu, Cit or U (X);

aa25 is absent or is Trp, Nal2 or U (X);

aa26 is absent or is Leu or U (X);

aa27 is absent or is Met, Val, Leu, Nle, Lys, or U (X);

aa28 is absent or is Asn, Lys, Glu, Gln, or U (X);

aa29 is absent or is Thr, Gly, Aib, Ac4c, Ac5c, or U (X);

any two of aa1-aa29 may optionally be cyclized through their side chains to form a lactam; And

provided that one or at least one of aa10-aa12 and aa16-aa29 is a natural or non-natural U amino acid covalently linked to a surfactant X.

In certain embodiments, the peptide products of Formula III-A have the structure:

aa ₁ -aa ₂ -aa ₃ -aa ₄ -aa ₅ -aa ₆ -aa ₇ -aa ₈ -aa ₉ -aa ₁₀ -aa ₁₁ -aa ₁₂ -aa ₁₃ -aa ₁₄ -aa ₁₅ -aa ₁₆ -aa ₁₇ -aa _18-

aa ₁₉ -aa ₂₀ -aa ₂₁ -aa ₂₂ -aa ₂₃ -aa ₂₄ -aa ₂₅ -aa ₂₆ -aa ₂₇ -aa ₂₈ -aa ₂₉ -Z

Formula III-A (SEQ. ID. NO. 1110)

wherein:

Z is -OH or -NHR3, where R ³ is H, unsubstituted or substituted C ₁ -C ₁₂ alkyl, or a PEG-containing group of less than 10 Da;

aa1 is His;

aa2 is Aib;

aa3 is Gln;

aa4 is Gly;

aa5 is Trp;

aa6 is Phe;

aa7 is Trp;

aa8 is Ser;

aa9 - Asp;

aa10 is Tyr, Glu, Lys or U(X);

aa11 - Ser;

aa12 is Lys or Glu;

aa13 is Tyr;

aa14 is Leu, Glu or Lys;

aa15 is Asp;

aa16 is Glu or Lys;

aa17 is Gln, Glu or U(X);

aa18 is Ala;

aa19 is Ala;

aa20 is Glu, Lys or U(X);

aa21 is Glu;

aa22 is Phe;

aa23 is Ile;

aa24 is Gln, Glu or U(X);

aa25 is Trp;

aa26 represents Leu;

aa27 represents Leu;

aa28 is Glu or Gln;

aa29 is Trp;

aa10 and aa14 or aa12 and aa16 or aa16 and aa20 may optionally be cyclized through their side chains to form a lactam; And

with the proviso that one or at least one of aa10, aa17, aa20 and aa24 is a natural or non-natural U amino acid covalently linked to a surfactant X.

In further embodiments, Formula I-A peptide products have Formula III-B:

His ₁ -aa ₂ -aa ₃ -Gly ₄ -Thr ₅ -aa ₆ -Thr ₇ -Ser ₈ -Asp ₉ -aa ₁₀ -aa ₁₁ -aa ₁₂ -aa ₁₃ -aa ₁₄ -aa ₁₅ -aa ₁₆ -

aa ₁₇ -aa ₁₈ -aa ₁₉ -aa ₂₀ -aa ₂₁ -aa ₂₂ -aa ₂₃ -aa ₂₄ -aa ₂₅ -aa ₂₆ -aa ₂₇ -aa ₂₈ -aa ₂₉ -aa ₃₀ -Z

Formula III-B (SEQ. ID. NO. 1111)

wherein:

Z is -OH or -NHR ₃ where R ³ is H, unsubstituted or substituted C ₁ -C ₁₂ alkyl or a PEG-containing group of less than 10 Da;

aa2 is Gly, MePro or Aib;

aa3 is Gln or Cit;

aa6 is Phe, 2FPhe, MePhe, 2FMePhe or Nal2;

aa10 is Tyr, Nal2, Bip, Bip2EtMeO, Glu, Lys, or U(X);

aa11 is absent or is Ser, Asn, Bip or U (X);

aa12 is absent or is Lys, Glu, Ser, or U (X);

aa13 is absent or is Tyr, Gln, Cit or U (X);

aa14 is absent or is Leu, Nle, Glu, Lys, or U(X);

aa15 is absent or is Asp, Glu or U (X);

aa16 is absent or is Ser, Gly, Glu, Ala, Aib, Lys, Arg, or U (X);

aa17 is absent or is Arg, hArg, Gln, Glu, Lys, Cit, Aib, or U (X);

aa18 is absent or is Arg, hArg, Ala, Aib, Ac4c, Ac5c or U (X);

aa19 is absent or is Ala, Aib or U (X);

aa20 is absent or is Gln, Lys, Arg, Cit, Glu, Aib, or U (X);

aa21 is absent or is Asp, Glu, Leu, Aib, or U (X);

aa22 is absent or is Phe or U (X)

aa23 is absent or is Val, Ile, Aib, or U (X);

aa24 is absent or is Ala, Glu, Gln or U (X);

aa25 is absent or is Trp or U (X);

aa26 is absent or is Leu or U (X);

aa27 is absent or is Met, Val, Leu, Nle, Lys, or U (X);

aa28 is absent or is Asn, Glu, Gln, Cit or U (X);

aa29 is absent or is Thr, Aib or U (X);

aa30 is absent or is Arg or U (X);

any two of aa1-aa23 may optionally be cyclized through their side chains to form a lactam; And

with the proviso that one or at least one of aa10-aa12, aa16-aa24 and aa28 is a natural or non-natural U amino acid covalently linked to a surfactant X.

In some embodiments of the peptide products of Formula I-A, III-A or III-B:

aa2 is Gly, Aib or Ac4c; or

aa12 is lysine; or

aa14 is leucine; or

aa17 is glycine or homoarginine (hArg); or

aa17, aa18, aa20, aa24 or aa28, or any combination thereof, is a lysine attached to surfactant X; or

aa16 and aa20 cyclize through the side chains to form a lactam; or

surfactant X contains an unsubstituted or substituted dodecyl, tetradecyl, hexadecyl or octadecylalkyl group; or

any combination or all of the above.

In some embodiments, the peptide of the peptide products described herein contains one or more Aib residues at or near the N-terminus, at or near the C-terminus or within, or any combination or all of them. The Aib residue can protect the peptide from degradation by proteases such as dipeptidyl peptidase 4 (DPP-4). In certain embodiments, aa2 is Aib.

In some embodiments, the peptide products of Formulas I-A, III-A, or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ -Glu ₂₁ -Phe ₂₂ -aa ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -aa ₂₈ -

Thr ₂₉ -NH ₂

(SEQ ID NO 1126)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ser, Ala, Lys or Aib;

aa17 is Gln, Lys or U(X);

aa20 is Lys, Glu or Arg;

aa23 is Ile or Val;

aa24 is Ala, Gln or U(X);

aa27 is Met, Val or Leu; And

aa28 is Asn, Gln or U(X).

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Arg ₁₈ -Ala ₁₉ -aa ₂₀ -Asp ₂₁ -Phe ₂₂ -aa ₂₃ -aa 24 _{-Trp 25} -Leu ₂₆ -aa ₂₇ -aa ₂₈ -Thr ₂₉ -NH ₂

(SEQ ID NO 1127)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ala or Aib;

aa17 is Arg, hArg or Gln;

aa20 is U(X) [eg Lys(X)];

aa23 is Ile or Val;

aa24 is Gln or Ala;

aa27 is Leu or Val; And

aa28 is Asn or Gln.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ - aa ₁₆ -aa ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ -Glu ₂₁ -Phe ₂₂ -aa ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -aa ₂₈ -

Thr ₂₉ -NH ₂

(SEQ ID NO 774)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ser, Ala, Lys or Aib;

aa17 is Gln, Glu, Lys or U(X);

aa20 is Lys, Glu or Arg;

aa23 is Ile or Val;

aa24 is Ala, Gln or U(X);

aa27 is Met, Val or Leu; And

aa28 is Asn, Gln or U(X).

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -

Asn ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 775)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ala or Aib;

aa17 is U(X) [eg Lys(X)]; And

aa27 is Leu or Val.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Arg ₁₈ -Ala ₁₉ -aa ₂₀ -Asp ₂₁ -Phe ₂₂ -aa ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -aa ₂₈ -

Thr ₂₉ -NH ₂

(SEQ ID NO 776)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ser, Ala or Aib;

aa17 is Arg, hArg or Gln,

aa20 is Lys or U(X);

aa23 is Ile or Val;

aa24 is Ala, Gln or U(X);

aa27 is Leu or Val; And

aa28 is Asn, Gln or U(X).

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Arg ₁₈ -Ala ₁₉ -aa ₂₀ -Asp ₂₁ -Phe ₂₂ -aa ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -aa ₂₈ -

Thr ₂₉ -NH ₂

(SEQ ID NO 777)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ser, Ala or Aib;

aa17 is Arg, hArg or Gln,

aa20 is Lys or U(X);

aa23 is Ile or Val;

aa24 is Gln, Ala or U(X);

aa27 is Leu or Val; And

aa28 is Asn, Gln or U(X).

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ *-aa ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega-X) ₂₄ -Trp ₂₅ -

Leu ₂₆ -aa ₂₇ -aa ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 778)

wherein:

aa2 is Aib or Gly;

aa16* and aa20* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa17 is Arg, hArg or Gln;

aa27 is Met, Val, Leu or Nle; And

aa28 is Asn or Gln.

In some embodiments, surfactant X is 1'-alkyl beta-D-glucuronyl. In some embodiments, the alkyl group is linear C8-C20 alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Ala ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

Asn ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 779)

wherein:

aa2 is Aib or Gly;

aa16 is Glu, Ala or Aib; And

aa17 is Lys (N-omega-X).

In some embodiments, surfactant X is 1'-alkyl beta-D-glucuronyl. In some embodiments, the alkyl group is linear C8-C20 alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ -aa ₁₇ -Arg ₁₈ -Ala ₁₉ -aa ₂₀ -Asp ₂₁ -Phe ₂₂ -aa ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -aa ₂₇ -aa ₂₈ -

Thr ₂₉ -NH ₂

(SEQ ID NO 780)

(SEQ ID NO 780)

wherein:

aa2 is Gly or Aib;

aa16 is Glu, Ala or Aib;

aa17 is Arg or hArg;

aa20 is Lys (N-omega-X);

aa23 is Ile or Val;

aa24 is Gln or Ala;

aa27 is Leu or Val; And

aa28 is Asn or Gln.

In some embodiments, surfactant X is 1'-alkyl beta-D-glucuronyl. In some embodiments, the alkyl group is linear C8-C20 alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -aa ₆ -Thr ₇ -Ser ₈ -Asp ₉ -aa ₁₀ -aa ₁₁ -Z (SEQ. ID. NO. 781)

wherein:

aa2 is Gly, Aib or MePro;

aa6 is Phe, 2FPhe, MePhe or 2FMePhe;

aa10 is Tyr, Nal2, Bip, Bip2Et or Bip2EtMeO; And

aa11 is Lys (N-omega-X).

In some embodiments, surfactant X is 1'-alkyl beta-D-glucuronyl. In some embodiments, the alkyl group is linear C8-C20 alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -aa ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ -U(X) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -aa ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 795)

wherein:

aa2 is Gly or Aib; And

aa28 is Asn or Gln.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -Asp ₁₅ -aa ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega-X) ₂₄ -Trp ₂₅ -Leu 26 -Leu ₂₇ -aa _{28 -Thr 29} -NH ₂ (SEQ ID No. 796)

wherein:

aa16* and aa20* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa28 is Asn or Gln; And

surfactant X contains 1-alkyl beta-D-glucoside, 1-alkyl beta-D-maltoside, 1-alkyl beta-D-melibioside or the like, or the corresponding alpha anomer, where alkyl is linear C8 -C20-alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega-X) ₂₄ -

Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 797)

wherein:

Glu16* and Lys20* cyclize through side chains to form lactam; And

surfactant X contains 1-alkyl beta-D-glucoside, 1-alkyl beta-D-maltoside, 1-alkyl beta-D-melibioside or the like, or the corresponding alpha anomer, where alkyl is linear C8 -C20-alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -U(X) ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ *-aa ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -aa ₂₈ -

Thr ₂₉ -Z

(SEQ ID NO 1025)

wherein:

Z is -OH or -NHR3, where R ³ is H or a PEG-containing group of less than 10 Da;

aa16* and aa20* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa17 is Glu or Gln;

aa24 is Ala, Glu or Gln; And

aa28 is Asn or Gln.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe _{6 -Thr 7 -Ser 8} -Asp 9 -Tyr 10 -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -Asp ₁₅ -aa _{16 *} -U (X) ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -aa ₂₈ -Thr ₂₉ -Z (SEQ. ID. NO. 1026)

wherein:

Z is -OH or -NHR3, where R ³ is H or a PEG-containing group of less than 10 Da;

aa16* and aa20* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa24 is Ala, Glu or Gln; And

aa28 is Asn or Gln.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -aa ₁₀ *-Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -

aa ₁₄ *-Asp ₁₅ -Ser ₁₆ -aa ₁₇ -Ala ₁₈ -Ala ₁₉ -U(X) ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -aa ₂₈ -Thr ₂₉ -Z

(SEQ ID NO 1027)

wherein:

Z is -OH or -NHR3, where R ³ is H or a PEG-containing group of less than 10 Da;

aa10* and aa14* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa17 is Glu or Gln;

aa24 is Ala, Glu or Gln; And

aa28 is Asn or Gln.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -aa ₁₂ *-Tyr ₁₃ -Gln ₁₄ -

Asp ₁₅ -aa ₁₆ *-aa ₁₇ -Ala ₁₈ -Ala ₁₉ -U(X) ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -aa ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

aa ₂₈ -Thr ₂₉ -Z

(SEQ ID NO 1028)

wherein:

Z is -OH or -NHR3, where R ³ is H or a PEG-containing group of less than 10 Da;

aa12* and aa16* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa17 is Glu or Gln;

aa24 is Ala, Glu or Gln; And

aa28 is Asn or Gln.

[0127] In other embodiments, the peptide products of Formulas I-A, III-A, or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -aa ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -aa ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -U(X) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

aa ₂₈ -Thr ₂₉ -Z (SEQ. ID. NO. 1029)

wherein:

Z is -OH or -NHR3, where R ³ is H or a PEG-containing group of less than 10 Da;

aa16* and aa20* are independently Lys or Glu and cyclize through the side chains to form a lactam;

aa28 is Asn or Gln; And

surfactant X contains 1-alkyl beta-D-glucoside, 1-alkyl beta-D-maltoside, 1-alkyl beta-D-melibioside or the like, or the corresponding alpha anomer, where alkyl is linear C8 -C20-alkyl.

In other embodiments, the peptide products of Formulas I-A, III-A or III-B have the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega-X) ₂₄ -

Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -Z (SEQ. ID. NO. 1113)

wherein:

Z is -OH or -NHR3;

Glu16* and Lys20* are cyclized through side chains to form lactam; And

surfactant X contains 1-alkyl beta-D-glucoside, 1-alkyl beta-D-maltoside, 1-alkyl beta-D-melibioside or the like, or the corresponding alpha anomer, where alkyl is linear C8 -C20-alkyl.

In some embodiments, the peptide product has the structure:

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-dodecyl

beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 601);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-tetradecyl

beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 602);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-

hexadecyl beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ ID NO 603);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu ₁₆ *-Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys ₂₀ *-Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-octadecyl beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ ID NO 604);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-octyl beta-D-melibiouronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ ID NO 630);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-dodecyl beta-D-melibiouronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 631);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-tetradecyl beta-D-melibiouronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 632);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-hexadecyl beta-D-melibiouronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 633);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-octadecyl beta-D-melibiouronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 634);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys (N-omega

[1-hexadecyl alpha-D-melibiouronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 805);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp 9 _{-Tyr 10} -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -Asp ₁₅ -Glu* ₁₆ -Lys (N-omega[1-tetradecyl alpha-D-melibiouronil]) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 819);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-hexadecyl alpha-D-melibiouronyl]) ₁₇ -Ala ₁₈ -

Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 820);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-octadecyl alpha-D-melibiouronyl]) ₁₇ -

Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 821);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-dodecyl alpha-D-melibiouronyl]) ₁₇ -Ala ₁₈ -

Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-dodecyl beta-D-glucuronil]) ₂₄ -

Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 1114);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-tetradecyl alpha-D-melibiouronyl]) ₁₇ -Ala ₁₈ -

Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-tetradecyl beta-D-

glucuronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 1115);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-hexadecyl alpha-D-melibiouronyl]) ₁₇ -Ala ₁₈ -

Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-hexadecyl beta-D-

glucuronil]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂

(SEQ. ID. NO. 1116);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-(13-carboxyltridecyloxy)beta-D-

glucuronyl]) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1117);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-(15-carboxyl-pentadecyloxy) beta-D-

glucuronyl]) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1118);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Lys(N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-

glucuronyl]) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1119);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-

(13-carboxy-tridecyloxy) beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1120);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-

(15-carboxyl-pentadecyloxy) beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1121);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-

(17-carboxyl-heptadecyloxy) beta-D-glucuronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -

Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1122);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-(13-

carboxyl tridecyloxy) beta-D-melibiouronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -

Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1123);

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-(15-

carboxyl-pentadecyloxy) beta-D-melibiouronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1124); or

His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp ₉ -Tyr ₁₀ -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -

Asp ₁₅ -Glu* ₁₆ -Gln ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Lys(N-omega[1-(17-

carboxyl-heptadecyloxy) beta-D-melibiouronyl]) ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -

Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ. ID. NO. 1125); or

their pharmaceutically acceptable salt, where Glu16* and Lys20* denote residues that are cyclized through their side chains with the formation of lactam.

Additional peptide products are described in Table 1 in FIG. 1, table 2 in Fig. 2, table 3 in FIG. 3 and table 4 in FIG. 4.

Fig. 5 illustrates the X-ray crystal structure of the N-terminal/extracellular domain binding site of the GLP-1 receptor and shows the critical hydrophobic ligand-binding region (Val19*, Phe22*, Trp25* and Leu26* from exendin-4 ligand and the exendin-4 sequence beyond Glu15 interacts as an amphiphilic helix with this region). The 1-alkyl group of the surfactant component of the peptide product can enter into such a hydrophobic interaction with the GLP-1 receptor.

In some embodiments, the surfactant moiety is linked to the linker amino acid U of the peptide via a spacer. The spacer can increase the water solubility of the peptide and increase the flexibility of the peptide-surfactant attachment point. In certain embodiments, the spacer is an amino acid spacer containing one or more amino acids. In some embodiments, the presence of R ² surfactant X is an amino acid spacer used to attach to the peptide. In some embodiments, the amino acid spacer is Gly _m , Glu _{m ,} or Lys _m , where m is an integer from 1 to 10. For example, W ¹ may be -(C=O)- and R ² may be a Gly _m spacer, which attached via the carboxyl group of a terminal glycine residue, or by a Glu _m spacer that is attached via an alpha or gamma carboxyl group of a terminal glutamic acid residue to the amino side chain of a lysine residue or to the N-terminus of a peptide or R ² may be a Lys _m spacer, which connected through the carboxyl group of the terminal lysine residue to the amino group of the side chain of the lysine residue or the N-terminus of the peptide.

In other embodiments, the spacer is a hydrophilic spacer that does not contain an amino acid residue. For example, such a spacer may be where n is 1, 2, or 3. The amino group of such a spacer may be attached, for example, to the carboxyl group at the C-6 position of the saccharide of the surfactant moiety, and the carboxyl group of such a spacer may be attached, for example, to the side chain of the amino group of the amino acid (eg, lysine) residue or N-terminus of the peptide.

Three examples of attaching a surfactant moiety to a peptide via a spacer are shown below. The peptide is on top, the spacer is in the middle, and the surfactant containing the C12 alkyl group (referred to as "C12") is on the bottom. In the example on the left, the spacer is a single ornithine residue in which the carboxyl group forms an amide bond with the side chain amino group of the lysine residue of the peptide. In the example in the middle, the spacer is a single glutamic acid residue whose gamma carboxyl group forms an amide bond with the side amino group of the lysine residue of the peptide. In the example on the right, the spacer contains one glutamic acid residue.

The peptide product may optionally have one or more additional modifications. Such modifications include, but are not limited to, acylation (e.g., acetylation) at the N-terminus and attachment of a natural or synthetic polymer (e.g., a hydrophilic synthetic polymer such as polyethylene glycol [PEG], which can increase the water solubility of the peptide product) or/and lipidation (eg, acylation with a saturated or unsaturated C8-C20 fatty acid/diacid, or linkage to a steroid group containing a nucleus, such as cholesterol) at the N-terminus, C-terminus, and/or one or more side chains.

The disclosure covers analogues and variants of the peptide products described herein. Such analogs and variants include, but are not limited to, those that have a conservative substitution at one or more positions in the amino acid sequence of the particular peptide products disclosed herein. Reference to the peptide products described herein includes all pharmaceutically acceptable salts thereof.

The covalent attachment of a surfactant moiety to a peptide confers a unique combination of beneficial properties to peptide products. The hydrophobic nature of the surfactant moiety facilitates the binding of peptide-surfactant conjugates to hydrophobic carrier proteins such as human serum albumin (HSA), thereby increasing the half-life and duration of action of peptide products through multiple mechanisms, including increased protease resistance and other types of hydrolytic enzymes, decreased renal clearance, and slow release of peptide products from carrier proteins. The strong, but reversible, non-covalent binding of the hydrophobic moiety of the surfactant moiety of peptide products to the hydrophobic pocket of carrier proteins such as HSA (MW about 67 kDa) protects the peptide products from proteases (eg DPP-4) and other types of degrading enzymes, circulating in the blood and expressed on the cell surface, make the peptide products less immunogenic and increase the molecular weight of the peptide products above the filtration threshold of about 60-70 kDa, so that the peptide products avoid renal clearance through glomerular filtration into the urine. In addition, binding of peptide products to HSA increases their half-life through pH-dependent HSA recycling mediated by the neonatal Fc receptor (FcRn). In some embodiments, the peptide products have a half-life (e.g., circulating half-life and/or elimination half-life) of at least about 3 days, 1 week, 10 days, or 2 weeks (e.g., at least about 1 week).

In addition, the amphiphilic nature of the surfactant moiety containing a hydrophilic saccharide group and a hydrophobic group increases the bioavailability and duration of action of the peptide products. A portion of the surfactant moiety can disrupt the tight junction between cells in mucosal membranes, thereby facilitating penetration of peptide products across mucosal barriers. The surfactant moiety can also form micelles that can facilitate the penetration of peptide products through membranes. Moreover, the process of breaking micelles can prolong the duration of action of peptide products. A surfactant forms micelles when its concentration exceeds its critical micelle concentration (CMC), and alkyl glycosides having the same saccharide group tend to have a lower CMC the longer the alkyl chain.

With a significantly increased plasma half-life and compared to peptides not bound to a surfactant moiety, the peptide products themselves are pharmacological agents. In other words, the stable portion of the surfactant moiety remains attached to the peptide in vivo, and the intact peptide-surfactant conjugate can exhibit biological activity by binding to the main class receptor(s) of the peptide. For example, the peptide products disclosed herein may exhibit biological activity by binding to and activating the GLP-1 receptor (GLP1R) and/or the glucagon receptor (GCGR). In some embodiments, the peptide products are GLP1R/GCGR dual agonists. The activity and/or selectivity of receptor binding or activation can be finely tuned by varying the surfactant component and/or the peptide component.

Pharmaceutical compositions

The disclosure also provides pharmaceutical compositions comprising the peptide product described herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The pharmaceutical composition includes a therapeutically effective amount of the peptide product or its corresponding fraction. The composition may optionally include an additional therapeutic agent. In some embodiments, the peptide product is at least about 90%, 95%, or 98% pure.

Pharmaceutically acceptable excipients and carriers include pharmaceutically acceptable substances, materials and carrier media. Non-limiting examples of types of excipients include liquid and solid fillers, diluents, binders, lubricants, glidants, surfactants, dispersing agents, disintegrating agents, emulsifying agents, wetting agents, suspending agents, thickening agents, solvents, isotonic agents, buffers, pH adjusters, absorption delaying agents, stabilizers, antioxidants, preservatives, antimicrobial agents, antibacterial agents, antifungal agents, chelating agents, adjuvants, sweeteners, flavoring agents, colorants, encapsulating materials and coating materials. The use of such excipients in pharmaceutical formulations is known in the art. For example, common carrier media and carriers include, but are not limited to, oils (e.g., vegetable oils such as olive oil and sesame oil), aqueous solvents (e.g., saline, buffered saline (e.g., phosphate buffered saline [PBS ]) and isotonic solutions (eg, Ringer's solution)} and organic solvents (eg, dimethyl sulfoxide and alcohols [eg, ethanol, glycerol, and propylene glycol]).Except where any conventional excipient or carrier is incompatible with the peptide product, this the invention covers the use of conventional excipients and carriers in formulations containing the peptide product See, for example, Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania) (2005); Handbook of Pharmaceutical Excipients, 5th Ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical A dditives, 3rd Ed., Ash and Ash, Eds., Gower Publishing Co. (2007); and Pharmaceutical Pre-formulation and Formulation, Gibson, Ed., CRC Press (Boca Raton, Florida) (2004).

The appropriate formulation may depend on various factors such as the route of administration chosen. Potential routes of administration of a pharmaceutical composition containing a peptide product include, but are not limited to, oral, parenteral (including intradermal, subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intraperitoneal, intracavitary, and topical) and topical (including transdermal, transmucosal, intranasal ) [eg, nasal spray or drops], ocular [eg, eye drops], pulmonary [eg, oral or nasal inhalation], buccal, sublingual, rectal [eg, suppository], and vaginal [eg, using a suppository]). In some embodiments, the peptide product is administered parenterally (eg, subcutaneously, intravenously, or intramuscularly). In other embodiments, the peptide product is administered by oral inhalation or nasal inhalation or insufflation.

In some embodiments, the carrier is an aqueous carrier, such as a parenteral (eg, subcutaneous, intravenous, or intramuscular) formulation. In other embodiments, the carrier is a non-aqueous carrier. In some embodiments, the non-aqueous carrier is a hydrofluoroalkane (HFA) or HFA-like solvent which may contain submicron anhydrous α-lactose and/or other excipients such as in compositions for administration by oral inhalation or nasal inhalation or insufflation.

In some embodiments, the peptide product is administered parenterally (eg, subcutaneously, intravenously, or intramuscularly) by injection. Parenteral administration bypasses the highly acidic environment of the stomach, gastrointestinal tract (GIT) and first pass metabolism. Excipients and carriers that may be used to prepare parenteral formulations include, but are not limited to, solvents (e.g., aqueous solvents such as water, saline, saline, buffered saline [e.g., PBS], balanced salt solutions [eg Ringer's BSS] and aqueous dextrose), isotonic/isoosmotic agents (eg salts [eg NaCl, KCl and CaCl2] and sugars [eg sucrose]), buffering agents and pH adjusters (eg sodium dihydrogen phosphate [ monobasic sodium phosphate]/disodium hydrogen phosphate [dibasic sodium phosphate], citric acid/sodium citrate and L-histidine/L-histidine HCl) and emulsifiers (e.g. non-ionic surfactants such as polysorbates [e.g. polysorbate 20 and 80] and poloxamers [eg, poloxamer 188]). Peptide formulations and delivery systems are discussed, for example, in A. J. Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3rd Ed., CRC Press (Boca Raton, Florida) (2015).

The excipients may optionally include one or more substances that increase the stability of the peptide, increase the solubility of the peptide, inhibit aggregation of the peptide, or decrease the viscosity of the solution, or any combination or all of them. Such substances include, but are not limited to, hydrophilic amino acids (eg, arginine and histidine), polyols (eg, myo-inositol, mannitol, and sorbitol), saccharides (eg, glucose (including D-glucose [dextrose]), lactose, sucrose, and trehalose} osmolytes (eg, trehalose, taurine, amino acids [eg, glycine, sarcosine, alanine, proline, serine, β-alanine, and γ-aminobutyric acid] and betaines [eg, trimethylglycine and trimethylamine N-oxide]), and nonionic surfactants active substances (eg, alkyl polyglycosides, ProTek® alkyl saccharides (eg, a monosaccharide [eg, glucose] or disaccharide [eg, maltose or sucrose] linked to a long chain fatty acid or corresponding long chain alcohol) and polypropylene glycol/polyethylene glycol block copolymers (e.g., poloxamers [e.g., Pluronic TM F-68] and Genapol® PF-10 and variants thereof)} Since such substances increase the solubility of peptides, they can be used to increase the concentration of peptides in the formulation. . The higher concentration of peptide in the formulation is particularly useful for subcutaneous administration, which has a limited bolus volume (eg, ≤ about 1.5 ml). In addition, such substances can be used to stabilize peptides during preparation, storage and reconstitution of lyophilized peptides.

Examples of excipients for aqueous formulations preformed with the peptide therapeutic agent, or prepared after reconstitution of the peptide therapeutic agent in lyophilized or powder form, for parenteral (eg, subcutaneous or intravenous) administration include, but are not limited to, those shown in Table 5. Any the composition in table 5, for which sodium chloride (NaCl) is not explicitly indicated, may optionally contain NaCl. An exemplary parenteral formulation includes a peptide product, mannitol, methionine, sodium thioglycolate, polysorbate 20, a pH adjuster (eg, NaOH or/and HCl), and deionized water.

Table 5. Typical excipients for parenteral (eg, intravenous and subcutaneous) formulations

NaCl, sodium acetate and water NaCl, acetic acid, sodium acetate and water NaCl, citric acid, sodium citrate and water Mannitol, histidine, glycine and water NaCl, sucrose, mannitol, glycine, potassium dihydrogen phosphate, disodium hydrogen phosphate and water NaCl, sodium phosphate or sodium dihydrogen phosphate/disodium hydrogen phosphate, polysorbate 80 and water NaCl, sodium citrate, polysorbate 80 and water NaCl, citric acid, sodium citrate, polysorbate 80 and water NaCl, glycine, citric acid, NaOH, polysorbate 80 and water NaCl, KCl, potassium dihydrogen phosphate, disodium hydrogen phosphate, polysorbate 80, disodium edetate and water Sucrose, lactic acid, polysorbate and water NaCl, sucrose, sodium dihydrogen phosphate, disodium hydrogen phosphate, polysorbate 20 or 80 and water NaCl, sucrose, citric acid, sodium citrate, polysorbate 80 and water NaCl, sucrose, glycine, citric acid, sodium citrate, polysorbate 80 and water NaCl, trehalose, sodium phosphate, polysorbate 20 and water NaCl, trehalose, citric acid, sodium citrate, polysorbate 80 and water NaCl, mannitol, sodium dihydrogen phosphate/disodium hydrogen phosphate or/and citric acid/sodium citrate, polysorbate 80 and water and optionally NaOH for pH adjustment NaCl, mannitol, sodium citrate, polysorbate 80, pentetic acid and water, and optionally HCl and/or NaOH for pH adjustment NaCl, Mannitol, Tris HCl, Polysorbate 80, Pentetic Acid and Water Mannitol or sorbitol, acetic acid, NaOH, polysorbate 20 and water NaCl, sucrose, L-histidine, polysorbate 80 and water and optionally HCl and/or NaOH for pH adjustment NaCl, sucrose, L-histidine, acetic acid, polysorbate 20 and water Sucrose, L-Histidine, L-Histidine HCl, Polysorbate 20 or 80, and Water Trehalose, L-Histidine, L-Histidine HCl, Polysorbate 20 and Water NaCl, trehalose, L-histidine, L-histidine HCl, poloxamer 188 and water Trehalose, L-histidine, L-histidine HCl, polysorbate 20 and water and optional bacteriostat (e.g. benzyl alcohol) Trehalose, L-Histidine, L-Histidine HCl, L-Methionine, Polysorbate 80 and Water Sorbitol, L-Histidine, L-Histidine HCl, Polysorbate 80 and Water NaCl, glycine, L-histidine, L-histidine HCl, polysorbate 80 and water NaCl, sucrose, L-arginine HCl, L-histidine, L-histidine HCl, polysorbate 80 and water Sucrose, sodium acetate, optionally acetic acid, L-arginine HCl, L-histidine, polysorbate 80 and water L-Arginine, L-Arginine HCl, L-Histidine, L-Histidine HCl, L-Methionine, Polysorbate 80 and Water Proline, glutamate, polysorbate 20 and water propylene glycol, phenol, disodium hydrogen phosphate and water and optionally HCl and/or NaOH for pH adjustment NaCl, sucrose or maltose, sodium dihydrogen phosphate and water Sucrose, sodium dihydrogen phosphate, disodium hydrogen phosphate, poloxamer 188 and water NaCl, sucrose, sodium phosphate, L-arginine HCl and water Sucrose, glycine, L-arginine HCl, L-histidine, L-histidine HCl, PEG 3350 and water Mannitol, trehalose, sodium phosphate, polysorbate 80 and water Mannitol, citric acid, trisodium citrate, polysorbate 80 and water NaCl, CaCl2, sucrose, L-histidine, polysorbate 20 and water Sucrose, mannitol, L-histidine, HCl, polysorbate 20 and water NaCl, sucrose, mannitol, L-histidine, HCl, NaOH, polysorbate 20 and water

For parenteral (e.g., subcutaneous, intravenous, or intramuscular) administration, a sterile solution or suspension of the peptide product in an aqueous vehicle containing one or more excipients may be prepared in advance and may be provided, for example, in a pre-filled syringe of a disposable pen or syringe. pens with a dose counter. Alternatively, the peptide product may be dissolved or suspended in an aqueous solvent, which may optionally contain one or more excipients prior to lyophilization (freeze drying). Shortly before parenteral administration, the lyophilized peptide product stored in a suitable container (eg vial) may be reconstituted with, for example, sterile water, which may optionally contain one or more excipients.

In other embodiments, the peptide product is administered intranasally. The nasal mucosa provides a large surface area, porous endothelium, a highly vascular subepithelial layer, and a high rate of absorption and therefore provides high bioavailability. The intranasal composition may contain a peptide product along with excipients such as a solubility enhancer (e.g. propylene glycol), a humectant (e.g. mannitol or sorbitol), a buffer and water, and optionally a preservative (e.g. benzalkonium chloride), a mucoadhesive agent (e.g. hydroxyethyl cellulose) or/and penetration enhancer. The intranasal solution or suspension preparation can be administered to the nasal cavity by any suitable means, including but not limited to a dropper, pipette or spray, for example, using a metered spray pump. Table 6 lists typical excipients for nasal spray formulations.

Table 6. Typical excipients and carriers for nasal and pulmonary formulations

Dosage form Ingredients in addition to the peptide product nasal spray microcrystalline cellulose, sodium carboxymethyl cellulose, dextrose, water and possibly a pH regulator (eg HCl) nasal spray microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, polysorbate 80, disodium edetate, potassium sorbate, pH adjuster (eg HCl), water and possibly alcohol (eg ethanol) nasal spray microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, polysorbate 80, benzalkonium chloride, phenylethyl alcohol, water, and possibly an alcohol (eg, ethanol) nasal spray hypromellose, benzalkonium chloride, NaCl, EDTA, citric acid, dibasic sodium phosphate, water and possibly an alcohol (eg ethanol) inhalation
(DPI) mannitol, glycine, sodium citrate and NaOH inhalation
(DPI) lactose, starch, a starch derivative (eg hydroxypropylmethylcellulose) or polyvinylpyrrolidine and optionally magnesium stearate or leucine. inhalation
(MDI) propellant (eg 1,1,1,2-tetrafluoroethane), surfactant (eg lecithin or oleic acid) and co-solvent (eg ethanol) inhalation
(spray) polysorbate 80, disodium edetate, sodium chloride, pH buffering agents (eg, citric acid/sodium citrate), and water

In other embodiments, the peptide product is administered to the lungs, for example, by oral or nasal inhalation. A drug administered to the lungs can treat a lung disorder or a systemic disorder because the lungs serve as a portal to the systemic circulation. The benefits of pulmonary drug delivery include, for example: 1) prevention of first pass metabolism; 2) fast drug action; 3) large surface area of the alveolar region for absorption, high lung permeability (thin air-blood barrier) and abundant airway vasculature; and 4) reduced levels of extracellular enzyme compared to the gastrointestinal tract due to the large alveolar surface area. The advantage of oral inhalation over nasal inhalation includes a deeper penetration/deposition of the drug into the lungs, although nasal inhalation can deliver the drug into the systemic circulation through the mucosa in the nasal cavity as well as in the lungs.

Oral or nasal inhalation can be carried out, for example, using a metered dose inhaler (MDI), nebulizer or dry powder inhaler (DPI). For example, the peptide product may be formulated for aerosol administration to the respiratory tract by oral or nasal inhalation. The drug is delivered in a small particle size (eg, about 0.5 micron to about 5 micron), which can be obtained by micronization to improve, for example, drug deposition in the lungs and drug suspension stability. The drug may be supplied in a pressure pack with a suitable propellant such as hydrofluoroalkane (HFA, e.g. 1,1,1,2-tetrafluoroethane [HFA-134a]), chlorofluorocarbon (CFC, e.g. dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane), or a suitable gas (for example, oxygen, compressed air or carbon dioxide). The aerosolized drug is dissolved or more commonly suspended in a propellant for delivery to the lungs. The aerosol may contain excipients such as a surfactant (which improves pulmonary penetration by reducing high surface tension forces at the air-water interface within the alveoli, may also emulsify, solubilize and/or stabilize the drug, and may, for example, present is a phospholipid such as lecithin) and/or a stabilizer, although the surfactant portion of the peptide product may function as a surfactant. For example, an MDI formulation may include a peptide product, a propellant (for example, an HFA such as 1,1,1,2-tetrafluoroethane) and a co-solvent (for example, an alcohol such as ethanol), and optionally a surfactant (for example, fatty acid such as oleic acid). The MDI composition may optionally include a dissolved gas (eg, CO ₂ ). Upon actuation of the device, the explosion of CO ₂ bubbles within the emitted aerosol droplets breaks the droplets into smaller droplets, thereby increasing the respirable fraction of the drug. As another example, the nebulizer composition may include a peptide product, a chelator or preservative (eg, disodium edetate), an isotonicity agent (eg, NaCl), pH buffering agents (eg, citric acid/sodium citrate), and water, and optionally a surfactant. active agent (eg Tween® such as polysorbate 80). The drug can be delivered using, for example, a nebulizer or MDI with or without a spacer, and the dose of drug delivered can be controlled by a metering chamber (nebulizer) or a metering valve (MDI). Table 6 lists typical MDI, nebulizer, and DPI formulations.

Metered dose inhalers (also called pressurized metered dose inhalers [pMDI]) are the most widely used inhalation devices. The metering valve delivers a precise amount of aerosol (eg, about 20-100 µl) each time the device is turned on. MDIs typically generate aerosol faster than the user can inhale, which can result in a significant amount of aerosol being deposited in the mouth and throat. The problem of poor coordination between actuation of the device and its inhalation can be solved by using, for example, a breath-actuated MDI or a coordinating device. A breath-actuated MDI (eg, Easibreathe®) is activated when the device senses the user's inhalation and delivers a dose of medication in response. The inhalation flow rate is coordinated through the actuator and the user has time to reliably activate the device during inhalation. In a coordinating device, a spacer (or valve holding chamber), which is a tube attached to the end of the mouthpiece of the inhaler, serves as a reservoir or chamber that contains the medicine that is nebulized by the inhaler and reduces the rate at which the aerosol enters the mouth, thereby allowing evaporation of propellant from larger droplets. The spacer makes it easier to use the inhaler and increases the amount of drug deposited in the lungs instead of the upper airways. The spacer may be made from an antistatic polymer to minimize the electrostatic adhesion of emitted drug particles to the interior walls of the spacer.

Nebulizers generate aerosol droplets about 1-5 microns in size. They do not require user coordination between device activation and inhalation, which can significantly affect the amount of drug deposited in the lungs. Compared to MDI and DPI, nebulizers can deliver large doses of drug, albeit for a longer time. Examples of nebulizers include, but are not limited to, human powered nebulizers, jet nebulizers (e.g. AeroEclipse® II BAN [breath actuated], CompAIRTM NE-C801 [virtual valve], PARI LC® Plus [increased breathing], and SideStream Plus [breath-advanced]), ultrasonic wave nebulizers, and vibrating mesh nebulizers (eg, Akita2® Apixneb, I-neb AAD system with measurement chambers, MicroAir® NE-U22, Omron U22, and PARI eFlow® rapid). For example, a pulsed ultrasonic nebulizer may nebulize a fixed amount of medication per pulse and may contain an optoacoustic trigger that allows the user to synchronize each breath with each pulse.

For oral or nasal inhalation using a dry powder inhaler (DPI), the peptide product may be provided in the form of a dry micronized powder, where the drug particles have a certain small size (e.g., about 0.5 micron to about 5 micron) to improve, for example , aerodynamic properties of the dispersed powder and drug deposition in the lungs. Particles ranging in size from 0.5 to 5 microns are deposited by sedimentation in the terminal bronchioles and alveolar regions. In contrast, most larger particles (>5 microns) do not follow the airflow into many airway bifurcations, but rather are deposited by impacts in the upper airways, including the oropharyngeal region of the throat. The DPI formulation may include drug particles alone or mixed with a suitable larger base/carrier powder such as lactose, starch, a starch derivative (eg, hydroxypropyl methylcellulose), or polyvinylpyrrolidine. Carrier particles improve flow, reduce aggregation, improve dose uniformity, and promote dispersion of drug particles. The DPI composition may optionally include an excipient, such as magnesium stearate or leucine, which enhances the performance of the composition by inhibiting interparticle binding (due to the anti-adhesion effect). The powder composition may be provided in unit dose form, such as a capsule (eg, gelatin capsule) or blister cartridge, which can be manually loaded or pre-loaded into an inhaler. The drug particles can be drawn into the lungs by placing the mouthpiece or the inhaler nose into the mouth or nose, taking a sharp deep breath to create turbulent airflow, and holding the breath for a while (for example, about 5-10 seconds) to allow the drug particles to settle in bronchioles and alveolar regions. When the user activates the DPI and inhales, the air flow through the device creates shear and turbulence, the inhaled air is introduced into the powder bed and the static powder mixture fluidizes and enters the user's airways. There, the drug particles separate from the carrier particles due to turbulence and are transported deep into the lungs, while the larger carrier particles impact the oropharyngeal surfaces and are cleared. Thus, the user's inhaled airflow provides deagglomeration and air ionization of the powder and determines the deposition of the drug in the lungs. (Although passive DPI requires fast inhaled airflow to deagglomerate drug particles, fast inhalation is not recommended when using an MDI or nebulizer because it creates turbulent airflow and rapid velocity that increase drug deposition at the expense of entry into the upper respiratory tract.) Compared to MDI, DPI (including breath-activated DPI) may be able to deliver large doses of drugs and drugs of large size (eg, macromolecules) to the lungs.

Lactose (eg, alpha-lactose monohydrate) is the most commonly used carrier in DPI formulations. Example categories/types of lactose monohydrate for DPI formulations include, but are not limited to, DCL 11, Flowlac® 100, Inhalac® 230, Lactohale® 300, Lactopress® SD 250 (spray-dried lactose), Respitose® SV003, and Sorbolac® 400. Composition The DPI may include a single lactose grade or a combination of different lactose grades. For example, finely ground lactose such as Lactohale® 300 or Sorbolac® 400 may not be a suitable DPI carrier and may need to be mixed with coarsely ground lactose such as DCL 11, Flowlac® 100, Inhalac® 230 or Respitose® SV003 (e.g. , in a ratio of about 1:9 of finely divided lactose and coarsely divided lactose) to improve fluidity. Tables 7 and 8 provide non-limiting examples of categories/types of lactose that can be used in DPI formulations. The particle size distribution of the carrier affects the fine particle fraction/dose (FPF or FPD) of the drug, with a high FPF being desirable for drug delivery to the lungs. FPF/FPD is the fraction/dose respirable mass from the DPI device with an aerodynamic particle size of ≤ 5 microns in the inspiratory air. High FPF and hence good DPI performance can be obtained, for example, from DPI formulations having a 1:9 ratio of finely ground lactose (eg Lactohale® 300) to coarsely ground lactose (eg Respitose® SV003) and about 20 wt. ./mass to prevent drug deposition in the capsule shell or DPI device and to deliver substantially all of the drug to the respiratory tract.

Table 7

Product Type Particle size range (µm) 10% 50% 90% Lactohale® LH200 <9 <69 <141 InhaLac® 230 <35 <93 <138 Respitose® ML001 <4 <43 <146 ML003 <4 <35 <106 SV003 <30 <59 <90 SV004 <32 <61 <93

Table 8

Product Type Particle size range <45 µm <100 µm <150 µm <250 µm Respitose® ML003 65% 98% 100% Not available Respitose® ML002 65% 98% Not available 100%

Other carriers for DPI formulations include, but are not limited to, glucose, mannitol (eg, crystallized mannitol [Pearlitol 110 C] and spray dried mannitol [Pearlitol 100 SD]), maltitol (eg, crystallized maltitol [Maltisorb P90]), sorbitol, and xylitol .

Most DPIs are breath-activated ("passively"), relying on the user's inhalation to generate an aerosol. Examples of passive DPIs include but are not limited to Airmax®, Novolizer® and Otsuka DPI (compact cake). Air Classification Technology (ACT) is an efficient passive powder dispersion mechanism used in DPI. In ACT, multiple delivery channels generate a tangential airflow, which results in a vortex inside the device during inhalation. There are also active ("active") DPIs (based on e.g. pneumatics, shock or vibration force) which use energy to aid e.g. particle deagglomeration. For example, the active mechanism of Exubera® inhalers uses mechanical energy stored in compressed air sources or chambers. Examples of active DPIs include, but are not limited to, Actispire® (single standard dose), Aspirair® (multiple standard dose), Exubera® (single standard dose), MicroDose® (multiple standard dose and electronically activated), Omnihaler® (single standard dose). dose), Pfeiffer DPI (single standard dose) and Spiros® (multiple standard dose).

The peptide product can also be administered by other routes, such as orally. The oral composition may include a peptide product and conventional excipients known in the art, and optionally an absorption enhancer such as sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC). SNAC protects against enzymatic degradation through local buffering and enhances GI absorption. An oral dosage form (eg, tablet, capsule, or pill) may optionally be enteric-coated to protect its contents from the strong acids and proteolytic enzymes of the stomach.

In some embodiments, the peptide product is delivered from a sustained release composition. As used herein, the term "sustained release composition" encompasses sustained release, sustained release, sustained release, sustained release, and controlled release compositions, systems, and devices. In some embodiments, the sustained release composition delivers the peptide product over a period of at least about 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, or longer.

In some embodiments, the sustained release composition is formulated as nanoparticles or microparticles consisting of a biodegradable polymer and including a peptide product. In some embodiments, the biodegradable polymer comprises lactic acid and/or glycolic acid [e.g., an L-lactic acid copolymer such as poly(L-lactide-co-glycolide) or poly(L-lactic acid-co-D, L- 2-hydroxyoctanoic acid).

In other embodiments, the sustained release composition is in the form of a depot that is formed when the mixture of the peptide product and polymer is administered intramuscularly or subcutaneously to a subject. In some embodiments, the polymer is or contains PEG, polylactic acid (PLA) or polyglycolic acid (PGA), or a copolymer thereof (eg, PLGA or PLA-PEG).

The pharmaceutical composition may be presented in unit dosage form as a unit dose in which all active and inactive ingredients are combined in a suitable system and the components do not need to be mixed to form a composition for administration. A unit dosage form will typically contain a therapeutically effective dose of the drug, but may contain an appropriate portion of it so that a therapeutically effective dose is achieved when multiple unit dosage forms are taken. Examples of unit dosage form include tablet, capsule or pill for oral administration; solution in a pre-filled disposable pen-syringe or pen-syringe with a dose counter for parenteral (eg, intravenous, subcutaneous or intramuscular) administration; and a capsule, cartridge or blister, pre-loaded into the inhaler or manually loaded.

Alternatively, the pharmaceutical composition may be presented as a kit in which the active ingredient, excipients and carriers (e.g. diluents) are supplied in two or more separate containers (e.g. ampoules, vials, tubes, bottles or syringes) and must be combined to form a composition for administration. The kit may include instructions for storing, preparing, and administering the composition (eg, parenteral solution).

A kit may include all active and inactive ingredients in unit dosage form, or the active ingredient and inactive ingredients in two or more separate containers, and may include instructions for administering or using a pharmaceutical composition for the treatment of a medical condition disclosed herein. The kit may further include a device for delivering the composition, such as an injection pen or an inhaler.

In some embodiments, the kit contains a peptide product, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing it, and instructions for administering or using the peptide product or composition for the treatment of a medical condition disclosed herein, such as insulin resistance, diabetes, obesity, metabolic syndrome, or heart disease. - vascular disease or condition associated with it (for example, NASH or PCOS). In certain embodiments, the kit further comprises a device for delivering the peptide product or composition, such as an injection pen or inhaler.

Therapeutic applications of peptide products

The disclosure further provides for the use of the peptide products described herein for the treatment of, for example, insulin resistance, diabetes, obesity, metabolic syndrome, and cardiovascular disease and related conditions such as NASH and PCOS.

In some embodiments, the peptide products are used to treat hyperglycemia, insulin resistance, hyperinsulinemia, prediabetes, diabetes (including types 1 and 2, gestational and juvenile diabetes), diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, blood free fatty acids, obesity, metabolic syndrome, syndrome X, cardiovascular disease (including coronary heart disease), atherosclerosis, acute cardiovascular syndrome, ischemia (including myocardial ischemia and cerebral ischemia/stroke), ischemia-reperfusion injury (including myocardial and cerebral infarction), infarction (including myocardial and cerebral infarction), angina pectoris, heart failure (eg, congestive heart failure), peripheral vascular disease, thrombosis (eg, deep vein thrombosis), embolism (eg, emboli pulmonary artery i), systemic inflammation (eg, characterized by elevated levels of C-reactive protein in the blood), and hypertension. Peptide products may achieve their therapeutic effects through a variety of mechanisms, including stimulation of glucose-dependent insulin secretion in the blood, increased insulin sensitivity, stimulation of fat burning, and weight loss. Peptide products may also contribute to, for example, pancreatic beta cell protection, cardioprotection, and wound healing.

The peptide products described herein can be used to treat other conditions associated with insulin resistance and/or obesity. Other conditions associated with insulin resistance and/or obesity include, but are not limited to, arthritis (eg, osteoarthritis), low back pain, respiratory disorders (eg, asthma, obesity hypoventilation syndrome [Pickwickian's syndrome], and obstructive sleep apnea), dermatological disorders (eg, diabetic) ulcers, acanthosis nigricans, cellulitis, hirsutism, diaper rash, and lymphedema), gastroenterological disorders (eg, cholelithiasis [gallstone], gastroesophageal reflux disease [GERD], and gastroparesis), gout, hypercortisolism (eg, Cushing disease) kidney disease (eg, chronic kidney disease), liver disease (eg, fatty liver disease [FLD], including alcoholic and non-alcoholic FLD), neurological disorders (eg, carpal tunnel syndrome, dementias [eg, Alzheimer's disease and vascular dementia) , meralgia paresthetica, migraines and multiple sclerosis), urological disorders (eg, erectile dysfunction, hypogonadism, and urinary incontinence), polycystic ovary syndrome, infertility, menstrual disorders, mood disorders (eg, depression), and cancers (eg, cancer of the endometrium, esophagus, colon, gallbladder, kidney, liver [eg, hepatocellular carcinoma] , pancreas, and skin [eg, melanoma] and leukemia).

In certain embodiments, the peptide product described herein is used to treat polycystic ovary syndrome (PCOS). In other embodiments, the peptide product is used to treat chronic kidney disease (CKD), also known as chronic kidney/renal failure (CKF/CRF). The most common causes of CKD are diabetes and long-term uncontrolled hypertension.

In other embodiments, the peptide product described herein is used to treat fatty liver disease (FLD). In some embodiments, the FLD is non-alcoholic fatty liver disease (NAFLD). In certain embodiments, NAFLD is non-alcoholic steatohepatitis (NASH). FLD, also known as hepatic steatosis, is characterized by excessive accumulation of fat in the liver. FLD includes alcoholic fatty liver disease (AFLD) and NAFLD. Chronic alcoholism causes fatty liver due to the production of toxic metabolites such as aldehydes during the metabolism of alcohol in the liver. NAFLD is described below. FLD is associated with diabetes, obesity, and metabolic syndrome. Fatty liver can develop into cirrhosis or liver cancer (eg, hepatocellular carcinoma [HCC]). Less than 10% of people with AFLD cirrhosis develop HCC, but about 45% of people with NASH without cirrhosis may develop HCC. HCC is the most common type of primary liver cancer in adults and occurs when the liver becomes chronically inflamed.

NAFLD is characterized by fatty liver, which occurs when fat, specifically free fatty acids and triglycerides, accumulates in liver cells (hepatic steatosis) due to causes other than excessive alcohol consumption such as nutrient overload, high calorie intake, and metabolic dysfunction (eg, dyslipidemia and impaired glucose control). The liver can remain fatty without impairing liver function, but fatty liver can progress to NASH, a condition in which steatosis is accompanied by inflammation, hepatocyte ballooning, and cell damage with or without liver fibrosis. Fibrosis is the strongest predictor of NASH mortality. NAFLD may be characterized by steatosis alone; steatosis with lobular or portal inflammation but no bloat; steatosis with swelling but no inflammation; or steatosis with inflammation and swelling.

NASH is the most extreme form of NAFLD. NASH is a progressive disease, approximately 20% of patients develop cirrhosis of the liver and approximately 10% die from liver disease such as cirrhosis or liver cancer (eg, HCC). NAFLD is the most common liver disease in developed countries, and NASH is projected to replace hepatitis C as the leading cause of liver transplant in the US by 2020. About 12-25% of US residents have NAFLD, with NASH affecting about 2-5% of people in the US.

NAFLD, including NASH, is associated with insulin resistance, obesity, and metabolic syndrome. For example, insulin resistance contributes to the progression of fatty liver disease, liver inflammation and fibrosis, and hence NASH. In addition, obesity stimulates and exacerbates NASH, and weight loss may alleviate NASH. Therefore, the peptide products described herein, including GLP-1 receptor (GLP1R) agonists, glucagon receptor (GCGR) agonists, and GLP1R/GCGR dual agonists, can be used to treat NAFLD, including NASH.

In some embodiments, peptide products used to treat the condition associated with insulin resistance and/or obesity disclosed herein, such as NAFLD (eg, NASH) or PCOS, are selected from SEQ peptide products. ID. NOs. 601 602 603 604 630 631 632 633 634 805 819 820 821 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 11.2 and their pharmaceutically acceptable salts.

The peptide product may be administered by any suitable route for the treatment of the condition disclosed herein. Potential routes of administration of the peptide product include, but are not limited to, oral, parenteral (including intradermal, subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intraperitoneal, intracavitary, and topical) and topical (including transdermal, transmucosal, intranasal [e.g., by nasal spray or drop], ophthalmic [eg, eye drop], pulmonary [eg, by oral or nasal inhalation], buccal, sublingual, rectal [eg, via suppository], and vaginal [eg, via suppository]). In some embodiments, the peptide product is administered parenterally, such as subcutaneously, intravenously, or intramuscularly. In other embodiments, the peptide product is administered by oral inhalation or nasal inhalation or insufflation.

The therapeutically effective amount and frequency of administration and duration of treatment with a peptide product for the treatment of the condition disclosed herein may depend on various factors, including the nature and severity of the condition, the potency of the compound, the route of administration, age, body weight, general health, sex, and diet. the subject and the subject's response to treatment, and may be determined by the attending physician.

In some embodiments, the peptide product is administered parenterally (e.g., subcutaneously [sc], intravenously [i.v.], or intramuscularly [im]) at a dose of from about 0.1 mg to about 1.5 or 10 mg or about 0.1-1 mg or 1-10 mg over a period of about one week for the treatment of a condition disclosed herein (eg, a condition associated with insulin resistance and/or obesity such as NASH or PCOS). In other embodiments, the peptide product is administered parenterally (eg, subcutaneously, intravenously, or intramuscularly) at a dose of about 0.1-0.5 mg, 0.5-1 mg, 1-5 mg, or 5-10 mg over a period of about one week. . In some embodiments, the peptide product is administered parenterally (eg, subcutaneously, intravenously, or intramuscularly) at a dose of about 0.1-1 mg or about 0.1-0.5 mg or 0.5-1 mg over a period of about one week.

The peptide product may be administered at any suitable frequency for the treatment of a condition disclosed herein (eg, one associated with insulin resistance and/or obesity, such as NASH or PCOS). In some embodiments, the peptide product is administered, for example, subcutaneously or intravenously once a day, once every two days, once every three days, twice a week, once a week, or once every two weeks. In some embodiments, the peptide product is administered, for example, subcutaneously or intravenously once a week.

The peptide product can be administered at any time of day convenient for the patient. The peptide product can be taken substantially with a meal (for example, with a meal, or within about 1 hour or 30 minutes before or after a meal) or substantially without a meal (for example, at least about 1 or 2 hours before or after a meal ).

The duration of treatment of a medical condition with a peptide product may be based on, for example, the nature and severity of the condition and the subject's response to treatment, and may be determined by the attending physician. In some embodiments, the peptide product is administered on a long-term basis to treat a condition disclosed herein, such as at least about 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 3 years, 5 years, 10 years or longer. The peptide product may also be taken proportionately (as needed) until the clinical manifestations of the condition resolve or clinical goals such as blood glucose, blood pressure, blood lipids, body weight or body mass index, ratio are met. waist and hip circumferences or body fat percentage, or any combination thereof. If clinical manifestations of the condition reappear or clinical goals are not maintained, administration of the peptide product may be resumed.

The disclosure of the invention provides a method for treating a medical condition described herein, comprising administering to an object in need of treatment a therapeutically effective amount of a peptide product described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing it. The disclosure of the invention further provides the peptide product described herein, or a pharmaceutically acceptable salt or composition containing it, for use as a medicine. In addition, the present invention contemplates the use of the peptide product described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament. The drug containing the peptide product can be used to treat any medical condition described in this document. The peptide product may optionally be used in combination with one or more additional therapeutic agents.

Combination Therapies

The peptide product described herein can optionally be used in combination with one or more additional therapeutic agents for the treatment of any disorder disclosed herein, such as insulin resistance, diabetes, obesity, metabolic syndrome, or cardiovascular disease, or any condition associated with them, for example, NASH or PCOS. In some embodiments, one or more additional therapeutic agents are selected from anti-diabetic agents, anti-obesity agents (including lipid-lowering agents and satiety-promoting agents), anti-atherosclerotic agents, anti-inflammatory agents, antioxidants, anti-fibrotic agents, anti-hypertensive agents, and combinations thereof.

Antidiabetic agents include, but are not limited to:

AMP-activated protein kinase (AMPK) agonists, including biguanides (eg, buformin and metformin);

peroxisome proliferator-activated receptor (PPAR-γ) agonists, including thiazolidinediones (eg, balaglitazone, siglitazone, darglitazone, englitazone, lobeglitazone, netoglitazone, pioglitazone, rivoglitazone, rosiglitazone, and troglitazone) and saroglitazar (dual PPAR-α/γ agonist) ;

glucagon-like peptide-1 (GLP-1) receptor agonists, including exendin-4, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, taspoglutide, CNTO736, CNTO3649, HM11260C (LAPS-exendin), NN9926 (OG9S7GT), TT401 and ZY0G401 ;

dipeptidyl peptidase 4 (DPP-4) inhibitors including alogliptin, anagliptin, dutogliptin, evogliptin, gemigliptin, gosogliptin, linagliptin, omarigliptin, saxagliptin, septagliptin, sitagliptin, teneligliptin, trelagliptin and vildagliptin;

sodium glucose transport protein 2 (SGLT2) inhibitors including canagliflozin (also inhibits SGLT1), dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, sotagliflozin (also inhibits SGLT1), and tofogliflozin;

ATP-dependent K+ (KATP) channel blockers on pancreatic beta cells, including meglitinides (eg, mitiglinide, nateglinide, and repaglinide) and sulfonylurea {including first generation (eg, acetohexamide, carbutamide, chlorpropamide, glycylamide [tolhexamide], metahexamide, tolazamide and tolbutamide) and second generation (e.g. glibenclamide [glyburide], glibornuride, gliclazide, glimepiride, glipizide, glycidone, glisoxepide and gliclopyramide)};

insulin and analogues thereof, including rapid-acting insulin (eg, insulin aspart, insulin glulisine, and insulin lispro), intermediate-acting insulin (eg, NPH insulin), and long-acting insulin (eg, insulin degludec, insulin detemir, and insulin glargine); And

their analogues, derivatives and salts.

In some embodiments, the antidiabetic agent is or includes a biguanide (eg, metformin), a thiazolidinedione (eg, pioglitazone or rosiglitazone), or an SGLT2 inhibitor (eg, empagliflozin or tofogliflozin), or any combination thereof.

Anti-obesity agents include, but are not limited to:

appetite suppressants (anorectics), including amphetamine, dexamphetamine, amfepramone, clobenzorex, mazindol, phentermine (with or without topiramate), and lorcaserin;

satiety-promoting agents, including ciliary neurotrophic factor (eg, axokine) and long-acting analogs of amylin, calcitonin, cholecystokinin (CCK), GLP-1, leptin, oxyntomodulin, pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY);

lipase inhibitors including caulerpenin, cetilistat, ebelactone A and B, esterastin, lipstatin, orlistat, perciquinin, panclicin A-E, valilactone and vibralactone;

antihyperlipidemic agents; And

their analogues, derivatives and salts.

Antihyperlipidemic agents include, but are not limited to:

HMG-CoA reductase inhibitors, including statins (eg, atorvastatin, cerivastatin, fluvastatin, mevastatin, monacolins (eg, monacolin K [lovastatin]), pitavastatin, pravastatin, rosuvastatin, and simvastatin} and flavanones (eg, naringenin);

squalene synthase inhibitors including lapaquistat, saragosinic acid, and RPR-107393;

acetyl-CoA carboxylase (ACC) inhibitors including anthocyanins, avenaciolides, chloroacetylated biotin, cyclodim, diclofop, haloxyfop, sorafenes (e.g. soraphene A1α), 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA), CP-64, 64-0976, NDI-010976; 7-(4-propyloxyphenylethynyl)-3,3-dimethyl-3,4-dihydro-2H-benzo[b][1,4]dioxepin; N-ethyl-N'-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]deca-7-yl)piperidin-1-yl]carbonyl}- 1-benzothien-2-yl) urea; 5-(3-acetamidobut-1-ynyl)-2-(4-propyloxyphenoxy)thiazole; and 1-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]deca-7-yl)piperidin-1-yl]carbonyl}-5-(pyridine -2-yl)-2-thienyl)-3-ethyl-urea;

PPAR-α agonists, including fibrates (eg, bezafibrate, ciprofibrate, clinofibrate, clofibric acid, clofibrate, aluminum clofibrate [alfibrate], clofibride, etofibrate, fenofibric acid, fenofibrate, gemfibrozil, ronifibrate, and simfibrate), isoflavones (eg, daidzein and genistein ) and perfluoroalkanoic acids (eg perfluorooctanoic acid and perfluoronanoic acid);

PPAR-δ agonists including elafibranor (dual PPAR-α/δ agonist), GFT505 (dual PPAR-α/δ agonist), GW0742, GW501516 (dual PPAR-/δ agonist), sodelglitazar (GW677954), MBX-8025 and isoflavones (e.g. daidzein and genistein); β

PPAR-γ agonists, including thiazolidinediones (above), saroglitazar (dual PPAR-α/γ agonist), 4-oxo-2-thioxothiazolines (eg, rhodanine), berberine, honokiol, perfluoronanoic acid, cyclopentenone-15-prostaglandins (eg, deoxy-Δ-prostaglandin J2 [15d-PGJ2]) and isoflavones (eg daidzein and genistein);

Liver X receptor (LXR) agonists, including endogenous ligands (eg, oxysterols such as 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 27-hydroxycholesterol, and cholestenic acid) and synthetic agonists (eg, acetyl-podocarpic dimer , hypocholamide, N,N-dimethyl-3β-hydroxycholenamide [DMHCA], GW3965 and T0901317);

retinoid X receptor (RXR) agonists, including endogenous ligands (eg, 9-cis-retinoic acid) and synthetic agonists (eg, bexarotene, AGN 191659, AGN 191701, AGN 192849, BMS649, LG100268, LG100754 and LGD346);

acyl-CoA cholesterol acyltransferase (ACAT, also known as sterol-O-acyltransferase [SOAT], including ACAT1 [SOAT1] and ACAT2 [SOAT2]) inhibitors, including avazimibe, pactimib, pellitorin, terpendol C, and flavanones (eg, naringenin );

inhibitors of stearoyl-CoA desaturase-1 (SCD-1, or stearoyl-CoA delta-9 desaturase) activity or expression, including aramchol, CAY-10566, CVT-11127, SAR-224, SAR-707, XEN-103; 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3- trifluoromethylbenzyl)thiazol-2-yl]benzamide; 1'-{6-[5-(pyridin-3-yl-methyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[ chromene-2,4'-piperidine]; 5-fluoro-1'-{6-[5-(pyridin-3-yl-methyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromen- 2,4'-piperidine]; 6-[5-(cyclopropylmethyl)-4,5-dihydro-1'H,3H-spiro[1,5-benzodiazepine-2,4'-piperidin]-1'-yl]-N-(2-hydroxy- 2-pyridin-3-ylethyl) pyridazine-3-carboxamide; 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide; 4-(2-chlorophenoxy)-N-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide; cis-9, trans-11 isomer and trans-10 isomer, cis-12 conjugated linoleic acid, substituted heteroaromatic compounds disclosed in WO 2009/129625 A1, antisense polynucleotide ph and peptide nucleic acids (PNA) that target mRNA for SCD -1, siRNAs targeting SCD-1;

cholesterol transfer protein (CETP) inhibitors including anacetrapib, dalcetrapib, evacetrapib, torcetrapib, and AMG 899 (TA-8995);

inhibitors of microsomal triglyceride transfer protein (MTTP) activity or expression, including implitapide, lomitapide, dirlotapide, mitratapide, CP-346086, JTT-130, SLx-4090, antisense polynucleotides, and PNAs that target mRNA for MTTP, target MTTP microRNAs (eg, miRNA-30c) and MTTP-targeted siRNAs;

GLP-1 receptor agonists (supra);

fibroblast growth factor 21 (FGF21) and its analogs and derivatives, including BMS-986036 (pegylated FGF21);

inhibitors of subtilisin-kexin type 9 (PCSK9) proprotein convertase activity or expression, including berberine (reduces PCSK9 levels), annexin A2 (inhibits PCSK9 activity), anti-PCSK9 antibodies (eg, alirocumab, bococizumab, evolocumab, LGT-209, LY3015014, and RG7652 ), peptides that mimic the epidermal growth factor-A (EGF-A) domain of the LDL receptor that binds to PCSK9, PCSK9-binding adnectins (e.g., BMS-962476), antisense polynucleotides, and PNAs that target mRNA for PCSK9 and siRNA, targeting PCSK9 (eg, inclisiran [ALN-PCS] and ALN-PCS02);

apolipoprotein mimic peptides, including apoA-I mimetics (e.g., 2F, 3F, 3F-1, 3F-2, 3F-14, 4F, 4F-P-4F, 4F-IHS-4F, 4F2, 5F, 6F, 7F , 18F, 5A, 5A-C1, 5A-CH1, 5A-CH2, 5A-H1, 18A, 37pA [18A-P-18A], ELK [name], ELK-1A, ELK-1F, ELK-1K1A1E, ELK - 1L1K, ELK-1W, ELK-2A, ELK-2A2K2E, ELK-2E2K, ELK-2F, ELK-3E3EK, ELK-3E3K3A, ELK-3E3LK, ELK-PA, ELK-P2A, ELKA [name], ELKA- CH2, ATI-5261, CS-6253, ETC-642, FAMP [name], FREL [name], and KRES [name]), and apoE mimics (eg, Ac-hE18A-NH2 [AEM-28], Ac-[R ] hE18A-NH2, AEM-28-14, EpK, hEp, mR18L, COG-112, COG-133 and COG-1410);

omega-3 fatty acids, including docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), α-linolenic acid (ALA), fish oil (which contains e.g. DHA and EPA), and esters (e.g. , their glyceryl and ethyl esters); And

their analogues, derivatives and salts.

In some embodiments, the anti-obesity agent is or includes a lipase inhibitor (eg, orlistat) and/or an antihyperlipidemic agent (eg, a statin such as atorvastatin and/or a fibrate such as fenofibrate).

Antihypertensive agents include, but are not limited to:

renin-angiotensin-aldosterone system (RAAS) antagonists, including renin inhibitors (eg aliskiren), angiotensin-converting enzyme (ACE) inhibitors (eg benzazpril, captopril, enalapril, fosinopril, lisinopril, moexipril, perilripril, perinapril and trandolapril), angiotensin II type 1 (AT1) receptor antagonists (eg azilsartan, candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan medoxomil, olmesartan, telmisartan and valsartan) and aldosterone receptor antagonists (eg eplerenone and spironolactone);

diuretics, including loop diuretics (eg, bumetanide, ethacrynic acid, furosemide, and torasemide), thiazide diuretics (eg, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, epitizide, meticlothiazide, and polythiazide), thiazide-like diuretics (eg, chlorthalidone, indapamide, and metolazone), cicletanine (an early distal tubular diuretic), potassium-sparing diuretics (eg, amiloride, eplerenone, spironolactone, and triamterene), and theobromine;

calcium channel blockers, including dihydropyridines (eg, amlodipine, levamlodipine, cilnidipine, clevidipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine, nisoldipine, and nitrendipine) and non-dihydropyridines (eg, diltiazem and verapamil);

α2-adrenergic agonists including clonidine, guanabenz, guanfacine, methyldopa and moxonidine;

α1-adrenergic antagonists (alpha-blockers), including doxazosin, indoramin, nicergoline, phenoxybenzamine, phentolamine, prazosin, terazosin and tolazoline;

β-adrenergic antagonists (β1 or/and β2) (beta-blockers), including atenolol, betaxolol, bisoprolol, cartolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol and timolol;

mixed alpha/beta blockers including bucindolol, carvedilol and labetalol;

endothelin receptor antagonists, including selective ETA receptor antagonists (eg, ambrisentan, atrasentan, edonentan, sitaxentan, zibotentan, and BQ-123) and ETA/ETB dual antagonists (eg, bosentan, macitentan, and tezosentan);

other vasodilators, including minoxidil, theobromine, sodium nitroprusside, organic nitrates (eg, isosorbide mononitrate, isosorbide dinitrate, and nitroglycerin, which are converted to nitric oxide in the body), endothelial nitric oxide synthase (eNOS) stimulators (eg, cicletanine), soluble guanylate cyclases (eg, cynaciguat and riociguat), phosphodiesterase type 5 (PDE5) inhibitors (eg, avanafil, benzamidenafil, dasantafil, dinafil, lodenafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, dipyridamole, papaverine, propentofylline, zaprinast, and T-1032 ), prostaglandin E1 (alprostadil) and analogs (eg, limaprost and misoprostol), prostacyclin and analogs (eg, ataprost, beraprost [eg, esuberaprost], 5,6,7-trinor-4,8-inter-m- phenylene-9-fluoro-PGI2, carbacycline, isocarbacicline, clinprost, ciprosten, eptaloprost, cicaprost, iloprost, pimilprost, SM-10906 (des-methyl pimilprost), naxaprosten, taprosten, treprostinil, CS-570, OP-2507 and TY-11223), non-prostanoid prostacyclin receptor agonists (eg, 1-phthalazinol, ralinpag, selexipag, ACT-333679 [MRE-269, active metabolite of selexipag] and TRA-418), phospholipase C (PLC) inhibitors, and protein kinase C (PKC) (eg, BIM-1, BIM-2, BIM-3, BIM-8, chelerythrin, cicletanin, gossypol, miyabenol C, myricitrin, ruboxystaurine, and verbascoside;

minerals, including magnesium and magnesium sulfate; And

their analogues, derivatives and salts.

In some embodiments, the antihypertensive agent is or includes a thiazide or thiazide-like diuretic (eg, hydrochlorothiazide or chlorthalidone), a calcium channel blocker (eg, amlodipine or nifedipine), an ACE inhibitor (eg, benazepril, captopril, or perindopril), or an angiotensin II receptor antagonist (eg. , olmesartan medoxomil, olmesartan, telmisartan or valsartan) or any combination thereof.

In some embodiments, the peptide product described herein is used in combination with one or more additional therapeutic agents for the treatment of NAFLD, such as NASH. In some embodiments, one or more additional therapeutic agents are selected from anti-diabetic agents, anti-obesity agents, anti-inflammatory agents, anti-fibrotic agents, antioxidants, anti-hypertensive agents, and combinations thereof.

Therapeutic agents that can be used to treat NAFLD (eg, NASH) include, but are not limited to:

PPAR agonists, including PPAR-δ agonists (eg, MBX-8025, elafibranor [dual PPAR-α/δ agonist] and GW501516 [dual PPAR-β/δ agonist]) and PPAR-γ agonists (eg, thiazolidinediones such as pioglitazone , and saroglitazar [dual PPAR-α/γ agonist]) - PPAR-δ and -γ agonism increases insulin sensitivity, PPAR-α agonism reduces hepatic steatosis, and PPAR-δ agonism inhibits macrophage and Kupffer cell activation;

farnesoid X receptor (FXR) agonists such as obeticholic acid and GS-9674, FXR agonists that reduce gluconeogenesis, lipogenesis, steatosis, and hepatic fibrosis;

fibroblast growth factor 19 (FGF19) and its analogs and derivatives, such as NGM-282 analogs - FGF19, reduce gluconeogenesis and hepatic steatosis;

fibroblast growth factor 21 (FGF21) and its analogues and derivatives, such as BMS-986036 (pegylated FGF21) analogues of FGF21 that reduce hepatic steatosis, cell damage and fibrosis;

inhibitors of HMG-CoA reductase, including statins (eg, rosuvastatin) - statins that reduce steatohepatitis and fibrosis;

ACC inhibitors such as NDI-010976 (for the liver) and GS-0976 - ACC inhibitors that reduce de novo lipogenesis and hepatic steatosis;

SCD-1 inhibitors such as aramchol - SCD-1 inhibitors that reduce hepatic steatosis and increase insulin sensitivity;

SGLT2 inhibitors such as canagliflozin, ipragliflozin and luceogliflozin - SGLT2 inhibitors that reduce body weight, liver ALT levels and fibrosis;

antagonists of CCR2 and/or CCR5, such as cenicriviroc - antagonists of CCR2 (binds to CCL2 [MCP1]) and CCR5 (binds to CCL5 [RANTES]), which inhibit the activation and migration of inflammatory cells (eg, macrophages) to the liver and reduce hepatic fibrosis;

apoptosis inhibitors, including inhibitors of apoptosis-regulating kinase 1 (ASK1) (for example, seloncertib) and caspase inhibitors (for example, emricazan [pancaspase inhibitor]) - apoptosis inhibitors that reduce liver steatosis and fibrosis;

lysyl oxidase-like 2 (LOXL2) inhibitors such as simtuzumab - LOXL2 is a key matrix enzyme in collagen formation and is highly expressed in the liver;

galectin-3 inhibitors such as GR-MD-02 and TD139 - galectin-3 is critical for the development of liver fibrosis;

antioxidants, including vitamin E (eg, α-tocopherol) and reactive oxygen species (ROS) and free radical scavengers (eg, cysteamine, glutathione, melatonin, and pentoxifylline [also anti-inflammatory by inhibiting TNF-α and phosphodiesterases])- vitamin E reducing hepatic steatosis, hepatocyte ballooning and lobular inflammation; And

their analogues, derivatives and salts.

In some embodiments, the peptide product described herein is used in combination with a PPAR agonist (e.g., a PPAR-δ agonist such as elafibranor or/and a PPAR-γ agonist such as pioglitazone), an HMG-CoA reductase inhibitor (e.g., a statin such as rosuvastatin), an FXR agonist (eg obeticholic acid) or an antioxidant (eg vitamin E), or any combination thereof, for the treatment of NAFLD (eg NASH). In certain embodiments, one or more additional NAFLD therapeutic agents (eg, NASH) are or include vitamin E and/or pioglitazone.

Obtaining peptide products

WO 2015/184177 A1 describes the synthesis of peptide products. The examples below also describe the synthesis of typical peptide products.

EXAMPLES

The following examples are only intended to illustrate the present invention. Other processes, assays, studies, protocols, procedures, methodologies, reagents, and conditions may alternatively be used as needed.

Example 1 Reagents such as N-α-Fmoc, N-ε-(1-octyl β-D-glucuronid-6-yl)-L-lysine

An oven-dried 250 ml Erlenmeyer flask was charged with 1-octyl β-D-glucuronic acid (3.06 g, 10 mmol, Carbosynth Ltd.), 50 ml anhydrous DMF, and anhydrous 1-hydroxybenzotriazole (1.62 g, 12 mmol ). A cooled (4° C.) solution of N,N'-dicyclohexylcarbodiimide (2.48 g, 12 mmol) in 50 ml DMF was added with stirring and the reaction was allowed to proceed for 5 minutes. An abundant white precipitate of N,N'-dicyclohexylurea was filtered through a glass bottom funnel and the filtrate was added to a solution of N-α-Fmoc-L-lysine (3.68 g, 10 mmol) in 25 ml anhydrous DMF. The reaction was allowed to proceed for 25 minutes at room temperature or until the color of the ninhydrin became very faint. The reaction mixture was filtered, evaporated to dryness and crystallized from MeOH/Et2O by dissolving in MeOH and slowly diluting to the cloud point with Et2O followed by cooling. Further purification can be achieved by silica gel chromatography using a solvent gradient from EtOAc to EtOAc/EtOH/AcOH.

A similar reaction using N-α-Boc-L-lysine gives N-α-Boc, N-ε-(1-octyl β-D-glucuronide-6-yl)-L-lysine, which is suitable for N-terminal insertion and cleavage to the free N-terminus. A similar reaction using N-α-Ac-L-lysine gives N-α-Ac, N-ε-(1-octyl β-D-glucuronide-6-yl)-L-lysine, which is suitable for incorporation into N- the end of the peptide with a blocked N-terminus. A similar reaction using the appropriate amount of N-α-Fmoc-L-ornithine gives N-α-Fmoc, N-δ-(1-octyl β-D-glucuronid-6-yl)-L-ornithine. Similar reactions using other N-mono-protected diamino acids give the corresponding reagents. Otherwise, the use of a temporary Me3Si ester protecting group during coupling and without prior activation of 1-octyl-β-D-glucuronic acid provides an easy route to the formation of reactants. The Me3Si intermediate ester was obtained by the reaction of Fmoc-Lys-OH with an equimolar amount of N,O-bis(trimethylsilyl)acetamide in dichloromethane (CH ₂ Cl ₂ ). The organic layer contains the desired reagent as a solution in CH ₂ Cl ₂ ready for coupling with 1-alkylglucononide as described above. The filtered reaction mixture was washed with aqueous NaHSO ₄ to hydrolyze the Me ₃ Si ester and then dried over MgSO ₄ and then the solvent was removed.

Similarly, but using peracetyl- or perbenzoyl-1-octyl-D-glucuronic acid, an Ac- or Bz-protected form of the reagents was obtained (for example, 2,3,4-trisacetyl-1-octyl-β-D-glucuronic acid and similar, formed during the processing of Ac ₂ O). Such reagents have increased stability in removing acid from the resin and are used when instability is found during deprotection. Final deprotection of such products was accomplished by base catalyzed transesterification after cleavage using MeOH/NH ₃ , MeOH/NaOMe or MeOH/NH ₂ NH ₂ as described above.

Example 2 Synthetic Peptides

Typically, peptide synthesis methods involve the sequential addition of protected amino acids to a growing peptide chain. Typically, either the amino or carboxyl group of the first amino acid and any side chain reactive group are protected. This protected amino acid is then either attached to an inert solid support or used in solution, and the next amino acid in sequence, also suitably protected, is added under conditions conducive to amide bond formation. Once all the desired amino acids have been linked in the correct sequence, the protecting groups and any solid support are removed to give the crude peptide. The peptide is desalted and purified chromatographically.

One method for producing peptides containing less than about fifty amino acids involves solid phase peptide synthesis. In this method, the α-amino (Nα) group and any reactive side chain functional groups are protected by acid or base sensitive groups. The protecting group must be resistant to the conditions of formation of the peptide bond, at the same time easily removed without affecting the existing peptide chain. Suitable α-amino protecting groups include, but are not limited to, t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), o-chlorobenzyloxycarbonyl, biphenylisopropyloxycarbonyl, t-amyloxycarbonyl (Amoc), isobornyloxycarbonyl, α,α-dimethyl-dimethoxybenzyloxycarbonyl, o- nitrophenylsulphenyl, 2-cyano-tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc) and the like, preferably Boc or Fmoc. Suitable side chain protecting groups include, but are not limited to, acetyl, benzyl (Bzl or Bn), benzyloxymethyl (Bom), Boc, t-butyl, o-bromobenzyloxycarbonyl, t-butyl, t-butyldimethylsilyl, 2-chlorobenzyl (Cl-z ), 2,6-dichlorobenzyl, cyclohexyl, cyclopentyl, isopropyl, pivalyl, tetrahydropyran-2-yl, tosyl (Tos), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), trimethylsilyl, and trityl. The preferred Nα protecting group for compound synthesis is Fmoc. Preferred side chain protecting groups include -O-tert-butyl for Glu, Tyr, Thr, Asp and Ser; Boc for Lys and Trp side chains; Pbf for Arg; and Trt for Asn, Gln and His. For selective modification of the Lys residue, orthogonal protection with a protecting group not removed by reagents that cleave Fmoc or t-butyl protecting groups is preferred. Preferred examples of Lys side chain modification include, but are not limited to, those removed with hydrazine but not with piperidine, such as 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde) , 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) and allyloxycarbonyl (Alloc).

The Fmoc-Lys (ivDde) or Fmoc-Lys (Dde) protecting group scheme is preferred in cases where formation of lactam side chains is desired because Fmoc-Glu (O-allyl) and Fmoc-Lys (Alloc) can be included and used. provide temporary protection and then deprotect to form the lactam while the Lys (Dde) protecting group remains for subsequent removal and reaction with the functionalized surfactant. Side chain lactams between acidic and basic residues (e.g., Glu and Lys) were obtained after removal of the allyl-based protecting group by activating the carboxyl side chain function with N,N'-diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) or 2- (1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU)/N,N-diisopropylethylamine (DIEA) using standard protocols in the art.

In solid phase synthesis, the C-terminal amino acid is first attached to a suitable polymer carrier. Suitable resin carriers are those materials that are inert to the reactants and reaction conditions of the stepwise condensation and deprotection reactions, and are also insoluble in the media used. Examples of commercially available resins include styrene/divinylbenzene resins modified with a reactive group, such as chloromethylated copoly-(styrene-divinylbenzene), hydroxymethylated copoly-(styrene-divinylbenzene), and the like. Benzylated, hydroxymethylated phenylacetamidomethyl (PAM) resin and hydroxymethylphenoxyacetylamidomethyl (HMPA) are preferred for making peptide C-terminal acids. When the C-terminus of the compound is an amide, the preferred resins are p-methylbenzhydrylamino-co-poly(styrene-divinylbenzene) resin and 2,4-dimethoxybenzhydrylamino resin ("Rink's amide") and the like. The preferred vehicles for the synthesis of larger peptides are commercially available resins containing PEG sequences grafted onto other polymeric matrices, such as Rink Amide-PEG and PAL-PEG-PS resins (Applied Biosystems) and similar resins designed for the synthesis of peptide amides using fmoc protocol. Thus, in some cases it may be desirable to have an amide bond to the PEG chain. In such cases, it is convenient to couple the N-Fmoc-amino-PEG-carboxylic acid to the amide-forming resin above (eg, Rink's amide resin, etc.). The first amino acid in the chain may be linked as an N-Fmoc amino acid to the amino function of the PEG chain. The final deprotection gives the desired product peptide-NH-PEG-CO-NH2.

Attachment to the PAM or HMPA resin can be accomplished by reacting an Nα-protected amino acid such as Boc-amino acid as its ammonium, cesium, triethylammonium, 1,5-diazabicyclo-[5.4.0]undec-5-ene, tetramethylammonium, or the analogous salt in ethanol, acetonitrile, N,N-dimethylformamide (DMF) and the like, preferably the cesium salt in DMF, with the resin at an elevated temperature such as about 40°C to about 60°C, preferably about 50° C, for 12 to 72 hours, preferably about 48 hours. This ultimately results in the formation of a peptide acid product after acid cleavage or an amide after aminolysis.

The Nα-Boc-amino acid may be coupled to the benzhydrylamine resin via, for example, DIC/HOBt-mediated coupling for about 2 to 24 hours, preferably about 2 hours, at about 10° to about 50° C., preferably about 25 °C, in a solvent such as CH ₂ Cl ₂ or DMF, preferably CH ₂ Cl ₂ .

For Boc-based protocols, sequential binding of protected amino acids can be performed by methods known in the art, typically in an automated peptide synthesizer. After neutralization with triethylamine, DIEA, N-methylmorpholine (NMM), collidine, or a similar base, each protected amino acid is introduced in about 1.5-2.5-fold molar excess and the coupling is carried out in an inert, non-aqueous, polar solvent such as CH ₂ Cl ₂ , DMF, N-methylpyrrolidone (NMP), N,N-dimethylacetamide (DMA) or a mixture thereof, preferably in dichloromethane, at ambient temperature. For Fmoc-based protocols, no acid is used for deprotection, but a base, preferably DIEA or NMM, is usually added to the binding mixture. Coupling is usually carried out in DMF, NMP, DMA or mixed solvents, preferably DMF. Typical coupling agents are N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC) and other carbodiimides, either alone or in the presence of HOBt, O-acylurea, benzotriazol-1-yl-oxytris(pyrrolidino) phosphonium hexafluorophosphate (PyBop), N-hydroxysuccinimide, other N-hydroxyimides or oximes. Otherwise, protected active amino acid esters (eg, p-nitrophenyl, pentafluorophenyl, etc.) or symmetrical anhydrides can be used. Preferred coupling agents are of the amine/uronium class such as HBTU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(6-chloro-1H-) . benzotriazol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) and the like.

A preferred method of attachment to the Fmoc-PAL-PEG-PS resin can be accomplished by deprotecting the resin linker with 20% piperidine in DMF, followed by reacting the protected N-α-Fmoc amino acid in about 5 molar excess of the N-α-Fmoc-amino acid with using HBTU:diisopropylethylamine (DIEA) (1:2) in DMF in a microwave peptide synthesizer at 5 min, max. 75°C binding cycle.

The peptides of the invention may include a PEG group (dPEG) at the C-terminus. Such PEG groups can be short chains of polyethylene glycol with an amino-terminus and a carboxyl-terminus. Thus, they are essentially unnatural amino acids and are processed similarly to other amino acids for synthesis. For example, Fmoc-amidooxy-dPEG4-acid is commercially available from Quanta Biodesign (#10213) and is coupled to Rink's resin or HMPA in the first step of the synthesis in a manner similar to that used for N-Fmoc or N-Boc amino acids described above. Deprotection under standard strong acid conditions yields the corresponding short peptide-modified dPEG C-terminus with the corresponding acidic or amide C-terminus.

For the Fmoc-based protocol in a microwave peptide synthesizer, the amino acid N-α-Fmoc was deprotected with 20% piperidine in DMF containing 0.1 M 1-hydroxybenzotriazole (HOBt) in a double deprotection protocol for 30 s and then for 3 minutes with maximum temperature set to 75°C. HOBt was added to the deprotection solution to reduce the formation of aspartimide. A 5-fold molar excess was then used to bind the next amino acid using HBTU:DIEA (1:2) with 5 min, max. 75°C double bond cycle.

At the end of the solid phase synthesis, the fully protected peptide was removed from the resin. When the bond to the resin support is of the benzyl ether type, cleavage can be by aminolysis with an alkylamine or fluoroalkylamine for peptides with an alkylamide C-terminus, or by ammonolysis using, for example, ammonia/methanol or ammonia/ethanol for peptides with an unsubstituted amide C-terminus. end at a temperature of from about -10 to about 50°C, preferably at about 25°C, for about 12 to 24 hours, preferably about 18 hours. Hydroxy C-terminal peptides can be cleaved off with HF or other highly acidic deprotection or saponification. Otherwise, the peptide can be removed from the resin by transesterification, for example using methanol, followed by aminolysis or saponification. The protected peptide can be purified using silica gel or reverse phase HPLC.

The side chain protecting groups can be removed from the peptide by treatment of the aminolysis product, e.g., anhydrous liquid HF in the presence of anisole or other carbonium ion scavenger, treatment with an HF/pyridine complex, treatment with tris(trifluoroacetyl)boron and trifluoroacetic acid, by reduction with hydrogen and palladium on carbon, or polyvinylpyrrolidone or sodium reduction in liquid ammonia, preferably liquid HF and anisole, at about −10 to 10° C., preferably at about 0° C., from about 15 minutes to 2 hours, preferably about 1.5 hours.

For peptides on resins such as benzhydrylamine, the resin cleavage and deprotection steps can be combined in one step using liquid HF and anisole as described above, or preferably by using lighter cleavage cocktails. For example, for PAL-PEG-PS resin, the preferred method is to use a double deprotection protocol in a microwave peptide synthesizer using one of the mild cleavage cocktails known in the art, such as TFA (trifluoroacetic acid)/water/trio-isopropylsilane/3, 6-dioxa-1,8-octanedithiol (DODT) (92.5/2.5/2.5/2.5) for 18 min at 38°C each time. Cleavage of alkyl glycoside-containing materials demonstrated alkyl glycosidic bond survival using protocols with TFA (trifluoroacetic acid)/water ratios ranging from 9/1 to 19/1. A typical cocktail is 94% TFA (trifluoroacetic acid): 2% EDT; 2% H2O; 2% TIS. Typically, the completely purified product was precipitated and washed with cold (-70 to 4°C) Et2O, dissolved in deionized water and lyophilized.

The peptide solution can be desalted (eg, using BioRad AG-3® anion exchange resin) and the peptide purified by a sequence of chromatographic steps using any or all of the following types: ion exchange on a weakly basic resin in acetate form; hydrophobic adsorption chromatography on non-derivatized copoly(styrene-divinylbenzene) such as Amberlite® XAD; adsorption chromatography on silica gel; ion exchange chromatography on carboxymethyl cellulose; separation chromatography on Sephadex® G-25, for example; distribution of countercurrents; supercritical liquid chromatography; and HPLC, especially reverse phase HPLC on an octyl- or octadecylsilicone (ODS) coupled-phase column.

Provided herein are methods for preparing the covalently modified peptides described herein and their pharmaceutically acceptable salts, which include sequentially condensing protected amino acids on a suitable resin support, removing the protecting groups and resin support, and purifying the product to obtain covalently modified peptides. The methods may use any protocol for peptide synthesis known in the art, such as solid phase synthesis using microwave radiation. In some embodiments, the peptides are attached to an alkyl glycoside.

Example 3. Oxidation method for obtaining uronic acids

(diacetoxyiodo)benzene (4.4 g, 13.7 mmol, Fluka) and TEMPO (0.180 g, 1.15 mmol). The resulting mixture was stirred at room temperature for 20 hours. The reaction was followed by mass spectrometry (e.g. LCQ ESI) and upon completion the reaction mixture was diluted with water and lyophilized to dryness to give 1.52 g (yield 73% crude) of the crude product, 1-dodecyl β-D-glucuronic acid, as a white powder that was used directly for solid phase synthesis without further purification. For longer alkyl groups, 1,4-dioxane was used instead of acetonitrile and the temperature was raised to 30°C. Similarly received the desired alkylsaccharide uronic acids used to obtain products and reagents described in this document.

Similarly, but using, for example, the corresponding 1-octyl, 1-decyl, 1-undecyl, 1-tetradecyl, 1-hexadecyl, and 1-octadecyl glycosides (Anatrace, Momi, Ohio), the desired 1-alkylsaccharide uronic acids were prepared, which used to make the products and reagents described herein. Similarly, but using, for example, the corresponding 1-octyl, 1-decyl, 1-undecyl, 1-tetradecyl, 1-hexadecyl and 1-octadecyl β-D-melibiosides or β-D-maltosides (Anatrace), the desired 1-alkyldisaccharide uronic acids, which were used to prepare the products and reagents described in this document.

Example 4 Preparation of C-Terminal Amide Peptide Product (EU-A387)

Sample Fmoc-His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Bip-Ser-Lys-Tyr-Leu-Glu-Ser-Lys (Alloc)-Rink's amide resin (SEQ ID NO: 782) was obtained by sequential addition of Nα-Fmoc-protected amino acids as described in Example 1 and deprotection at the Lys-N-epsilon position by incubation with Pd(PPh3)4 (0.5 eq.) and DMBA (20 eq.) in DMF/CH ₂ Cl ₂ (1:1) overnight in the dark at room temperature. After washing with DMF/CH ₂ Cl ₂ , the Lys side chain was acylated with 1'-dodecyl-D-glucuronic acid in DMF/CH ₂ Cl ₂ using DIC/HOBt. Completion of the binding was checked with ninhydrin and the product washed thoroughly with CH ₂ Cl ₂ .

The product resin was subjected to a final deprotection and resin cleavage treatment with a cleavage cocktail (94% TFA, 2% EDT, 2% H2O, 2% TIS) for a period of 240 minutes at room temperature. The mixture was treated with Et2O to precipitate the product and washed extensively with Et2O to give the crude title peptide product after vacuum drying.

Purification was performed in two batches by reverse phase HPLC (C18). The crude peptide was applied to a 4.1×25 cm HPLC column with a flow rate of 15 ml/min (15% organic modifier, acetic acid buffer) and eluted with a 15-45% buffer B gradient over 60 min at 50°C. The product fraction was lyophilized to give the title peptide product of 98% purity by analytical HPLC (18.6 min; 30-60% CH3CN in 0.1% TFA (trifluoroacetic acid))/mass spectrometry (peak M + 1 = 2382, 14). Other peptide products of the present invention were prepared similarly, the characteristics of which are shown below.

The corresponding 1-methyl and 1-octyl analogues of the title compound were prepared in a similar manner, but using 1'-methyl-β-D-glucuronic acid and 1'-octyl-β-D-glucuronic acid reagents (Carbosynth). The corresponding 1-decyl, 1-dodecyl, 1-tetradecyl, 1-hexadecyl, 1-octadecyl, 1-eicosyl and higher analogs were prepared using the respective monosaccharide and disaccharide uronic acids prepared as described above. Alternatively, 1-alkylglucuronyl or other uronic acylated analogs can be prepared by first purifying the deprotected or partially deprotected peptide followed by acylation with the desired uronic acid.

Example 5 Preparation of C-Terminal Acid Peptide Products

Sample Boc-His(Trt)-Aib-Gln(Trt)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Tyr(tBu)-Ser(tBu)-Lys (Boc)-Tyr(tBu)-Leu-Asp(OtBu)-Glu(O-Allyl)-Gln(Trt)-Ala-Ala-Lys(Alloc)-Glu(O-tBu)-Phe-Ile-Lys( Dde)-Trp(Boc)-Leu-Leu-Gln(Trt)-Thr(tBu)-HMPA (SEQ ID NO: 783) (from Fmoc-Thr(tBu)-HMPA resin), displacement 0.45 mmol/g ) was obtained by sequential addition of Nα-Fmoc-protected amino acids as described in Example 1. The allyl-protected side chains of Glu and Lys residues were deprotected by incubation with Pd(PPh ₃ ) ₄ (0.5 eq.) and DMBA (20 eq.) In DMF/CH ₂ Cl ₂ (1:1) overnight in the dark at room temperature. The resin was washed with 0.5% DIEA in DMF (twice), 0.5% sodium diethyldithiocarbamate in DMF (twice) and DMF/CH ₂ Cl ₂ until a light yellow resin was obtained. The side chain lactam was formed by combining the Glu and Lys residues with DIC/HOBT (5 eq.) in DMF. The reaction was checked for completeness with ninhydrin and repeated if necessary. After washing with DMF/CH ₂ Cl ₂ , the Lys side chain was deprotected by incubation with 5% hydrazine hydrate in DMF (10 eq.) twice, in each case for 15 minutes. After washing with DMF/CH ₂ Cl _{2 ,} the side chain amino group of the deprotected Lys residue was reacted with 1'-tetradecyl-D-melibiuronic acid in DMF/CH ₂ Cl ₂ using DIC/HOBt. Completion of the binding was checked with ninhydrin and the product washed thoroughly with CH ₂ Cl ₂ . Any binding that was not completed with ninhydrin was repeated. In general, 10-12 g of peptide product resin was obtained from a 2 mmol synthesis.

The product resin was subjected to a final deprotection and resin cleavage treatment with a cleavage cocktail (94% TFA, 2% EDT, 2% H2O, 2% TIS) for a period of 240 minutes at room temperature. The mixture was treated with Et ₂ O to precipitate the product and washed extensively with Et ₂ O to give the crude title peptide product after vacuum drying. In general, 5-8 g of crude peptide product was obtained.

Purification was performed in two batches by reverse phase HPLC (C18). The crude peptide (1-1.5 g) was applied to a 4.1 x 25 cm HPLC column at a flow rate of 15 ml/min (15% organic modifier, 0.1% TFA (trifluoroacetic acid) buffer) and eluted with a gradient from 35-55% buffer B for 70 minutes at room temperature. Re-purification of less pure fractions was carried out for fractions with a purity > 70%. The product fraction was lyophilized to give EU-A1077 with a purity of 98.7% by analytical HPLC (10.3 min, 45-75% CH3CN in 0.1% TFA (trifluoroacetic acid))/mass spectrometry (1317.67, + 3 charge; 1976.13, +2 charge; molecular weight 3950.44). Other peptide products of the present invention were prepared similarly, the characteristics of which are shown below.

The corresponding 1-methyl and 1-octyl analogues of the title compound were prepared in a similar manner, but using 1'-methyl-β-D-glucuronic acid and 1'-octyl-β-D-glucuronic acid reagents (Carbosynth). Similarly, but using the respective 1-octyl, 1-decyl, 1-undecyl, 1-tetradecyl, 1-hexadecyl and 1-octadecyl β-D-glucuronic acids (obtained as described above), the peptide products of the present invention were prepared. . Similarly, but using the corresponding 1-octyl, 1-decyl, 1-undecyl, 1-tetradecyl, 1-hexadecyl and 1-octadecyl β-D-melibiuronic acid or β-D-malturonic acid (obtained as described above) , received the peptide products of the present invention. Alternatively, 1-alkylglucuronyl or other uronic acylated analogs may be prepared by first purifying the unprotected or partially unprotected peptide followed by acylation with the desired uronic acid reagent. Otherwise, ammonolysis of the resin-bound HMPA intermediate gives the corresponding C-terminal amide.

Analysis and characterization were performed by HPLC/mass spectrometry in positive ion mode using the eluent gradients shown in the table below.

Connection number Expected molecular Wt Detected molecular Wt HPLC
(min; elution) EU-A387 2379.66 2380.14 18.6[b] EU-A388 2393.69 2393.74 16.0[a] EU-A391 2317.62 2318.26 11.2[b] EU-A455 2988.36 2988.00 11.5[b] EU-A474 2570.86 2570.54 11.3[b] EU-A478 2459.75 2459.74 11.1[b] EU-A484 2544.86 2545.06 9.6[b] EU-A501 2904.2 2903.34 7.9[b] EU-A502 2776.07 2776.14 8.0[b] EU-A503 2704.98 2704.40 8.0[b] EU-A504 2548.80 2548.00 9.1[b] EU-A505 2392.61 2392.40 10.5[b] EU-A506 2305.53 2305.06 10.7[b] EU-A507 3763.23 3762.66 9.0[b] EU-A521 2303.56 2303.60 8.2[s] EU-A522 2315.60 2315.60 14.2[d] EU-A523 2615.94 2616.00 8.1[b] EU-A524 2459.75 2459.74 12.7[d] EU-A525 2459.75 2459.06 6.0[s] EU-A526 2473.75 2473.60 12.7[d] EU-A527 2390.64 2390.40 14.6[d] EU-A529 2546.83 2546.80 9.5[b] EU-A531 2546.83 2546.80 9.5[b] EU-A532 2559.00 2558.66 9.6[b] EU-A533 2560.96 2560.66 9.5[b] EU-A534 2544.99 2544.94 9.7[b] EU-A535 2573.05 2574.00 12.0[b] EU-A536 2602.96 2603.46 14.3[b] EU-A538 2516.99 2516.40 10.3[b] EU-A539 2657.20 2656.80 10.8[b] EU-A540 2685.20 2684.94 9.8[s] EU-A541 2713.20 2712.80 13.0[s] EU-A544 2631.94 2632.26 10.8[b] EU-A546 2687.94 2688.80 9.1[s] EU-A549 2388.67 2388.66 6.3[e] EU-A551 2444.67 2445.20 11.4[e] EU-A552 2472.67 2473.14 10.7[f] EU-A554 2560.86 2560.40 10.3[s] EU-A556 2616.86 2616.40 11.7[e] EU-A557 2644.86 2645.74 10.4[f] EU-A560 2570.86 2571.06 8.3[s] EU-A562 2626.86 2626.66 9.9[e] EU-A563 2654.86 2655.06 8.7[f] EU-A565 2542.80 2542.54 9.5[s] EU-A567 2598.80 2599.06 12.0[e] EU-A568 2626.80 2626.54 10.1[f]

HPLC gradients in 0.1% TFA (trifluoroacetic acid):

[a] 35 to 65% CH3CN for 30 min.

[b] 30 to 60% CH3CN for 20 min.

[c] 35 to 65% CH3CN for 20 min.

[d] 25 to 55% CH3CN for 20 min.

[e] 40 to 70% CH3CN for 20 min.

[f] 45 to 75% CH3CN for 20 min.

HPLC was performed on a Phenomenex Luna C18 5 micron 250x4.6 mm analytical column.

The following table lists other compounds synthesized and analyzed as described above:

Connection number Expected molecular Wt Detected molecular Wt HPLC
(min; elution) EU-A570 2656.16 2656.00 10.4[b] EU-A571 2684.16 2683.34 11.2[c] EU-A575 2670.16 2670.94 11.8[b] EU-A576 2698.16 2697.20 11.2[c] EU-A580 2668.20 2667.20 12.3[b] EU-A581 2696.20 2695.46 11.1[c] EU-A592 2724.20 2724.58 9.9[e] EU-A595 2682.20 2682.40 9.7[s] EU-A596 2710.20 2710.46 10.4[s] EU-A597 2738.20 2738.18 10.9[e] EU-A721 2461.85 2461.74 10.3[b] EU-A722 2475.85 2475.34 10.8[b] EU-A723 2459.88 2459.86 7.7[s] EU-A724 2473.88 2473.34 11.1[b] EU-A725 2471.92 2472.00 10.8[b] EU-A726 2557.03 2556.80 11.0[b] EU-A727 2485.92 2485.74 10.9[b] EU-A728 2513.92 2513.86 10.6[s] EU-A729 2541.92 2541.86 9.7[e] EU-A730 2569.92 2569.74 9.4[f] EU-A731 2425.88 2425.32 10.6[d] EU-A732 2476.95 2476.40 9.4[s] EU-A733 2381.83 2382.02 11.4[b] EU-A734 2616.09 2616.18 11.4[b] EU-A750 1611.89 1611.56 9.4[s] EU-A751 1625.89 1625.35 9.7[s] EU-A752 1709.93 1709.41 11.7[g] EU-A753 1637.84 1637.46 12.5[b] EU-A754 1651.84 1651.18 9.9[s] EU-A755 1711.93 1711.46 10.3[h] EU-A756 1671.98 1671.37 9.8[e] EU-A757 1770.02 1769.17 14.9[g] EU-A770 3333.61 3334.65 9.5[b] EU-A771 3678.25 3677.96 11.3[c] EU-A772 3762.25 3763.35 14.9[e] EU-A773 3790.31 3791.31 11.1[f] EU-A774 3475.74 3477.15 10.5[d] EU-A775 3820.38 3821.52 10.4[s] EU-A776 3904.38 3905.76 10.2[f] EU-A777 3932.44 3933.69 9.7[f] EU-A792 3793.43 3793.52 8.9[f] EU-A793 3821.43 3821.60 10.8[f] EU-A794 3849.43 3848.78 10.5[g] EU-A945 3777.18 3777.54 12.2[e] EU-A948 3861.18 3862.14 13.0[f] EU-A993 3759.22 3759.00 9.3[f] EU-A994 3787.22 3787.44 11.4[f] EU-A995 3815.22 3815.52 14.5[g] EU-A996 3843.22 3843.12 12.3[g] EU-A999 3935.35 3934.66 13.4[e] EU-A1011 3854.21 3854.38 14.2[s] EU-A1017 3896.26 3895.77 12.3[c] EU-A1023 3921.35 3921.15 10.5[e] EU-A1024 3949.42 3950.22 5.8[g] EU-A1025 3977.47 3976.84 7.96[g] EU-A1026 4005.55 4004.64 12.8[g] EU-A1029 3939.31 3939.06 10.7[e] EU-A1032 4023.51 4025.22 13.9[f] EU-A1035 3840.21 3838.21 9.8[e] EU-A1041 3882.26 3880.50 9.6[e] EU-A1044 3966.46 3965.46 12.6[f] EU-A1167 3731.15 3731.42 8.9[f] EU-A1168 3745.15 3745.20 10.8[i] EU-A1173 3978.49 3977.00 12.9[f] EU-A1576 3922.37 3922.08 10.2[e] EU-A1577 3950.44 3949.95 10.3[f] EU-A1581 3923.35 3921.21 13.1[j] EU-A1587 3949.42 3949.92 9.6[f] EU-A1588 3977.47 3977.97 8.3[f] EU-A1589 4005.55 4005.18 9.2[g] EU-A1590 3922.37 3923.01 12.5[j] EU-A1591 3922.33 3922.80 12.4[j] EU-A1592 3923.35 3921.74 13.0[j] EU-A1595 3914.38 3915.45 11.5[e] EU-A1596 3942.43 3942.48 7.1[g] EU-A1598 3887.29 3886.80 12.4[j] EU-A1599 3888.31 3888.00 12.5[j] EU-A1601 4049.52 4051.35 10.1[e] EU-A1602 4077.59 4075.41 12.4[n] EU-A1606 4050.46 4051.77 10.4[e] EU-A1607 4078.53 4077.99 12.7[n] EU-A1611 4050.54 4051.44 10.1[e] EU-A1612 4078.61 4078.86 12.3[e] EU-A1617 4079.55 4079.55 13.0[j] EU-A1620 4180.59 4181.49 11.0[e] EU-A1622 4208.66 4208.31 12.9[j] EU-A1627 4207.64 4208.28 12.8[j] EU-A1634 4035.78 4037.34 13.9[e] EU-A1635 4063.78 4065.54 9.5[g] EU-A1639 4169.54 4167.99 7.7[k] EU-A1645 4183.76 4182.60 13.2[e] EU-A1646 4211.99 4213.32 23.5[l] EU-A1647 4239.74 4239.21 12.2[m] EU-A1651 4345.89 4345.41 10.8[o] EU-A1679 3704.17 3704.85 9.0[e] EU-A1680 3732.17 3732.45 7.0[f] EU-A1681 3760.24 3761.31 8.8[f] EU-A1682 3788.24 3788.52 11.9[f] EU-A1710 3859.32 3859.71 6.4[f] EU-A1711 3887.39 3888.12 8.0[f] EU-A1712 3915.39 3915.72 12.1[e] EU-A1713 3943.39 3943.32 11.2[f] EU-A1716 3860.26 3860.49 9.8[e] EU-A1717 3888.33 3889.23 8.4[f] EU-A1718 3916.33 3916.98 12.6[i] EU-A1719 3944.33 3944.31 9.0 [g] EU-A1722 3989.37 3990.03 6.1[f] EU-A1723 4017.44 4017.54 7.8[f] EU-A1730 3916.35 3917.76 7.8[f] EU-A1734 3726.10 3726.63 14.0[e] EU-A1735 3754.10 3754.26 12.9[f] EU-A1739 3949.38 3950.31 13.0[f] EU-A1740 3977.43 3978.30 8.9[g] EU-A1745 3815.18 3815.10 13.8[g] EU-A1784 3915.35 3917.31 11.0[f] EU-A1785 3943.35 3944.40 14.6[i] EU-A1787 3916.25 3917.46 9.1[g] EU-A1788 3944.29 3945.45 10.8[f] EU-A1841 3788.20 3789.36 6.6[f] EU-A1842 3816.20 3817.80 11.3[m] EU-A1847 3727.08 3728.46 10.9[f] EU-A1848 3755.08 3756.96 10.2[g]

HPLC gradients in 0.1% TFA (trifluoroacetic acid):

[a] 35 to 65% CH3CN for 30 min.

[b] 30 to 60% CH3CN for 20 min.

[c] 35 to 65% CH3CN for 20 min.

[d] 25 to 55% CH3CN for 20 min.

[e] 40 to 70% CH3CN for 20 min.

[f] 45 to 75% CH3CN for 20 min.

[g] 50 to 80% CH3CN for 20 min.

[h] 10 to 40% CH3CN for 20 min.

[i] 30 to 90% CH3CN for 20 min.

[j] 10 to 90% CH3CN for 20 min.

[k] 30 to 95% CH3CN for 20 min.

[l] 30 to 60% CH3CN for 30 min.

[m] 20 to 100% CH3CN for 20 min.

[n] 20 to 80% CH3CN for 20 min.

[o] 30 to 50% CH3CN for 20 min.

HPLC was performed on a Phenomenex Luna C18 5 micron 250x4.6 mm analytical column.

Example 6 In Vitro Stability of Peptide Products in Human Plasma

One mg/ml stock solution was prepared in DMSO/CH3CN (1/1). Standard working solutions in 50% CH3CN were prepared using the stock solution. The concentrations of working solutions were 20, 50, 100, 200, 500, 1000, 2000, 5000, 10000 and 20000 ng/mL. Ten µl of working solutions were added to 90 µl of empty plasma and the mixture was shaken. 300 μl of an internal standard solution (verapamil, 20 ng/ml in 100% CH3CN) was added and the mixture was shaken and centrifuged. The supernatant was transferred to an HPLC injection plate for loading onto an HPLC column. Standard samples were in the amount of 2, 5, 10, 20, 50, 100, 200, 500, 1000 and 2000 ng/ml. QC samples were 5 (LQC), 50 (MQC) and 500 (HQC) ng/mL. For plasma stability studies, samples of EU-A993, EU-A1023 and human GLP-1 (7-36) (Bachem) were prepared in human plasma (about 6-20 ng/ml or similar concentrations above the limit of quantitation) and sampled at time points t = 0, 0.5, 1, 2, 4 and 8 hours during incubation at 30°C. Samples were treated with an internal standard solution (100% CH3CN) as described above to precipitate peptides and supernatants were loaded onto an injection plate to be loaded onto an HPLC column for quantitation by mass spectrometry.

The following instruments were used: API-4000 mass spectrometer, ESI positive, MRM scan; and Shimadzu HPLC/CTC autosampler with ACE C8 column (2.1 x 50 mm, 5 µm), mobile phase A: 0.1% formic acid and 5 mM NH ₄ OAc in water, mobile phase B: 0.1% formic acid in CH3CN, 10 µl of the sample was injected.

A plot of signal (amount) of the compound versus time shows essentially complete cleavage of GLP-1 (7-36) at 4 hours, but there is no noticeable change in the amount of intact peptide products in human plasma for at least 8 hours (Fig. 8). Both peptide products showed protection against proteolysis and a long plasma half-life in an in vitro assay.

Example 7. Cellular analysis of the activity of peptide products in relation to GLP-1 receptors and glucagon

Compounds were accurately weighed in about 1 mg and analyzed in standard cell assays (Cerep SA). The indication was the amount of cAMP generated in cells treated with test compounds, either in agonist or antagonist mode. The assay used was stimulation of cAMP levels in cellular assays for glucagon (human, cloned in CHO cells) and GLP-1 (mouse cell line). Assays are described in Chicchi et al., J. Biol. Chem., 272:7765-7769 (1997) and Runge et al., Br. J. Pharmacol., 138:787-794 (2003).

For EU-A391, the GCGR cellular response did not change and the GLP1R cellular response increased dramatically with an EC50 of 420 nM.

Connection number 1-Alkyl EC50
GLP-1R
(nM) EC50 Glucagon R
(nM) EU-A391 1-dodecyl 420 n.c. EU-A455 1-dodecyl 59 770 EU-A474 1-dodecyl 3000 n.c. EU-A478 1-dodecyl n.c. n.c. EU-A484 1-dodecyl n.c. n.c. EU-A501 1-dodecyl 20000 12000 EU-A502 1-dodecyl 9400 n.c. EU-A503 1-dodecyl n.c. n.c. EU-A504 1-dodecyl 3100 1100 EU-A505 1-dodecyl 8500 6100 EU-A506 1-dodecyl +4600 1300 EU-A507 1-dodecyl 18 1 EU-A521 1-dodecyl n.c. n.c. EU-A522 1-dodecyl n.c. 9000 EU-A523 1-dodecyl n.c. n.c. EU-A524 1-dodecyl n.c. n.c. EU-A525 1-dodecyl n.c. n.c. EU-A526 1-dodecyl n.c. n.c. EU-A527 1-dodecyl n.c. 5000 EU-A529 1-dodecyl n.c. 7000 EU-A531 1-dodecyl 2100 1100 EU-A532 1-dodecyl 5000 2600 EU-A533 1-dodecyl 770 780 EU-A534 1-dodecyl 290 1900 EU-A535 1-tetradecyl §4800 2100 EU-A536 1-hexadecyl > 10000 4400 EU-A538 1-dodecyl 270 n.c. EU-A539 1-dodecyl 860 2300 EU-A540 1-tetradecyl n.c. 8800 EU-A541 1-hexadecyl 800 5000

n.c. means that EC50 is not computable

§ means superagonist

An additional series of cellular assays were performed using standard cellular assays (DiscoveRx, LeadHunter assays) using cAMP stimulation or arrestin activation readings. Compounds were weighed accurately at about 1 mg and sent to the DiscoveRx for dilution and analysis. Cellular assays used human glucagon receptor cloned in CHO cells and human GLP-1 receptor cloned in CHO cells.

Connection number EC50 cAMP
GLP-1R
(nM) EC50 Arrestin
GLP-1R
(nM) EC50 cAMP
Glucagon R
(nM) EC50 Arrestin Glucagon R
(nM) EU-A507 0.01 9 0.02 100 EU-A534 87 1100 EU-A538 55 3500 EU-A750 >1000 >1000 EU-A751 >1000 >1000 EU-A752 146 >1000 EU-A753 >1000 >1000 EU-A754 360 >1000 EU-A755 486 471 EU-A756 611 >1000 EU-A757 6.7 >1000 EU-A770 0.01 2.3 0.5 >100 EU-A771 0.07 14.2 0.4 >100 EU-A772 0.07 8.4 5.4 >100 EU-A773 0.08 8.3 1.5 >100 EU-A774 0.009 6.8 0.15 22.7 EU-A775 0.16 17 0.3 33.6 EU-A776 1.2 >100 6.5 >100 EU-A777 0.1 34.5 0.6 73 EU-A792 <0.05 27.9 <0.05 EU-A793 <0.05 23.8 <0.05 EU-A794 0.05 59.4 0.18 EU-A945 <0.05 9.4 0.06 EU-A948 0.08 25.6 9.1 EU-A992 0.009 0.019 EU-A993 <0.05 12.3 <0.05 EU-A994 0.05 10.2 <0.05 EU-A995 0.035 59.5 0.15 EU-A996 0.05 >100 0.87 EU-A999 0.05 0.015 EU-A1011 0.16 0.51 EU-A1017 0.44 0.10 EU-A1023 0.028 0.035 EU-A1024 0.005 0.035 EU-A1025 0.008 0.240 EU-A1026 0.034 0.486 EU-A1029 0.019 0.06 EU-A1032 0.03 5.4 EU-A1035 0.02 0.19 EU-A1041 0.02 0.13 EU-A1044 0.07 0.57 EU-A1167 0.013 0.019 EU-A1168 0.07 0.14 EU-A1173 0.021 0.463 EU-A1576 0.032 0.070 EU-A1577 0.007 0.069 EU-A1578 0.008 0.355 EU-A1581 0.086 1.032 EU-A1586 0.029 0.107 EU-A1587 0.081 0.253 EU-A1588 0.023 0.043 EU-A1589 0.236 0.655 EU-A1590 0.094 0.343 EU-A1591 0.073 0.286 EU-A1592 0.25 0.78 EU-A1594 0.011 0.068 EU-A1595 0.021 0.113 EU-A1596 0.493 1.230 EU-A1598 0.026 0.199 EU-A1599 0.061 0.317 EU-A1601 0.007 0.048 EU-A1602 0.035 0.162 EU-A1606 0.017 0.058 EU-A1607 0.022 0.126 EU-A1611 0.015 0.16 EU-A1612 0.011 0.059 EU-A1616 0.079 0.204 EU-A1617 0.119 0.598 EU-A1620 0.051 0.24 EU-A1622 0.774 2.08 EU-A1627 0.304 0.705 EU-A1633 0.008 0.053 EU-A1634 0.052 0.493 EU-A1635 0.071 1.983 EU-A1639 0.385 2.292 EU-A1645 0.029 0.091 EU-A1646 0.029 0.332 EU-A1647 0.113 1.895 EU-A1651 0.033 0.149 EU-A1679 0.009 0.14 EU-A1680 0.026 0.114 EU-A1681 ,0.009 0.132 EU-A1682 0.21 1.263 EU-A1710 0.026 0.065 EU-A1711 0.009 0.026 EU-A1712 0.037 0.175 EU-A1713 0.308 2.509 EU-A1716 0.013 0.032 EU-A1717 0.011 0.035 EU-A1718 0.043 0.097 EU-A1719 0.095 0.746 EU-A1722 0.006 0.012 EU-A1723 0.028 0.062 EU-A1729 0.006 0.558 EU-A1730 0.008 1.172 EU-A1734 0.006 0.387 EU-A1735 0.008 0.931 EU-A1739 0.056 2.223 EU-A1740 0.077 3.825 EU-A1745 1.017 10, EU-A1784 0.048 1.907 EU-A1785 0.239 5.145 EU-A1787 0.246 10.0 EU-A1788 0.232 10.0 EU-A1841 0.316 0.475 EU-A1842 1.209 2.109 EU-A1847 0.032 1.95 EU-A1848 0.060 3.064

Example 8 Glucose-lowering activity of peptide products in db/db mice

60 female d6/db B6BKS (D) Leprdb/J mice (line 000697) for this study were about 8-9 weeks old on arrival (Jackson Laboratory, Bar Harbor, Maine). Mice were randomized by weight and two treatment groups of 8 female mice each were treated with test compound EU-A994, EU-A995 or EU-A1026 at 100 or 300 nmol/kg. One group of 8 female mice served as vehicle controls and received vehicle, 0.2% BSA in saline, pH 7.4. One additional group of 8 female mice received the positive control compound, liraglutide, at a dose of 50 nmol/kg. Test compounds, vehicle and positive control compound were administered subcutaneously in a dose volume of 6 ml/kg on day 1 at about 0, 7 and 24 hours.

Clinical observations were made at admission, prior to randomization, and daily from days 1 to 5. Body weight was measured and recorded upon receipt, prior to randomization, and daily from days 1 to 5. Food intake was measured and recorded daily from day 1 to day 5. Blood samples for glucose analysis were collected pre-study (day -3) and 0, 1, 2, 4, 8, 10, 24, 48, 72, and 96 hours after the first dose on day 1. At the end of the study, all animals were euthanized, and the carcasses were discarded without further evaluation.

Significant changes in body weight compared to vehicle were noted for liraglutide and high doses of EU-A994 and high doses of EU-A1026 on days 2 and 3 and for low doses of EU-A1026 on days 3 and 4. With regard to food intake, animals treated liraglutide were significantly different from vehicle on days 1 and 2 and high dose EU-A994 on day 1, low dose EU-A995 on days 1 and 2, high dose EU-A994 on day 1, and low and high dose EU-A1026 on Day 2 was significantly different from liraglutide. Glucose levels for liraglutide at 10 hours and for high dose EU-A994 at 10 and 24 hours were significantly different from vehicle. Similarly, other peptide products were tested for their effect on blood glucose levels, body weight, and food intake.

Compound Dose
(nmol/kg) db/db Mice - mean blood glucose (mg/dl) 0 hours 10 hours 24 hours 48 hours liraglutide 50 595 265 347 377 EU-A994 300 554 242 209 385 EU-A995 300 503 471 493 527 EU-A1026 300 531 399 438 505 liraglutide 50 528 286 404 477 EU-A993 250 503 305 324 426 EU-A995 250 539 584 548 546 EU-А1023 50 507 310 355 375 EU-А1023 250 508 264 194 375 liraglutide 50 442 174 244 439 EU-A992 250 405 104 112 130 EU-A1167 250 379 171 117 113 EU-A1168 250 380 133 169. 164

On FIG. 9 shows that EU-A992 (250 nmol/kg), EU-A1167 (250 nmol/kg), and EU-A1168 (250 nmol/kg) injected subcutaneously at t = 0 and 7 h reduced elevated blood glucose in mice to the normal range of about 72 hours in the db/db diabetic mouse model.

Example 9 Activity of Peptide Products in DIO Mice

Fifty male mice with diet-induced obesity (DIO) C57BL/6J (JAX Labs) were received at 6 weeks of age. Mice were ear cut for identification and mice were housed individually in positively ventilated polycarbonate cages with HEPA-filtered air at a density of 5 mice per cage. The animal room was fully illuminated with artificial fluorescent lighting with a controlled 12-hour light/dark cycle. The normal temperature and relative humidity ranges in the animal rooms were 22 ± 4°C and 50 ± 15%, respectively. Filtered tap water acidified to pH 2.8-3.1 and a high fat diet (Research Diets D12492, 60 kcal%) were provided ad libitum.

After two weeks of acclimatization, 50 mice were randomized into groups (n = 10): group 1: treated with vehicle; Group 2: low dose EU-A994; Group 3: high dose EU-A594; Group 4: low dose EU-A1024; and group 5: high dose EU-A1024. Mice were injected subcutaneously on days 1 (at 0 and 7 hours), 3, 6, 9, 12, 15, 18, 21 and 24. Body weight and cage observations were recorded daily. Food and water intake was recorded weekly. Mice were subjected to NMR measurements to determine whole body fat and lean composition on days 1 (prior to dosing) and 26. On day 26, mice were fasted overnight for an oral glucose tolerance test. The next day, the first blood sample was taken through the tail incision (t = 0). The mice were then given a bolus of 1.0 g/kg glucose. Blood samples were obtained through the tail incision at 0, 15, 30, 60, 90 and 120 minutes after the glucose dose, and plasma glucose levels were immediately determined using a glucometer.

Mice were sacrificed on day 28. Terminal blood was processed to serum/plasma and aliquots sent for glucose, insulin and lipid profile analysis. Body composition was determined by NMR. EU-A1024 reduced glucose deviation in the oral glucose tolerance test (OGTT), decreased basal insulin secretion but increased glucose-dependent insulin secretion, decreased weight gain (Fig. 10), and decreased fat mass with little effect on lean mass (Fig. 11 ).

Example 10 Efficacy of SP-1373 in NASH mouse model

In a biopsy-tested mouse model of DIO-NASH SP-1373, a peptide-surfactant conjugate and a dual GLP-1/glucagon receptor agonist demonstrated superior outcomes in liver histopathology and metabolic parameters compared to semaglutide (a GLP-1 agonist) and elafibranor (a PPAR-α/δ agonist). Non-alcoholic steatohepatitis (NASH) was induced in male C57BL/6JRj mice (~20 g, 5 weeks at arrival, 37 weeks at baseline) by feeding them an AMLN diet containing 40% fat (18% trans fat), 2% cholesterol and 40% carbohydrates (20% fructose) for 32 weeks prior to study entry and during the study period.

All mice included in the study were stratified based on prior liver biopsy at week -3. Only mice with fibrosis score ≥1 and steatosis score ≥2 were included in the study. Stratified mice were randomized into treatment groups based on hepatic alpha-1 (col1α1) collagen quantitation at week-3. The NASH study groups were: 1) vehicle (0.05% Tween 80, 50 mM Na2HPO4, pH 8) administered subcutaneously (SC) once a day (QD) for 12 weeks (n = 12); 2) low dose (5 nmol/kg) SP-1373 based on CT QD for 12 weeks (n = 11); 3) high dose (10 nmol/kg) of SP-1373 subject to CT QD for 12 weeks (n = 11); 4) 78 µmol/kg elafibranor administered orally (PO) QD for 12 weeks (n = 12); and 5) 10 nmol/kg semaglutide based on CT for 12 weeks (n = 12).

Body weight was measured daily throughout the study period. Food intake was measured daily for the first 14 days and then weekly until the end of the study. Whole body echoMRI was performed at 11 weeks. At the end of the study, plasma levels of alanine transaminase (ALT), aspartate transaminase (AST), γ-glutamyl transferase (GGT), triglycerides (TG) and total cholesterol (TC), levels of TG, TC, col1α1 and galectin-3 in the liver, levels expression of a wide range of mRNA in the liver and liver mass, and performed liver biopsy/opening to assess steatosis, inflammation, ballooning and fibrosis of the liver.

For analysis of blood and plasma, blood samples were collected in heparinized tubes, and plasma was separated and stored at -80°C until analysis. ALT, AST, GGT, TG and TC levels were measured using commercial kits (Roche Diagnostics, Germany) and a Cobas™ C-501 autoanalyzer according to the manufacturer's instructions.

For liver tissue analysis, triglyceride and cholesterol levels in the liver were measured using Triglyceride and Cholesterol reagents (Cat. No. 22-045-795 and Cat. No. 22-045-780, respectively, Roche Diagnostics, Germany) and Cobas™ C-501 autoanalyzer . The homogenized liver tissue was heated twice to 80-100° C. and centrifuged in a microcentrifuge, and the content of triglycerides and cholesterol in the resulting supernatant was measured.

The body composition of mice was assessed using the EchoMRI 3-1 body composition analyzer (EchoMRI, USA). Mice without anesthesia were placed in a plastic tube inside the MRI scanner for about 80 seconds. Body composition was expressed as adipose tissue mass, lean tissue mass (muscle mass) and water.

For liver biopsy, mice were anesthetized with inhalation of isoflurane (2-3%). A small abdominal incision was made in the midline, and the left lateral lobe of the liver was exposed. A cone-shaped wedge of liver tissue (about 50 mg) was excised from the distal lobe and fixed in 10% formalin with neutral buffer (4% formaldehyde) for histology. The liver slice surface was electrocoagulated instantly using bipolar coagulation (ERBE VIO 100 electrosurgical unit). After a preliminary biopsy, the liver was returned to the abdominal cavity, the abdominal wall was sutured, and the skin was closed with staples. To recover from surgery, mice were injected with carprofen (5 mg/kg) subcutaneously on the day of surgery and on days 1 and 2 after surgery.

Briefly, for histological staining, paraffin-embedded slides were deparaffinized in xylene and then rehydrated in a series of stepwise ethanol. For hematoxylin and eosin (H&E) staining, slides were incubated in Mayer's hematoxylin (Dako), washed in tap water, stained in eosin Y solution (Sigma-Aldrich), hydrated, embedded with Pertex, and then allowed to dry before scanning. For picrosirius red (PSR) staining, slides were incubated in Weigert's iron hematoxylin (Sigma-Aldrich), washed in tap water, stained with picrosirius red (Sigma-Aldrich) and then washed twice in acidified water. Excess water was removed by shaking the slides, and the slides were dehydrated in three changes of 99% ethanol, cleared in xylene, embedded with Pertex, and then allowed to dry before scanning.

For immunohistochemical staining (IHC) of collagen type 1 alpha-1 (col1α1) and galectin-3 (GAL3), after antigen extraction and blocking of endogenous peroxidase activity, slides were incubated with primary antibody (Cat. No. 1310-01 from Southern Biotech for col1α1 or cat. No. 125402 from Biolegend for galectin-3). The primary anti-col1α1 antibody was detected using a polymeric horseradish peroxidase (HRP)-linker-antibody conjugate, and the primary anti-GAL3 antibody was detected using a secondary linker antibody followed by amplification using a polymeric HRP-linker-antibody conjugate. The primary antibody was then visualized with 3,3'-diaminobenzidine (DAB) as the chromogen. Finally, sections were stained in hematoxylin and covered with coverslips.

To evaluate liver steatosis, inflammation, ballooning, and fibrosis, liver specimens were fixed in formalin and embedded in paraffin, and sections were stained with hematoxylin and eosin or picrosirius red. Sample scores for steatosis, inflammation, ballooning, and fibrosis are summarized in Table 9.

SP-1373 (high dose) significantly reduced body weight in obese mice to the low normal range, while semaglutide and elafibranor caused less weight loss (Figures 12A and 12B [SP-1373 high dose was randomly administered to a group of carriers on the day 62]). SP-1373 caused a marked decrease in whole body adipose tissue mass (FIGS. 13A and 13B), with minimal effect on whole body lean muscle mass. Plasma total cholesterol (TC, Fig. 14B), alanine transaminase (ALT, Fig. 15A), and aspartate transaminase (AST, Fig. 15B) levels were also markedly reduced in animals treated with SP-1373. Plasma ALT and AST levels and the AST/ALT ratio are clinical biomarkers of liver health. The beneficial effects of SP-1373 demonstrate the benefits of dual GLP-1/glucagon receptor agonism. GLP-1 receptor agonism stimulates insulin production and glucose-dependent insulin secretion in the blood, lowers blood glucose levels, suppresses appetite, and induces weight loss. Glucagon receptor agonism has antihyperlipidemic and satiating effects, stimulates fat burning and energy expenditure, and reduces body weight.

SP-1373 caused a significant decrease in liver weight, more than semaglutide, while elafibranor actually increased liver weight (Fig. 16). Liver histology using hematoxylin and eosin staining revealed an almost complete absence of hepatic steatosis in animals treated with a high dose of SP-1373 (Fig. 17C [large white elliptical structure - vein]), in contrast to animals treated with semaglutide (Fig. 17E), which showed a moderate reduction in hepatosteatosis. On FIG. Figures 18A and 18B show liver steatosis after biopsy in terms of % affected area and total liver lipids in various groups of animals as determined by histological quantification, confirming the almost complete absence of liver steatosis in animals treated with high doses of SP-1373. SP-1373 significantly reduced hepatic triglyceride (TG) and total cholesterol (TC) levels to a greater extent than semaglutide, while elafibranor had little or no effect on hepatic TG and TC levels (FIGS. 19A and 19B). SP-1373 also significantly reduced total staining of liver alpha-1 collagen type 1 with anti-col1α1 antibody (an indicator of liver fibrosis), to a greater extent than semaglutide, while elafibranor had a modest effect (Fig. 20). Similarly, SP-1373 significantly reduced total liver galectin-3 staining with anti-GAL3 antibody (a biomarker for inflammation and liver fibrosis), to a greater extent than semaglutide, while elafibranor had essentially no effect (Fig. 21).

The high dose of SP-1373 significantly reduced or eliminated hepatic steatosis in all treated animals (FIG. 22C). On FIG. 22A-22E, for each animal, the transition from biopsy to study to study is marked with a line, and liver steatosis is scored 0-3 in terms of surface area with steatosis. Most of the treated animals showed less liver inflammation (FIGS. 23A-23E). On FIG. 23A-23E, for each animal, the transition from biopsy to study to study is marked with a line, and liver inflammation is scored as severity 0-3. Almost all animals that initially showed hepatocyte ballooning did not balloon after treatment with SP-1373, elafibranor, or semaglutide (FIGS. 24A-24E). On FIG. 24A-24E, for each animal, the transition from pre-examination biopsy to post-examination biopsy is indicated by a line, and hepatocyte ballooning is scored as severity 0-2. Liver steatosis, inflammation, and ballooning scores are described in Table 9.

NAS score (Non-Alcoholic Fatty Liver Disease Activity Score [NAFLD]), a clinical measure of NASH activity, improved in most treated animals and was reduced the most with high doses of SP-1373 (FIGS. 25A-25E). On FIG. 25A-25E, for each animal, the transition from biopsy to study to study is marked with a line. The NAS score is the sum of the scores for hepatic steatosis (0-3), inflammation (0-3), and ballooning (0-2), with a maximum score of 8. A person with a NAS score of 5 or higher is diagnosed as having NASH, and a person with a NAS score of 3 or less as having no NASH. When translated into a mouse model of NASH, a high dose of SP-1373 completely reversed NASH in all treated animals (FIG. 25C).

SP-1373 and elafibranor reduced hepatic fibrosis in most animals (FIGS. 26B-26D). Liver fibrosis was assessed using picrosirius red, which stains type 1 and 3 collagen. On FIG. 26A-26E, for each animal, the transition from pre-examination biopsy to post-examination biopsy is indicated by a line, and liver fibrosis is scored 0-4, as explained in Table 9.

Table 9. Scores for hepatic steatosis, inflammation, ballooning, and fibrosis

sign score Degree Steatosis of the liver 0 <5% surface area affected 1 5-33% 2 > 33-66% 3 > 66% Lobular inflammation ¹ 0 Without foci 1 <2 lesions/200x magnification 2 2-4 hearths/200x 3 > 4 fires/200x Ballooning degeneration ² 0 No 1 Several balloon hepatocytes 2 Many balloon cages/pronounced ballooning Fibrosis of the liver 0 No 1 Perisinusoidal or periportal 2 Perisinusoidal and portal/periportal 3 Bridge fibrosis 4 cirrhosis

¹ Lobular inflammation was assessed by counting the number of inflammatory lesions per field using 200x magnification (minimum 5 fields per animal). The focus was defined as a cluster rather than a row of >3 inflammatory cells. Acidophilic bodies were not included in the assessment.

² Ballooning degeneration was degenerating hepatocytes with cleared cytoplasm, dilatation, swelling, rounding, and reticulate cytoplasm.

SP-1373 reduced the expression of NASH-related mRNAs in the liver, including mRNA encoding proteins involved in fibrosis (e.g. collagen type 1 alpha 1 (col1α1), transforming growth factor-β1 (TGFβ1) and galectin-3 (GAL3, also known as as GAL3).MAC2)}, inflammation {eg, interleukin-1α (IL-1α), IL-1β, tumor necrosis factor-α (TNF-α), GAL3, CD14, toll-like receptor 4 (TLR4), p38 -mitogen-activated protein (MAP) kinase 11 and NF-κB}, monocyte recruitment {e.g., chemokine (CC motif) ligand 5 (CCL5, aka RANTES), monocyte chemoattractant protein 1 (MCP1, also known as CCL2), chemokine receptor 1 (CC motif) (CCR1)) and CCR2}, and differentiation of monocytes, e.g., into macrophages {e.g., GAL3 containing an EGF-like module, mucin-like hormone receptor 1 (EMR1, also known as F4/80), CD14 , CD68 and CD86} (FIGS. 27A-27F and FIGS. 28A-28F). More specifically with respect to fibrosis, SP-1373 reduced hepatic expression of mRNAs encoding proteins involved in fibrous fiber formation (Fig. 29A-29I) and activation of hepatic stellate cells (the main cell type involved in liver fibrosis) and myofibroblast proliferation (Fig. 30A-30F). In addition, SP-1373 reduced hepatic expression of mRNAs encoding proteins involved in pyroptosis, a highly inflammatory form of programmed cell death (FIGS. 31A-31F). For the figures mentioned in this paragraph, the expression level of a particular mRNA is the mean plus SEM, and *P<0.05, **P<0.01, and ***P<0.001 compared to vehicle after adjustment for multiple testing on the genes. SP-1373 also reduced hepatic expression of mRNAs encoding proteins involved in lipid synthesis (eg, fatty acid synthase [FAS], stearoyl-CoA desaturase-1 [SCD1], and 3-hydroxy-3-methylglutaryl-CoA synthase 1 [ HMGCS1]) and lipid uptake (eg CD36). In addition, SP-1373 increased hepatic expression of farnesoid X receptor (FXR) mRNA. In addition, SP-1373 modulates the expression of genes encoding proteins involved, for example, in insulin signaling and glucose homeostasis.

Thus, SP-1373 completely reversed hepatic steatosis, reduced hepatic inflammation and fibrosis, and markedly improved NAS score, and corrected metabolic and glucoregulatory deficiencies in the well-established translational mouse model of NASH. SP-1373 is a potent, balanced and complete GLP-1 and glucagon receptor agonist and has anti-diabetic and anti-obesity effects. Compared to semaglutide, a GLP-1 agonist, SP-1373 has a stronger antihyperglycemic effect, greater reduction in body weight, fat mass and food intake, and a longer duration of action. In a DIO-NASH mouse model, compared with treatment with semaglutide or elafibranor (a dual PPAR-α/δ agonist), treatment with SP-1373 resulted in greater reductions in body weight, plasma total cholesterol (TC), and alanine transaminase (ALT) scores on a scale of NAS, hepatosteatosis, triglycerides and TC levels in the liver, liver weight, content of alpha-1 type of collagen in the liver (an indicator of liver fibrosis) and the content of galectin-3 in the liver (an indicator of inflammation and liver fibrosis). Therefore, SP-1373 is useful in the treatment of, for example, insulin resistance, diabetes (including types 1 and 2), hyperlipidemia, obesity, metabolic syndrome, and cardiovascular disease and related conditions such as NAFLD (including NASH).

Although various embodiments of the present invention have been described, such embodiments are provided by way of illustration and example only. Those skilled in the art will recognize numerous variations and modifications thereof, which are covered by the present invention. It is understood that various alternatives to embodiments of the present invention may be used in the practice of the present invention and are encompassed by the present invention.

--->

SEQUENCE LIST

<110> SPITFIRE PHARMA, INC.

<120> IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER

DISORDERS

<130> 53459-702.601

<140> PCT/US2019/012194

<141> 2019-01-03

<150> 62/613.396

<151> 2018-01-03

<160> 1137

<170>PatentIn version 3.5

<210> 1

<211> 30

<212> PRT

<213> Homo sapiens

<400> 1

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg

20 25 30

<210> 2

<211> 29

<212> PRT

<213> Homo sapiens

<400> 2

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr

20 25

<210> 3

<211> 37

<212> PRT

<213> Homo sapiens

<400> 3

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn

20 25 30

Arg Asn Asn Ile Ala

35

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 4

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 5

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 6

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 7

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 8

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 8

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 9

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 9

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 10

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 10

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 11

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 11

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 12

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 12

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 13

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 14

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 14

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 15

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 15

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 16

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 16

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 17

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 17

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 18

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 19

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 19

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 20

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 20

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 21

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 21

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 22

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 22

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 23

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 23

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 24

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 24

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 25

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 25

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 26

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 26

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 27

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 27

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 28

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 28

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 29

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 29

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 30

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 30

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 31

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 31

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 32

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 32

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 33

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 33

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 34

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 34

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 35

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 35

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 36

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 36

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 37

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 37

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 38

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 38

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 39

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 39

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 40

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 40

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Gly

1 5 10 15

Arg Xaa

<210> 41

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 41

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 42

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 42

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 43

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Xaa

1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 44

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 45

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 46

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 46

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 47

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 47

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 48

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 48

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 49

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 49

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 50

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 50

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 51

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 51

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 52

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 52

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 53

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 53

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 54

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 54

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 55

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 55

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 56

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 56

His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 57

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 57

His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 58

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 58

His Xaa Gln Gly Thr Xaa Thr Ser Asp Leu Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 59

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 59

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 60

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 60

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 61

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 61

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 62

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 62

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 63

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 63

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 64

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 64

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 65

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 65

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 66

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 66

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 67

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 67

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Xaa

1 5 10 15

<210> 68

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 68

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 69

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 69

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 70

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 70

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 71

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 71

His Xaa Gln Gly Thr Phe Thr Ser Asp Leu Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 72

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 72

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 73

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 73

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 74

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 74

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 75

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 75

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 76

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 76

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 77

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 77

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 78

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 78

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 79

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 79

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 80

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> 2.6F-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Bip2Et4MeO

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 80

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 81

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 81

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser

1 5 10 15

xaa

<210> 82

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 82

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser

1 5 10 15

xaa

<210> 83

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 83

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ser

1 5 10 15

xaa

<210> 84

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 84

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 85

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 85

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 86

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 86

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 87

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 87

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 88

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 88

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 89

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 89

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

xaa

<210> 90

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 90

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 91

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 91

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 92

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 92

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 93

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 93

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Xaa Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 94

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 94

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Xaa

1 5 10 15

xaa

<210> 95

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 95

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 96

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 96

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 97

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 97

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Xaa

1 5 10

<210> 98

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 98

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa Xaa

1 5 10

<210> 99

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 99

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 100

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 100

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 101

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 101

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 102

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 102

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 103

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 103

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 104

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 104

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa Xaa

<210> 105

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 105

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa Xaa

<210> 106

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 106

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa Xaa

<210> 107

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (10)..(10)

<223>Nal(2)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 107

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa Lys Tyr Leu Glu Arg

1 5 10 15

Xaa Xaa

<210> 108

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 108

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 109

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 109

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 110

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 110

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 111

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 111

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa

1 5 10

<210> 112

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term NHEt"

<400> 112

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa

1 5 10

<210> 113

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 113

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa

1 5 10 15

<210> 114

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Aib

<220>

<221> source

<223> /note="C-term NHEt"

<400> 114

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa

1 5 10 15

<210> 115

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Aib

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 115

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa Lys Tyr Xaa Xaa

1 5 10 15

<210> 116

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 116

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 117

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 117

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 118

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 118

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 119

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 119

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 120

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 120

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 121

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 121

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 122

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 122

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 123

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 123

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 124

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 124

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 125

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 125

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 126

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 126

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 127

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 127

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 128

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 128

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 129

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 129

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 130

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 130

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 131

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 131

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 132

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 132

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 133

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 133

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 134

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 134

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 135

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 135

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 136

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 136

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 137

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 137

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 138

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 138

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 139

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 139

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 140

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 140

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 141

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 141

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 142

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 142

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 143

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 143

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 144

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 144

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 145

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 145

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 146

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 146

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 147

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 147

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 148

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 148

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 149

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 149

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 150

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 150

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 151

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 151

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 152

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 152

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 153

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 153

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 154

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 154

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 155

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 155

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 156

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 156

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 157

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 157

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 158

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 158

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 159

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 159

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Gln Xaa Phe Xaa

20

<210> 160

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 160

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 161

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 161

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 162

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 162

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 163

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 163

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 164

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 164

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 165

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Me-Phe

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 165

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 166

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 166

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 167

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 167

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 168

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 168

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 169

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 169

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 170

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 170

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 171

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 171

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Ala Lys Xaa Phe Xaa

20

<210> 172

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 172

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Xaa Phe Xaa

20

<210> 173

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 173

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Xaa Phe Xaa

20

<210> 174

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 174

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Ala Ala Lys Xaa Phe Xaa

20

<210> 175

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 175

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Ala Ala Lys Xaa Phe Xaa

20

<210> 176

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 176

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Ala Ala Lys Xaa Phe Xaa

20

<210> 177

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 177

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Ala Ala Lys Xaa Phe Xaa

20

<210> 178

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 178

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Xaa Phe Xaa

20

<210> 179

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 179

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Arg Tyr Leu Asp Glu

1 5 10 15

Arg Ala Ala Lys Xaa Phe Xaa

20

<210> 180

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 180

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 181

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 181

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 182

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 182

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 183

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 183

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 184

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 184

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 185

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 185

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 186

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 186

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 187

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C1)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 187

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 188

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 188

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 189

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 189

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa

<210> 190

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 190

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa

<210> 191

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 191

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa

<210> 192

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 192

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 193

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 193

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 194

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 194

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 195

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac5c

<220>

<221> source

<223> /note="C-term amide"

<400> 195

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 196

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 196

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa

<210> 197

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 197

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa

<210> 198

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 198

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Arg

1 5 10 15

Xaa Xaa

<210> 199

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 199

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 200

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 200

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 201

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 201

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 202

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 202

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 203

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 203

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 204

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 204

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 205

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 205

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg

1 5 10 15

Xaa Xaa

<210> 206

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 206

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg

1 5 10 15

Xaa Xaa

<210> 207

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 207

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Arg

1 5 10 15

Xaa Xaa

<210> 208

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(19)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 208

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

Arg Xaa Xaa

<210> 209

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(19)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 209

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

Arg Xaa Xaa

<210> 210

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(19)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 210

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

Arg Xaa Xaa

<210> 211

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 211

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 212

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 212

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 213

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 213

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 214

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 214

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 215

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 215

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 216

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 216

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 217

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 217

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

Xaa Xaa

<210> 218

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223>hArg

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 218

His Xaa Gln Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

Xaa Xaa

<210> 219

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (22)..(22)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 219

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Gln Xaa Xaa

20

<210> 220

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 220

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Xaa Xaa

20

<210> 221

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 221

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Xaa Xaa

20

<210> 222

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 222

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 223

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 223

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa

<210> 224

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 224

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 225

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 225

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 226

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 226

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Gln Xaa

20

<210> 227

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 227

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Xaa

20

<210> 228

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 228

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Xaa

<210> 229

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 229

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa

<210> 230

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 230

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

xaa

<210> 231

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 231

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

<210> 232

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 232

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Gln Ala Ala Xaa Xaa

20

<210> 233

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 233

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Gln Ala Xaa Xaa

20

<210> 234

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 234

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Gln Xaa Xaa

<210> 235

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 235

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly

1 5 10 15

Xaa Xaa

<210> 236

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 236

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Xaa

1 5 10 15

xaa

<210> 237

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 237

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Xaa

1 5 10 15

<210> 238

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 238

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 239

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Ac4c

<220>

<221> source

<223> /note="C-term amide"

<400> 239

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

xaa

<210> 240

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 240

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Xaa

<210> 241

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 241

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Arg

<210> 242

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 242

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa

<210> 243

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 243

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 244

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 244

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa

<210> 245

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Ac4c

<220>

<221> source

<223> /note="C-term amide"

<400> 245

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa

<210> 246

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 246

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Arg Xaa

<210> 247

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (18)..(18)

<223>hArg

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 247

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 248

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 248

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 249

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Ac4c

<220>

<221> source

<223> /note="C-term amide"

<400> 249

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 250

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 250

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa

<210> 251

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 251

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 252

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 252

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 253

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 253

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 254

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 254

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa

<210> 255

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 255

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Xaa Xaa

<210> 256

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 256

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Ala Lys

20

<210> 257

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 257

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Ala Lys

20

<210> 258

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 258

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Ala Lys

20

<210> 259

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 259

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Ala Lys

20

<210> 260

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 260

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Ala Lys

20

<210> 261

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 261

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 262

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 262

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 263

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 263

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 264

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 264

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 265

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 265

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 266

<400> 266

000

<210> 267

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 267

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 268

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 268

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 269

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 269

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 270

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 270

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 271

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 271

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 272

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 272

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 273

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 273

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 274

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 274

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 275

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 275

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 276

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 276

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 277

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C22)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 277

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 278

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 278

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 279

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 279

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 280

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 280

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 281

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 281

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 282

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 282

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa

<210> 283

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 283

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Xaa

<210> 284

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 284

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Xaa

<210> 285

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 285

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Xaa

<210> 286

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 286

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Xaa

<210> 287

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 287

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Xaa Xaa

<210> 288

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 288

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 289

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 289

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 290

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 290

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 291

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 291

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 292

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 292

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 293

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 293

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 294

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 294

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 295

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 295

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 296

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 296

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 297

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 297

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 298

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 298

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 299

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 299

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 300

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 300

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 301

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 301

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 302

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 302

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 303

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 303

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 304

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 304

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 305

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 305

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 306

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 306

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 307

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 307

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 308

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 308

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 309

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 309

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 310

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 310

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 311

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 311

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 312

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 312

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 313

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 313

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 314

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 314

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 315

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 315

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 316

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 316

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 317

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 317

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 318

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 318

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 319

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 319

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 320

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 320

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 321

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 321

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 322

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 322

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa Xaa

20

<210> 323

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 323

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 324

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 324

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 325

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 325

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 326

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 326

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 327

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 327

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa Xaa

20

<210> 328

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 328

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 329

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 329

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 330

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 330

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 331

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 331

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 332

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 332

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 333

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 333

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 334

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 334

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 335

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 335

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 336

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 336

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 337

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 337

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 338

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac3c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 338

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa Xaa

<210> 339

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 339

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Xaa

<210> 340

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 340

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Xaa Xaa

<210> 341

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 341

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa

<210> 342

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 342

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 343

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 343

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa

<210> 344

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> MOD_RES

<222> (19)..(19)

<223> Aib

<220>

<221> source

<223> /note="C-term amide"

<400> 344

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Xaa Xaa

<210> 345

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 345

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 346

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 346

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 347

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 347

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 348

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 348

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Xaa

<210> 349

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 349

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Arg Xaa

<210> 350

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Ac4c

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223>hArg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 350

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Xaa

1 5 10 15

Xaa Xaa

<210> 351

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (13)..(17)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (13)..(13)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 351

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Glu Leu Asp Ser

1 5 10 15

Lys Xaa

<210> 352

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 352

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Lys

20

<210> 353

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 353

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Arg Lys

20

<210> 354

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 354

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Arg Lys

20

<210> 355

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 355

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Arg Lys

20

<210> 356

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 356

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Arg Lys

20

<210> 357

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 357

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Arg Lys

20

<210> 358

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 358

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Gln Lys

20

<210> 359

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C14)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 359

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Gln Lys

20

<210> 360

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C16)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 360

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Gln Lys

20

<210> 361

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C18)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 361

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Gln Lys

20

<210> 362

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C20)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 362

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Ala Gln Lys

20

<210> 363

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (17)..(21)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (17)..(17)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Lys(C12)

<220>

<221> SITE

<222> (21)..(21)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 363

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Glu Xaa Val Arg Lys

20

<210> 364

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 364

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 365

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 365

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 366

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 366

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 367

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 367

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 368

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 368

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Xaa

1 5 10

<210> 369

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 369

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 370

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 370

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 371

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 371

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Xaa

1 5 10

<210> 372

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 372

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 373

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 373

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 374

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 374

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Xaa

1 5 10

<210> 375

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 375

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 376

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 376

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 377

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(16)

<220>

<221> source

<223> /note="C-term amide"

<400> 377

His Xaa Gln Gly Thr Xaa Thr Ser Asp Tyr Xaa

1 5 10

<210> 378

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 378

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 379

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 379

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 380

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 380

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 381

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 381

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 382

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 382

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 383

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 383

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 384

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 384

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 385

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 385

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 386

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 386

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 387

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 387

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 388

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> source

<223> /note="C-term amide"

<400> 388

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Lys Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 389

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 389

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 390

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 390

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 391

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 391

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 392

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> source

<223> /note="C-term amide"

<400> 392

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Lys Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 393

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 393

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 394

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 394

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 395

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 395

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 396

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 396

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 397

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 397

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 398

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 398

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 399

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 399

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 400

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 400

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 401

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 401

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 402

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 402

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 403

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 403

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 404

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 404

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 405

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 405

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 406

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 406

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 407

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 407

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 408

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 408

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 409

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 409

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 410

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 410

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 411

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 411

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 412

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 412

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 413

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 413

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 414

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 414

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 415

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 415

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 416

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 416

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 417

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 417

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 418

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 418

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 419

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 419

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 420

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 420

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 421

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 421

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 422

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 422

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 423

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 423

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 424

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 424

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 425

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 425

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 426

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 426

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 427

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 427

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 428

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 428

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 429

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 429

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 430

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 430

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 431

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 431

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 432

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 432

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 433

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 433

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 434

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 434

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 435

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 435

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 436

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 436

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 437

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 437

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 438

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 438

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 439

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 439

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 440

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 440

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 441

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 441

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 442

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 442

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 443

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 443

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 444

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 444

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 445

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 445

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 446

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 446

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 447

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 447

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 448

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 448

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 449

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 449

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 450

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 450

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 451

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 451

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 452

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 452

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 453

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 453

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 454

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 454

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 455

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 455

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 456

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 456

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 457

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 457

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 458

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 458

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 459

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 459

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 460

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 460

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 461

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 461

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 462

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 462

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 463

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 463

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 464

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 464

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 465

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 465

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 466

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 466

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 467

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 467

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 468

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 468

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 469

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 469

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 470

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 470

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 471

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 471

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 472

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 472

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 473

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 473

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 474

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 474

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 475

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 475

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 476

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 476

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 477

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 477

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 478

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 478

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 479

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 479

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 480

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 480

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 481

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 481

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 482

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 482

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 483

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 483

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 484

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 484

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 485

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 485

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 486

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 486

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 487

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 487

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 488

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 488

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 489

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 489

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 490

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 490

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 491

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 491

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 492

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 492

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 493

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 493

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 494

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 494

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 495

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 495

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 496

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 496

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 497

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 497

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 498

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 498

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 499

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 499

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 500

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(12)

<220>

<221> source

<223> /note="C-term amide"

<400> 500

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 501

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 501

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 502

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 502

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 503

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 503

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 504

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 504

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 505

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 505

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 506

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 506

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 507

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 507

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 508

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 508

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 509

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 509

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 510

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 510

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 511

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 511

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 512

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 512

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 513

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 513

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 514

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 514

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 515

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 515

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 516

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 516

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 517

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 517

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 518

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 518

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 519

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 519

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 520

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 520

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 521

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 521

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 522

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 522

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 523

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 523

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 524

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 524

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 525

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 525

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 526

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 526

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 527

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 527

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 528

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 528

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 529

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 529

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 530

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 530

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 531

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 531

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 532

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 532

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 533

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 533

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 534

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 534

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 535

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 535

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 536

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 536

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 537

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 537

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 538

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 538

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 539

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 539

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Asn Thr

20 25

<210> 540

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 540

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 541

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 541

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 542

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 542

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 543

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 543

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 544

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 544

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 545

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 545

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 546

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 546

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 547

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 547

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 548

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 548

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 549

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 549

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 550

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 550

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 551

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 551

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Xaa Trp Leu Leu Asn Thr

20 25

<210> 552

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 552

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 553

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 553

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 554

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 554

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 555

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 555

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 556

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 556

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 557

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 557

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 558

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 558

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 559

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 559

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 560

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 560

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 561

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 561

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 562

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 562

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 563

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 563

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 564

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 564

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 565

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 565

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 566

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 566

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 567

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 567

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 568

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 568

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 569

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 569

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 570

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 570

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 571

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 571

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 572

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 572

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 573

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 573

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 574

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 574

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 575

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 575

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 576

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 576

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 577

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 577

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 578

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 578

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 579

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 579

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 580

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 580

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 581

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Aib

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 581

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Xaa

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 582

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 582

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 583

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 583

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 584

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 584

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 585

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 585

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 586

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 586

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 587

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 587

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 588

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 588

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 589

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 589

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 590

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 590

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 591

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 591

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 592

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 592

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 593

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 593

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Val Gln Trp Leu Leu Gln Thr

20 25

<210> 594

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 594

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 595

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 595

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 596

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 596

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 597

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 597

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 598

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 598

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 599

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 599

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Gln Thr

20 25

<210> 600

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 600

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 601

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 601

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 602

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 602

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 603

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 603

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 604

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 604

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 605

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 605

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 606

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M8)

<220>

<221> source

<223> /note="C-term amide"

<400> 606

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 607

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M12)

<220>

<221> source

<223> /note="C-term amide"

<400> 607

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 608

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M14)

<220>

<221> source

<223> /note="C-term amide"

<400> 608

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 609

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M16)

<220>

<221> source

<223> /note="C-term amide"

<400> 609

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 610

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M18)

<220>

<221> source

<223> /note="C-term amide"

<400> 610

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 611

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M20)

<220>

<221> source

<223> /note="C-term amide"

<400> 611

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 612

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M8)

<220>

<221> source

<223> /note="C-term amide"

<400> 612

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 613

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M12)

<220>

<221> source

<223> /note="C-term amide"

<400> 613

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 614

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M14)

<220>

<221> source

<223> /note="C-term amide"

<400> 614

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 615

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M16)

<220>

<221> source

<223> /note="C-term amide"

<400> 615

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 616

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M18)

<220>

<221> source

<223> /note="C-term amide"

<400> 616

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 617

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(M20)

<220>

<221> source

<223> /note="C-term amide"

<400> 617

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 618

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M8)

<220>

<221> source

<223> /note="C-term amide"

<400> 618

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 619

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M12)

<220>

<221> source

<223> /note="C-term amide"

<400> 619

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 620

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M14)

<220>

<221> source

<223> /note="C-term amide"

<400> 620

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 621

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M16)

<220>

<221> source

<223> /note="C-term amide"

<400> 621

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 622

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M18)

<220>

<221> source

<223> /note="C-term amide"

<400> 622

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 623

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M20)

<220>

<221> source

<223> /note="C-term amide"

<400> 623

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 624

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M8)

<220>

<221> source

<223> /note="C-term amide"

<400> 624

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 625

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M12)

<220>

<221> source

<223> /note="C-term amide"

<400> 625

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 626

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M14)

<220>

<221> source

<223> /note="C-term amide"

<400> 626

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 627

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M16)

<220>

<221> source

<223> /note="C-term amide"

<400> 627

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 628

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M18)

<220>

<221> source

<223> /note="C-term amide"

<400> 628

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 629

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(M20)

<220>

<221> source

<223> /note="C-term amide"

<400> 629

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 630

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term amide"

<400> 630

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 631

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 631

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 632

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 632

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 633

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 633

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 634

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 634

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 635

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me20)

<220>

<221> source

<223> /note="C-term amide"

<400> 635

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 636

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term amide"

<400> 636

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 637

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 637

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 638

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 638

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 639

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 639

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 640

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 640

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 641

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me20)

<220>

<221> source

<223> /note="C-term amide"

<400> 641

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Arg Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 642

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term amide"

<400> 642

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 643

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 643

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 644

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 644

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 645

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 645

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 646

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 646

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 647

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me20)

<220>

<221> source

<223> /note="C-term amide"

<400> 647

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 648

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term amide"

<400> 648

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 649

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 649

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 650

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 650

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 651

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 651

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 652

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 652

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 653

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me20)

<220>

<221> source

<223> /note="C-term amide"

<400> 653

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Gln Thr

20 25

<210> 654

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 654

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 655

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 655

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 656

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 656

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 657

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 657

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 658

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 658

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 659

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 659

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 660

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 660

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 661

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 661

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 662

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 662

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 663

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 663

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 664

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 664

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 665

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 665

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 666

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 666

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 667

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 667

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 668

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 668

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 669

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 669

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 670

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 670

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 671

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 671

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 672

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 672

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 673

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 673

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 674

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 674

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 675

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 675

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 676

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 676

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 677

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 677

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 678

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 678

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 679

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 679

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 680

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 680

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 681

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 681

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 682

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 682

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 683

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 683

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 684

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 684

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 685

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 685

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 686

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 686

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 687

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 687

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 688

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 688

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 689

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 689

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 690

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 690

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 691

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 691

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 692

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 692

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 693

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 693

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 694

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 694

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 695

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 695

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 696

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 696

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 697

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 697

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 698

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 698

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 699

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 699

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 700

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 700

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 701

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 701

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 702

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 702

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 703

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 703

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 704

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 704

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 705

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 705

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 706

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 706

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 707

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 707

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 708

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 708

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 709

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 709

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 710

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 710

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 711

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 711

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 712

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 712

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 713

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 713

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 714

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 714

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 715

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 715

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 716

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 716

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 717

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 717

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 718

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 718

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 719

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 719

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 720

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 720

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 721

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 721

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 722

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 722

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 723

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 723

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 724

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 724

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 725

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> EtBip

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 725

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 726

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 726

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 727

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 727

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 728

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 728

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 729

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 729

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 730

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 730

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 731

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 731

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 732

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 732

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 733

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 733

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 734

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 734

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 735

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 735

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 736

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 736

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 737

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 737

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 738

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 738

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 739

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 739

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 740

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 740

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 741

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 741

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 742

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 742

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 743

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 743

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 744

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 744

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 745

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 745

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 746

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 746

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 747

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 747

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 748

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> MeLys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 748

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 749

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223>MeLys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 749

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 750

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 750

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 751

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 751

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 752

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 752

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 753

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 753

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 754

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 754

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 755

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 755

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 756

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 756

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 757

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 757

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 758

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 758

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 759

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 759

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 760

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 760

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 761

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Alpha-MePro

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 761

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 762

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 762

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 763

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 763

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 764

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 764

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 765

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 765

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 766

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 766

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 767

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 767

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 768

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me8

<220>

<221> source

<223> /note="C-term amide"

<400> 768

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 769

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me12

<220>

<221> source

<223> /note="C-term amide"

<400> 769

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 770

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me14

<220>

<221> source

<223> /note="C-term amide"

<400> 770

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 771

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me16

<220>

<221> source

<223> /note="C-term amide"

<400> 771

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 772

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me18

<220>

<221> source

<223> /note="C-term amide"

<400> 772

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 773

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys Me20

<220>

<221> source

<223> /note="C-term amide"

<400> 773

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 774

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ser" or "Ala" or "Lys" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Glu" or "Lys" or "U(X); where 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu" or "Arg"

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Gln" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="Val" or "Leu"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 774

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Met Asn Thr

20 25

<210> 775

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ala" or "Aib"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> U(X); when 'U' is a natural or unnatural amino

acid containing a functional group

covalently attached to the surfactant X

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="val"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 775

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Asn Thr

20 25

<210> 776

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ser" or "Ala" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg" or "Gln"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ala" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="val"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 776

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Lys Asp Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 777

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ser" or "Ala" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg" or "Gln"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ala" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="val"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 777

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Lys Asp Phe Ile Gln Trp Leu Leu Asn Thr

20 25

<210> 778

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="gly"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg" or "Gln"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega-X)

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="Val" or "Leu" or "Nle"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 778

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Arg Ala Ala Lys Glu Phe Ile Xaa Trp Leu Met Asn Thr

20 25

<210> 779

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="gly"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ala" or "Aib"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega-X)

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 779

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 780

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ala" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(N-omega-X)

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ala"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="val"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 780

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Ile Gln Trp Leu Leu Asn Thr

20 25

<210> 781

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib" or "MePro"

<220>

<221> VARIANT

<222>(6)..(6)

<223> /replace="2FPhe" or "MePhe" or "2FMePhe"

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Nal2" or "Bip" or "Bip2Et" or "Bip2EtMeO"

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(N-omega-X)

<220>

<221> source

<223> /note="C-term -OH or -NH-R3"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 781

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Xaa

1 5 10

<210> 782

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> source

<222> /note="N-term Fmoc"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Alloc)

<400> 782

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Glu Ser

1 5 10 15

xaa

<210> 783

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> source

<222> /note="N-term Boc"

<220>

<221> MOD_RES

<222> (1)..(1)

<223> His(Trt)

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Gln(Trt)

<220>

<221> MOD_RES

<222> (5)..(5)

<223> Thr(tBu)

<220>

<221> MOD_RES

<222>(7)..(7)

<223> Thr(tBu)

<220>

<221> MOD_RES

<222>(8)..(8)

<223> Ser(tBu)

<220>

<221> MOD_RES

<222>(9)..(9)

<223> Asp(OtBu)

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Tyr(tBu)

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Ser(tBu)

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Lys(Boc)

<220>

<221> MOD_RES

<222> (13)..(13)

<223> Tyr(tBu)

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Asp(OtBu)

<220>

<221> MOD_RES

<222> (16)..(16)

<223> Glu(O-Allyl)

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Gln(Trt)

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Alloc)

<220>

<221> MOD_RES

<222> (21)..(21)

<223> Glu(O-tBu)

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Dde)

<220>

<221> MOD_RES

<222> (25)..(25)

<223> Trp(Boc)

<220>

<221> MOD_RES

<222> (28)..(28)

<223> Gln(Trt)

<220>

<221> MOD_RES

<222> (29)..(29)

<223> Thr(tBu)

<220>

<221> source

<223> /note="C-term HMPA"

<400> 783

Xaa Xaa Xaa Gly Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa

1 5 10 15

Xaa Ala Ala Xaa Xaa Phe Ile Xaa Xaa Leu Leu Xaa Xaa

20 25

<210> 784

<400> 784

000

<210> 785

<400> 785

000

<210> 786

<400> 786

000

<210> 787

<400> 787

000

<210> 788

<400> 788

000

<210> 789

<400> 789

000

<210> 790

<400> 790

000

<210> 791

<400> 791

000

<210> 792

<400> 792

000

<210> 793

<400> 793

000

<210> 794

<400> 794

000

<210> 795

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 795

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Asn Thr

20 25

<210> 796

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega-X)

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 796

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 797

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega-X)

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 797

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 798

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C9)

<220>

<221> source

<223> /note="C-term amide"

<400> 798

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 799

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C10)

<220>

<221> source

<223> /note="C-term amide"

<400> 799

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 800

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(C11)

<220>

<221> source

<223> /note="C-term amide"

<400> 800

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 801

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me8)

<220>

<221> source

<223> /note="C-term amide"

<400> 801

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 802

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 802

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 803

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 803

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 804

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 804

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 805

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 805

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 806

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(alpha-Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 806

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 807

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term OH"

<400> 807

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 808

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term OH"

<400> 808

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 809

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term OH"

<400> 809

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 810

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term OH"

<400> 810

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 811

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term OH"

<400> 811

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 812

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term OH"

<400> 812

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 813

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term OH"

<400> 813

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 814

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term OH"

<400> 814

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 815

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term OH"

<400> 815

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 816

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term OH"

<400> 816

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 817

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 817

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 818

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 818

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 819

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 819

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 820

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 820

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 821

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 821

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 822

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term OH"

<400> 822

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 823

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 823

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 824

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term OH"

<400> 824

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 825

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me10)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 825

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 826

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me12)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 826

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 827

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me14)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 827

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 828

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me16)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 828

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 829

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me18)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 829

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 830

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me12)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 830

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 831

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Lys(Me12)

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term OH"

<400> 831

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 832

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 832

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 833

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 833

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 834

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 834

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 835

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 835

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 836

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 836

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 837

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 837

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 838

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 838

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 839

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 839

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 840

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 840

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 841

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 841

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 842

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me10)

<220>

<221> source

<223> /note="C-term OH"

<400> 842

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 843

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me12)

<220>

<221> source

<223> /note="C-term OH"

<400> 843

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 844

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me14)

<220>

<221> source

<223> /note="C-term OH"

<400> 844

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 845

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me16)

<220>

<221> source

<223> /note="C-term OH"

<400> 845

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 846

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Me18)

<220>

<221> source

<223> /note="C-term OH"

<400> 846

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 847

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me10)

<220>

<221> source

<223> /note="C-term OH"

<400> 847

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 848

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me12)

<220>

<221> source

<223> /note="C-term OH"

<400> 848

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 849

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me14)

<220>

<221> source

<223> /note="C-term OH"

<400> 849

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 850

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me16)

<220>

<221> source

<223> /note="C-term OH"

<400> 850

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 851

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Me18)

<220>

<221> source

<223> /note="C-term OH"

<400> 851

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 852

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me12)

<220>

<221> source

<223> /note="C-term OH"

<400> 852

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 853

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me10)

<220>

<221> source

<223> /note="C-term OH"

<400> 853

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 854

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me14)

<220>

<221> source

<223> /note="C-term OH"

<400> 854

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 855

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me16)

<220>

<221> source

<223> /note="C-term OH"

<400> 855

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 856

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me18)

<220>

<221> source

<223> /note="C-term OH"

<400> 856

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 857

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 857

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 858

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 858

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 859

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 859

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 860

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 860

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 861

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 861

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 862

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 862

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 863

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term PEG"

<400> 863

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 864

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term PEG"

<400> 864

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 865

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term PEG"

<400> 865

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 866

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term PEG"

<400> 866

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 867

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term PEG"

<400> 867

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 868

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term PEG"

<400> 868

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 869

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term PEG"

<400> 869

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 870

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term PEG"

<400> 870

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 871

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term PEG"

<400> 871

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 872

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term PEG"

<400> 872

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 873

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term PEG"

<400> 873

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 874

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term PEG"

<400> 874

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 875

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 875

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 876

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 876

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 877

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 877

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 878

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 878

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 879

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 879

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 880

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 880

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 881

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 881

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 882

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 882

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 883

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 883

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 884

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 884

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 885

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 885

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 886

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term PEGb"

<400> 886

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 887

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 887

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 888

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 888

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 889

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 889

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 890

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 890

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 891

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 891

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 892

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 892

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 893

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 893

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 894

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 894

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 895

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 895

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 896

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 896

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 897

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 897

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 898

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term PEGc"

<400> 898

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 899

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 899

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 900

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 900

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 901

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 901

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 902

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 902

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 903

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 903

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 904

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 904

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 905

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me8)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 905

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 906

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 906

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 907

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 907

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 908

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 908

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 909

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 909

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 910

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term PEGd"

<400> 910

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 911

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term OH"

<400> 911

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 912

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term OH"

<400> 912

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 913

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term OH"

<400> 913

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 914

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term OH"

<400> 914

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 915

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term OH"

<400> 915

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 916

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term OH"

<400> 916

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 917

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z8)

<220>

<221> source

<223> /note="C-term OH"

<400> 917

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 918

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term OH"

<400> 918

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 919

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term OH"

<400> 919

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 920

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term OH"

<400> 920

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 921

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term OH"

<400> 921

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 922

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term OH"

<400> 922

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 923

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z8)

<220>

<221> source

<223> /note="C-term OH"

<400> 923

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 924

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z10)

<220>

<221> source

<223> /note="C-term OH"

<400> 924

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 925

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z12)

<220>

<221> source

<223> /note="C-term OH"

<400> 925

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 926

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z14)

<220>

<221> source

<223> /note="C-term OH"

<400> 926

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 927

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z16)

<220>

<221> source

<223> /note="C-term OH"

<400> 927

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 928

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z18)

<220>

<221> source

<223> /note="C-term OH"

<400> 928

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 929

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z8)

<220>

<221> source

<223> /note="C-term OH"

<400> 929

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 930

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z10)

<220>

<221> source

<223> /note="C-term OH"

<400> 930

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 931

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z12)

<220>

<221> source

<223> /note="C-term OH"

<400> 931

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 932

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z14)

<220>

<221> source

<223> /note="C-term OH"

<400> 932

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 933

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z16)

<220>

<221> source

<223> /note="C-term OH"

<400> 933

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 934

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z18)

<220>

<221> source

<223> /note="C-term OH"

<400> 934

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 935

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z8)

<220>

<221> source

<223> /note="C-term OH"

<400> 935

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 936

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z10)

<220>

<221> source

<223> /note="C-term OH"

<400> 936

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 937

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z12)

<220>

<221> source

<223> /note="C-term OH"

<400> 937

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 938

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z14)

<220>

<221> source

<223> /note="C-term OH"

<400> 938

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 939

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z16)

<220>

<221> source

<223> /note="C-term OH"

<400> 939

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 940

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z18)

<220>

<221> source

<223> /note="C-term OH"

<400> 940

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 941

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z8)

<220>

<221> source

<223> /note="C-term amide"

<400> 941

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 942

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 942

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 943

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 943

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 944

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 944

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 945

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 945

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 946

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS1(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 946

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 947

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z8)

<220>

<221> source

<223> /note="C-term amide"

<400> 947

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 948

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 948

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 949

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 949

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 950

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 950

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 951

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 951

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 952

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS2(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 952

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 953

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z8)

<220>

<221> source

<223> /note="C-term amide"

<400> 953

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 954

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 954

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 955

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 955

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 956

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 956

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 957

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 957

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 958

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> LysS3(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 958

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 959

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 959

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 960

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 960

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 961

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 961

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 962

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 962

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 963

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 963

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 964

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 964

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 965

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 965

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 966

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 966

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 967

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 967

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 968

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 968

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 969

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 969

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 970

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 970

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 971

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 971

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 972

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 972

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 973

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 973

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 974

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 974

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 975

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 975

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 976

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 976

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 977

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 977

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 978

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 978

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 979

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 979

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 980

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 980

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 981

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 981

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 982

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 982

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 983

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 983

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 984

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 984

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 985

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 985

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 986

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 986

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 987

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 987

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 988

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 988

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 989

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 989

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 990

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 990

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 991

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 991

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 992

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 992

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 993

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 993

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 994

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 994

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 995

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 995

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 996

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 996

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 997

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 997

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 998

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 998

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 999

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 999

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1000

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1000

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1001

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1001

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1002

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 1002

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1003

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1003

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1004

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1004

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1005

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1005

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1006

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1006

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1007

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me10)

<220>

<221> source

<223> /note="C-term amide"

<400> 1007

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1008

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1008

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1009

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1009

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1010

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1010

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1011

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1011

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1012

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1012

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1013

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1013

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1014

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z10)

<220>

<221> source

<223> /note="C-term amide"

<400> 1014

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1015

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1015

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1016

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1016

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1017

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1017

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1018

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS1(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1018

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1019

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1019

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1020

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1020

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1021

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS2(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1021

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1022

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1022

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1023

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1023

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1024

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (12)..(12)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> LysS3(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1024

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Glu Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1025

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222> (10)..(10)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Gln"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "Gln"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1025

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Lys

1 5 10 15

Glu Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1026

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "Gln"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1026

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1027

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Glu"

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (14)..(14)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Gln"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "Gln"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1027

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1028

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclic"

<220>

<221> VARIANT

<222> (12)..(12)

<223> /replace="Glu"

<220>

<221> SITE

<222> (12)..(16)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Gln"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "Gln"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1028

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Gln Asp Lys

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1029

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu"

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclized through side chain to form a lactam linkage"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> U(X); when 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1029

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Lys

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Asn Thr

20 25

<210> 1030

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1030

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1031

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1031

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1032

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1032

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1033

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1033

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1034

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1034

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1035

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1035

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1036

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1036

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1037

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1037

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1038

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1038

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1039

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1039

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1040

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1040

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1041

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1041

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1042

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1042

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1043

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1043

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1044

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1044

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1045

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1045

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1046

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1046

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1047

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1047

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1048

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1048

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1049

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1049

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1050

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1050

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1051

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1051

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1052

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1052

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1053

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1053

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1054

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1054

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1055

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1055

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1056

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1056

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1057

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1057

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1058

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1058

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1059

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1059

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1060

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS1(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1060

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1061

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1061

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1062

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1062

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1063

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1063

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1064

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1064

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1065

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1065

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1066

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1066

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1067

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS2(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1067

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1068

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z10)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1068

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1069

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z12)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1069

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1070

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1070

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1071

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1071

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1072

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1072

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1073

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1073

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1074

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> LysS3(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1074

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1075

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1075

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1076

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1076

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1077

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Me18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1077

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1078

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z14)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1078

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1079

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z16)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1079

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1080

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z18)

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1080

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1081

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1081

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1082

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1082

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1083

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1083

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1084

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1084

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1085

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1085

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1086

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1086

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1087

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1087

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1088

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1088

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1089

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1089

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1090

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1090

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1091

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1091

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1092

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1092

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Glu Trp Leu Leu Gln Thr

20 25

<210> 1093

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1093

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1094

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1094

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1095

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Me18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1095

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1096

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1096

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1097

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1097

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1098

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Lys(Z18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1098

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Glu Ala Ala Xaa Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1099

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z12)

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1099

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1100

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z14)

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1100

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1101

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z16)

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1101

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1102

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z14CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1102

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1103

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z16CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1103

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1104

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(Z18CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1104

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Xaa Ala Ala Gln Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1105

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z14CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1105

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1106

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z16CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1106

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1107

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (10)..(14)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (10)..(10)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (14)..(14)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(Z18CO2)

<220>

<221> source

<223> /note="C-term amide"

<400> 1107

His Xaa Gln Gly Thr Phe Thr Ser Asp Glu Ser Lys Tyr Lys Asp Ser

1 5 10 15

Gln Ala Ala Gln Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1108

<211> 38

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

polypeptide"

<220>

<221> MOD_RES

<222> (1)..(1)

<223>pGlu

<220>

<221> VARIANT

<222> (1)..(1)

<223> /replace=" "

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="N(R3)His" or "N(R4)His"

<220>

<221> VARIANT

<222> (3)..(3)

<223> /replace="D-Ser" or "Ala" or "Gly" or "Pro" or "MePro" or

"Aib" or "Ac4c" or "Ac5c"

<220>

<221> VARIANT

<222> (4)..(4)

<223> /replace="cit"

<220>

<221> VARIANT

<222> (5)..(5)

<223> /replace="D-Ala"

<220>

<221> VARIANT

<222>(6)..(6)

<223> /replace="ser"

<220>

<221> VARIANT

<222>(7)..(7)

<223> /replace="Trp" or "2FPhe" or "MePhe" or "2FMePhe" or "Nal2"

<220>

<221> VARIANT

<222>(8)..(8)

<223> /replace="ser"

<220>

<221> VARIANT

<222>(9)..(9)

<223> /replace="Asp"

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (11)..(11)

<223> /replace="Leu" or "Met" or "Nal2" or "Bip" or "Bip2EtMeO" or

"Glu" or "Lys" or "U; where 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X"

<220>

<221> VARIANT

<222> (12)..(12)

<223> /replace="Asn" or "Bip" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (13)..(13)

<223> /replace="Glu" or "Ser" or "Arg" or "U; although 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (14)..(14)

<223> /replace="Gln" or "Cit" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (15)..(15)

<223> /replace="Met" or "Nle" or "Glu" or "Lys" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu" or "U; where 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Ac5c" or "Lys"

or "Arg" or "U; where 'U' is any natural

or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (18)..(18)

<223> /replace="hArg" or "Gln" or "Glu" or "Cit" or "Aib" or "Ac4c"

or "Ac5c" or "Lys" or "U; where 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (19)..(19)

<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or "Ac5c" or "U;

while 'U' is any natural or unnatural amino acid containing

a functional group used for covalent attachment to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Val" or "Aib" or "Ac4c" or "Ac5c" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (21)..(21)

<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib" or "Ac4c"

or "Ac5c" or "U; where 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (22)..(22)

<223> /replace="Glu" or "Leu" or "Aib" or "Ac4c" or "Ac5c" or "U;

while 'U' is any natural or unnatural amino acid containing

a functional group used for covalent attachment to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="Trp" or "Nal2" or "Aib" or "Ac4c" or "Ac5c" or "U;

while 'U' is any natural or unnatural amino acid containing

a functional group used for covalent attachment to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (25)..(25)

<223> /replace="Ala" or "Glu" or "Cit" or "U; although 'U' is any

natural or unnatural amino acids comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (26)..(26)

<223> /replace="Nal2" or "U; while 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="U; where 'U' is any natural or unnatural amino acid

comprising a functional group used for covalent attachment to

the surfactant X" or " "

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Val" or "Leu" or "Nle" or "Lys" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (29)..(29)

<223> /replace="Lys" or "Glu" or "Gln" or "Cit" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (30)..(30)

<223> /replace="Gly" or "Aib" or "Ac4c" or "Ac5c" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (31)..(31)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "Arg" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (32)..(32)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (33)..(33)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (34)..(34)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (35)..(35)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (36)..(36)

<223> /replace="Aib" or "Ac4c" or "Ac5c" or "U; when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (37)..(37)

<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or "U; when 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> MOD_RES

<222> (38)..(38)

<223>U; when 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X

<220>

<221> VARIANT

<222> (38)..(38)

<223> /replace=" "

<220>

<221> source

<223> /note="C-term OH, N-R4-His or -NH-R3"

<220>

<221> SITE

<222> (1)..(38)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 1108

Xaa His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp

1 5 10 15

Ser Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr Lys Arg

20 25 30

Asn Arg Asn Asn Ala Xaa

35

<210> 1109

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

polypeptide"

<220>

<221> MOD_RES

<222> (1)..(1)

<223>pGlu

<220>

<221> VARIANT

<222> (1)..(1)

<223> /replace=" "

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="N(R3)His" or "N(Ac)His"

<220>

<221> VARIANT

<222> (3)..(3)

<223> /replace="Ala" or "Gly" or "MePro" or "Aib" or

"Ac4c" or "Ac5c"

<220>

<221> VARIANT

<222> (4)..(4)

<223> /replace="cit"

<220>

<221> VARIANT

<222> (5)..(5)

<223> /replace="D-Ala"

<220>

<221> VARIANT

<222>(6)..(6)

<223> /replace="ser"

<220>

<221> VARIANT

<222>(7)..(7)

<223> /replace="Trp" or "2FPhe" or "MePhe" or "2FMePhe" or

"Nal2"

<220>

<221> VARIANT

<222>(8)..(8)

<223> /replace="ser"

<220>

<221> VARIANT

<222>(9)..(9)

<223> /replace="Asp"

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (11)..(11)

<223> /replace="Leu" or "Met" or "Nal2" or "Bip" or

"Bip2EtMeO" or "U(X); where 'U' is a natural or unnatural

amino acids containing a functional group covalently attached

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (12)..(12)

<223> /replace="Asn" or "Bip" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional group

covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (13)..(13)

<223> /replace="Glu" or "Ser" or "Arg" or "U(X); if 'U' is

a natural or unnatural amino acid containing a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (14)..(14)

<223> /replace="Gln" or "Cit" or "U(X); when 'U' is

a natural or unnatural amino acid containing a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (15)..(15)

<223> /replace="Met" or "Nle" or "Glu" or "Lys" or

"U(X); where 'U' is a natural or unnatural amino acid

comprising a functional group covalently attached to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Glu" or "U(X); while 'U' is a natural

or unnatural amino acids comprising a functional group

covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Ac5c"

or "Lys" or "Arg" or "U(X); where 'U' is a natural or

unnatural amino acids comprising a functional group covalently

attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (18)..(18)

<223> /replace="hArg" or "Gln" or "Glu" or "Lys" or "Cit"

or "Aib" or "Ac4c" or "Ac5c" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (19)..(19)

<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or

"Ac5c" or "U(X); where 'U' is a natural or unnatural

amino acids comprising a functional group covalently

attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Val" or "Aib" or "Ac4c" or

"Ac5c" or "U(X); where 'U' is a natural or unnatural

amino acids comprising a functional group covalently

attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (21)..(21)

<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib"

or "Ac4c" or "Ac5c" or "U(X); while 'U' is a natural

or unnatural amino acids comprising a functional group

covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (22)..(22)

<223> /replace="Glu" or "Leu" or "Aib" or "Ac4c" or "Ac5c"

or "U(X); where 'U' is a natural or unnatural amino acid

comprising a functional group covalently attached to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="Trp" or "Nal2" or "Aib" or "Ac4c" or

"Ac5c" or "U(X); where 'U' is a natural or unnatural

amino acids comprising a functional group covalently

attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ile" or "Aib" or "Ac4c" or "Ac5c" or

"U(X); when 'U' is a natural or unnatural amino

acid comprising a functional group covalently attached

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (25)..(25)

<223> /replace="Gln" or "Glu" or "Cit" or "U(X); when 'U' is

a natural or unnatural amino acid containing a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (26)..(26)

<223> /replace="Nal2" or "U(X); when 'U' is a

natural or unnatural amino acids comprising a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="U(X); when 'U' is a natural or

unnatural amino acids comprising a functional group

covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Val" or "Leu" or "Nle" or "Lys" or

"U(X); when 'U' is a natural or unnatural amino

acid comprising a functional group covalently attached

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (29)..(29)

<223> /replace="Lys" or "Glu" or "Gln" or "U(X); when 'U' is

a natural or unnatural amino acid containing a functional

group covalently attached to the surfactant X" or " "

<220>

<221> VARIANT

<222> (30)..(30)

<223> /replace="Gly" or "Aib" or "Ac4c" or "Ac5c" or "U(X);

while 'U' is a natural or unnatural amino acid containing

a functional group covalently attached to the surfactant X"

or""

<220>

<221> source

<223> /note="C-term -OH or -NH-R3"

<220>

<221> SITE

<222> (1)..(30)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 1109

Xaa His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp

1 5 10 15

Ser Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr

20 25 30

<210> 1110

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Glu" or "Lys" or "U(X); while 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (12)..(12)

<223> /replace="Glu"

<220>

<221> VARIANT

<222> (14)..(14)

<223> /replace="Glu" or "Lys"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Lys"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Glu" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Lys" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term -OH or -NH-R3"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 1110

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Glu Glu Phe Ile Gln Trp Leu Leu Glu Thr

20 25

<210> 1111

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

polypeptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="MePro" or "Aib"

<220>

<221> VARIANT

<222> (3)..(3)

<223> /replace="cit"

<220>

<221> VARIANT

<222>(6)..(6)

<223> /replace="2FPhe" or "MePhe" or "2FMePhe" or "Nal2"

<220>

<221> VARIANT

<222> (10)..(10)

<223> /replace="Nal2" or "Bip" or "Bip2EtMeO" or "Glu" or "Lys"

or "U(X); while 'U' is any natural or unnatural amino

acid comprising a functional group used for covalent

attachment to the surfactant X"

<220>

<221> VARIANT

<222> (11)..(11)

<223> /replace="Asn" or "Bip" or "U(X); where 'U' is any natural

or unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (12)..(12)

<223> /replace="Glu" or "Ser" or "U(X); where 'U' is any natural

or unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (13)..(13)

<223> /replace="Gln" or "Cit" or "U(X); while 'U' is any natural

or unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (14)..(14)

<223> /replace="Nle" or "Glu" or "Lys" or "U(X); when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (15)..(15)

<223> /replace="Glu" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Gly" or "Glu" or "Ala" or "Aib" or "Lys" or "Arg" or

"U(X); where 'U' is any natural or unnatural amino acid

comprising a functional group used for covalent attachment

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg" or "Gln" or "Glu" or "Lys" or "Cit" or "Aib"

or "U(X); where 'U' is any natural or unnatural amino acid

comprising a functional group used for covalent attachment

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (18)..(18)

<223> /replace="hArg" or "Ala" or "Aib" or "Ac4c" or "Ac5c" or "U(X);

while 'U' is any natural or unnatural amino acid containing

a functional group used for covalent attachment to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (19)..(19)

<223> /replace="Aib" or "U(X); when 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Lys" or "Arg" or "Cit" or "Glu" or "Aib" or "U(X);

while 'U' is any natural or unnatural amino acid containing

a functional group used for covalent attachment to the

surfactant X" or " "

<220>

<221> VARIANT

<222> (21)..(21)

<223> /replace="Glu" or "Leu" or "Aib" or "U(X); when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (22)..(22)

<223> /replace="U(X); where 'U' is any natural or unnatural amino

acid comprising a functional group used for covalent attachment

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="Ile" or "Aib" or "U(X); where 'U' is any natural or

unnatural amino acids containing a functional group used for

covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Glu" or "Gln" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used for

covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (25)..(25)

<223> /replace="U(X); where 'U' is any natural or unnatural amino

acid comprising a functional group used for covalent attachment

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (26)..(26)

<223> /replace="U(X); where 'U' is any natural or unnatural amino

acid comprising a functional group used for covalent attachment

to the surfactant X" or " "

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="Val" or "Leu" or "Nle" or "Lys" or "U(X); while 'U'

is any natural or unnatural amino acid comprising a functional

group used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Glu" or "Gln" or "Cit" or "U(X); when 'U' is any

natural or unnatural amino acids comprising a functional group

used for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (29)..(29)

<223> /replace="Thr" or "Aib" or "U(X); where 'U' is any natural

or unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X" or " "

<220>

<221> VARIANT

<222> (30)..(30)

<223> /replace="Arg" or "U(X); while 'U' is any natural or unnatural

amino acids comprising a functional group used for covalent

attachment to the surfactant X" or " "

<220>

<221> source

<223> /note="C-term OH or -NH-R3"

<220>

<221> SITE

<222> (1)..(30)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<220>

<221> source

<223> /note="See specification as filed for detailed description of

substitutions and preferred embodiments"

<400> 1111

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser

1 5 10 15

Arg Arg Ala Gln Asp Phe Val Ala Trp Leu Met Asn Thr Arg

20 25 30

<210> 1112

<400> 1112

000

<210> 1113

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega-X)

<220>

<221> source

<223> /note="C-term -OH or -NHR3"

<400> 1113

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1114

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-dodecyl alpha-D-melibiouronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-dodecyl beta-D-glucouronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1114

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1115

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-tetradecyl alpha-D-melibiouronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-tetradecyl beta-D-glucouronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1115

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1116

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-hexadecyl alpha-D-melibiouronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-hexadecyl beta-D-glucouronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1116

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1117

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-(13-carboxyl-tridecyloxy) beta-D-glucuronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1117

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1118

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-(15-carboxyl-pentadecyloxy) beta-D-glucuronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1118

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1119

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl))

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> source

<223> /note="C-term amide"

<400> 1119

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Xaa Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr

20 25

<210> 1120

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-(13-carboxyl-tridecyloxy) beta-D-glucuronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1120

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1121

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-(15-carboxyl-pentadecyloxy) beta-D-glucuronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1121

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1122

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl))

<220>

<221> source

<223> /note="C-term amide"

<400> 1122

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1123

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl])

<220>

<221> source

<223> /note="C-term amide"

<400> 1123

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1124

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega[1-(15-carboxyl-pentadecyloxy) beta-D-melibiouronyl])

<220>

<221> source

<223> /note="C-term amide"

<400> 1124

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1125

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> SITE

<222> (16)..(20)

<223> /note="Cyclic"

<220>

<221> SITE

<222> (16)..(16)

<223> /note="Glu cyclized through side chain to form a lactam linkage"

<220>

<221> SITE

<222> (20)..(20)

<223> /note="Lys cyclized through side chain to form a lactam linkage"

<220>

<221> MOD_RES

<222> (24)..(24)

<223> Lys(N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-melibiouronyl])

<220>

<221> source

<223> /note="C-term amide"

<400> 1125

His Xaa Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Xaa Trp Leu Leu Gln Thr

20 25

<210> 1126

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ser" or "Ala" or "Lys" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="Lys" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (20)..(20)

<223> /replace="Glu" or "Arg"

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Gln" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="Val" or "Leu"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln" or "U(X); while 'U' is any natural or

unnatural amino acids containing a functional group used

for covalent attachment to the surfactant X"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1126

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Met Asn Thr

20 25

<210> 1127

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> VARIANT

<222> (2)..(2)

<223> /replace="Aib"

<220>

<221> VARIANT

<222> (16)..(16)

<223> /replace="Ala" or "Aib"

<220>

<221> VARIANT

<222> (17)..(17)

<223> /replace="hArg" or "Gln"

<220>

<221> MOD_RES

<222> (20)..(20)

<223> U(X); when 'U' is any natural or unnatural

amino acids containing a functional group used

for covalent attachment to the surfactant X

<220>

<221> VARIANT

<222> (23)..(23)

<223> /replace="val"

<220>

<221> VARIANT

<222> (24)..(24)

<223> /replace="Ala"

<220>

<221> VARIANT

<222> (27)..(27)

<223> /replace="val"

<220>

<221> VARIANT

<222> (28)..(28)

<223> /replace="Gln"

<220>

<221> source

<223> /note="C-term amide"

<220>

<221> SITE

<222> (1)..(29)

<223> /note="Variant residues given in the sequence have no

preference with respect to those in the annotations

for variant positions"

<400> 1127

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu

1 5 10 15

Arg Arg Ala Xaa Asp Phe Ile Gln Trp Leu Leu Asn Thr

20 25

<210> 1128

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 1128

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1129

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 1129

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1130

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1130

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1131

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1131

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1132

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C16)

<220>

<221> source

<223> /note="C-term amide"

<400> 1132

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1133

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C18)

<220>

<221> source

<223> /note="C-term amide"

<400> 1133

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1134

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MOD_RES

<222>(6)..(6)

<223> Alpha-MeFF

<220>

<221> MOD_RES

<222> (10)..(10)

<223> Beep

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Lys(C20)

<220>

<221> source

<223> /note="C-term amide"

<400> 1134

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Xaa

1 5 10

<210> 1135

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C8)

<220>

<221> source

<223> /note="C-term amide"

<400> 1135

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1136

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C12)

<220>

<221> source

<223> /note="C-term amide"

<400> 1136

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<210> 1137

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic

peptide"

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys(C14)

<220>

<221> source

<223> /note="C-term amide"

<400> 1137

His Gly Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ala

1 5 10 15

Xaa Ala Ala Arg Glu Phe Ile Ala Trp Leu Leu Asn Thr

20 25

<---

Claims (14)

1. The use of a peptide product, which is His ₁ -Aib ₂ -Gln ₃ -Gly ₄ -Thr ₅ -Phe ₆ -Thr ₇ -Ser ₈ -Asp 9 _{-Tyr 10} -Ser ₁₁ -Lys ₁₂ -Tyr ₁₃ -Leu ₁₄ -Asp ₁₅ -Glu* ₁₆ -Lys (N-omega[1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl]) ₁₇ -Ala ₁₈ -Ala ₁₉ -Lys* ₂₀ -Glu ₂₁ -Phe ₂₂ -Ile ₂₃ -Gln ₂₄ -Trp ₂₅ -Leu ₂₆ -Leu ₂₇ -Gln ₂₈ -Thr ₂₉ -NH ₂ (SEQ ID NO: 1119), where Glu* ₁₆ and Lys* ₂₀ denote residues that are cyclized through their side chains to form lactam, or a pharmaceutically acceptable salt thereof, for the treatment of fatty liver disease, where the fatty liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) . 2. Use according to claim 1, characterized in that the peptide product is formulated to be administered once a week. 3. Use according to claim 1, characterized in that the peptide product is formulated for subcutaneous, intravenous or intramuscular administration. 4. Use according to claim 1, characterized in that the peptide product is formulated for oral inhalation, nasal inhalation or insufflation. 5. Use according to claim 1, wherein the peptide product is presented at a dose of about 0.1 to about 10 mg and is formulated to be administered over a period of about one week. 6. Use according to claim 1, wherein the peptide product is presented at a dose of about 0.1 mg to 1 mg and is formulated to be administered over a period of about one week. 7. Use according to claim 1, characterized in that the peptide product is formulated for administration once a week by subcutaneous, intravenous or intramuscular injection. 8. Kit for use in the treatment of fatty liver disease, comprising: a peptide product or a pharmaceutically acceptable salt thereof, used according to the use according to claim 1, or a pharmaceutical composition containing it(her); And instructions for administering or using the peptide product or pharmaceutical composition for the treatment of fatty liver disease, wherein the fatty liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). 9. The kit of claim. 8, where the peptide product or pharmaceutical composition is formulated for administration subcutaneously, intravenously, intramuscularly, by oral inhalation, nasal inhalation or insufflation. 10. The kit according to claim 8, further comprising a device for administering a peptide product or a pharmaceutical composition, where the device is selected from an injection pen or an inhaler.

Images